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ABSTRACT 
Microcin 24 is an antimicrobial peptide produced by Escherichia coli with activity 
against Salmonella typhimurium. In this study, microcin 24 was investigated for its potential 
use in food safety, resistance development, and structure-activity relationship following site-
directed mutagenesis. An attempt was made to produce microcin 24 from lactic acid bacteria 
by substituting the natural, dedicated leader peptide in the microcin-producing gene with a 
signal leader from divergicin A which accesses the general secretion pathway. RNA 
sequences could be recovered from Carnobacterium divergens harboring an expression 
vector with the fusion construct, but no microcin activity could be detected. Concurrently, 
development of and mechanism of resistance to microcin 24 was investigated by repeatedly 
exposing susceptible S. typhimurium to the microcin. The exposed S. typhimurium harbored 
an inducible regulator, marR, of the multiple antibiotic resistance (mar) regulon. These 
experiments showed that S. typhimurium could become resistant to microcin 24 through 
activation of the mar system leading to concurrent resistance to ciprofloxacin, 
chloramphenicol, rifampin, and tetracycline. Subsequently, an experiment was performed to 
demonstrate if microcin 24-producing E. coli could reduce S. typhimurium shedding in pigs 
and to demonstrate that this exposure could lead to microcin 24 resistance and mar activation 
in vivo. The results did not provide evidence of an effect on Salmonella shedding or mar 
activation under the conditions of the experiment. Site-directed mutagenesis performed in a 
conserved region of microcin 24 indicated that lysine substitutions introduced into a 
proposed hydrophobic face of a predicted amphipathic a-helix eliminated or severely reduced 
microcin activity. Other mutations in the microcin 24 gene were shown to affect microcin 
activity as well. Additional experiments provided evidence that microcin 24 is a bifunctional 
molecule with membrane and endonuclease activity. 
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CHAPTER 1 
GENERAL INTRODUCTION 
2 
Overview of antimicrobial peptides and bacteriocins 
Many animals, plants, invertebrates, and microorganisms produce peptides which are 
antagonistic to microbes including: mammals (Martin et al., 1995), birds (Harwig et al., 
1994), frogs (Moore et al., 1992; Zasloff, 1987), insects (Hultmark et al., 1980), vegetables 
(Broekaert et al., 1995; Cammue et al., 1994), as well as gram- positive and negative 
microbes (Braun et al., 1994; Sahl, 1994). Antimicrobial peptides that are ribosomally 
produced by bacteria are collectively referred to as bacteriocins (Tagg et al., 1976). They are 
distinguished from classical antibiotics, which are multi-enzyme pathway products or 
secondary metabolites produced by fungi or bacteria (Kleinkauf and von Dohren, 1987). 
Although bacteriocins are considered single gene products, they may undergo post-
translational modifications (Kolter and Moreno, 1992). Bacteriocins have a narrow spectrum 
of activity against other bacteria when compared to antibiotics and require a self-protection 
mechanism by the producer in the form of an immunity gene(s) (Sahl, 1994). Because 
antibiotics and bacteriocins adversely affect other microbes to varying degrees, it is tempting 
to speculate that their roles in microbial ecology are similar, i.e. to gain a competitive 
advantage. However, this may not be true. It is believed by some that antibiotics may have 
alternative or pheromonal qualities at the levels experienced naturally by bacteria (Davies, 
1990; Davies et al., 1992; Kell et al., 1997). Tetracycline, for example, is known to induce 
conjugal transfer of genetic elements (Ivins et al., 1988) and thiostrepton, well known as an 
inhibitor of protein synthesis, has been shown to induce transcription in Streptomyces 
lividans at low levels (Murakami et al., 1989). Therefore, the true functions of at least some 
antibiotics may be something other than adversarial. Bacteriocins, on the other hand, have 
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not had alternative functions ascribed to them as of yet and may, therefore, be the real 
"weapons of war" in microbial environments. 
Although the classification of bacteriocins is not consistent, they are generally 
grouped into those produced by gram-positive and those produced by gram-negative bacteria. 
Gram-positive bacteriocins form several classes based on biochemical and genetic data. 
Whereas Gram-negative bacteriocins, usually from Enterobacteriaceae, are referred to as 
colicins or microcins depending on size, production, secretion, and mechanism of action 
(Asensio et al., 1976; Ko Iter and Moreno, 1992; Pugsley, 1984a). The Gram-positive 
bacteriocins have been divided into four categories or classes (Klaenhammer, 1993). The 
class I bacteriocins, also called the lantibiotics, are <5 kDa and have undergone extensive 
post-translational modifications (Jack and Jung, 2000; Jack and Sahl, 1995). These 
compounds are characterized by their content of unusual thioether-containing amino acids 
such as lanthionine and (3-methyllanthionine. Nisin is the most thoroughly studied lantibiotic, 
although about 25 have been described in the literature (Jack and Jung, 2000). The class II 
bacteriocins are <10 kDa, heat stable, non-lanthionine containing peptides that do not 
undergo extensive post-translational alterations. They are characterized by a double glycine 
motif in the precursor that marks the cleavage site of the leader sequence during export 
(Klaenhammer, 1993). Some microcins fit this description and are sometimes referred to as 
class II bacteriocins (Path et al., 1994; Havarstein et al., 1994). Several class II subclasses 
exist including listeria-active peptides (Ha), poration complexes (lib), and thio-activated 
peptides (lie) (Klaenhammer, 1993). The class III bacteriocins are characterized as large-heat 
labile proteins (>30 kDa) and include helveticin J and helveticin VI829 (Klaenhammer, 
1993). Class IV bacteriocins are the least characterized. They are defined as protein 
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complexes containing other chemical moieties such as lipid or carbohydrate for activity. 
Pediocin SJ-1 is an example of a class IV bacteriocin (Klaenhammer, 1993). 
Colicins and microcins from Gram-negative bacteria have similarities and 
differences. Both are most commonly, but not exclusively, produced by strains of 
Escherichia coli. The mechanisms of action for both are similar and some examples include 
pore formation, protein synthesis inhibition, gyrase inhibition, and endonuclease activity 
(Khmel, 1999). They both require a self-protection mechanism in the form of an immunity 
gene and are generally encoded on plasmids. There are important differences, however. The 
microcins differ from the colicins in size. Microcins are so named because they are small 
(<10 kDa) as compared to colicins (30-70 kDa). Microcins have growth stage-dependent 
production as opposed to colicins which are produced under SOS conditions (i.e. requiring 
DNA damage) (Pugsley, 1984a). Colicins are not actively secreted but passively leak out of a 
producer cell with the help of a lysis gene product (Pugsley, 1984b). Therefore, colicin 
production leads to cell death, but cells harboring immunity are spared and benefit from 
localized colicin release (Riley and Gordon, 1999). Additional colicin resistance mechanisms 
such as receptor alteration and tolerance can protect against colicin-mediated activity as well 
(Feldgarden and Riley, 1998). Surveys of colicin production in natural populations suggest 
that resistant strains are more abundant than producer strains (Riley et al., 1992; Feldgarden 
and Riley, 1998). Producer cell death appears to make colicin production an option of last 
resort. Microcins, on the other hand, have active and dedicated transport mechanisms and 
their production is non-lethal. This distinction would appear to make microcins a more 
desirable antimicrobial toxin. Data to support this hypothesis are lacking, however, and 
environmental factors not considered may increase the advantage conferred by colicin 
producers. 
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Membrane activity of antimicrobial peptides and bacteriocins 
Although there is evidence that some of the microcins exert antimicrobial activity by 
acting on the bacterial membrane surface (de Lorenzo and Pugsley, 1985; Lagos et al., 1993; 
Rintoul et al, 2001; Yang and Konisky, 1984), the precise nature of their membrane activity 
is not known. It is likely that the mechanisms of membrane activity described for other 
bacteriocins and antimicrobial peptides would also be relevant for microcins. The following 
section reviews some of the models of membrane activity for antimicrobial peptides with 
particular attention to amphipathic a-helical antimicrobial peptides and similarities to 
bacteriocins. 
Amphipathic a-helical antimicrobial peptides are a common type of antimicrobial 
peptide produced by a variety of animals from insects to humans (Tossi et al., 2000). They 
tend to be linear, cationic and short (<40 amino acids) (Oren and Shai, 1998). They have a 
broad spectrum of activity including gram- positive and gram- negative bacteria, fungi, and 
protozoa; and, they act on the membrane in a non-receptor mediated manner (Tossi et al., 
2000). Some examples include cecropins from moths (Steiner et al., 1981), pleurocidin from 
winter flounder (Cole et al., 1997), magainins (Zasloff, 1987) and dermaseptins (Mor et al., 
1991) from the skin of frogs, and the human LL-37 from keratinocytes (Frohm et al., 1997). 
The characteristic motif that defines this group is the high propensity to adopt a-helical 
conformation in hydrophobic media, thus, conferring hydrophobic and hydrophilic faces to 
the peptide (Oren and Shai, 1998). 
Bacteriocins of lactic acid bacteria produce several types of pore forming peptides 
(Moll et al., 1999). These also tend to be short (12 to 45 amino acids), cationic, and 
amphipathic. They also tend to form an a-helix when mixed with solvents such as 
trifluoroethanol or phospholipid membranes (Moll et al., 1999). Therefore, they are similar to 
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the amphipathic a-helical antimicrobial peptides of higher organisms, although they are not 
usually discussed together. An important difference is that bacteriocins rely on receptor-
mediated interactions with to bacterial cell membranes, and amphipathic a-helical 
antimicrobial peptides do not. This receptor-mediated mechanism may be the primary reason 
for a narrower spectrum of activity for the bacteriocins (Moll et al., 1999). As previously 
mentioned, some microcins, such as colicin V, closely resemble class II bacteriocins from 
lactic acid bacteria (Path et al., 1994; Havarstein et al, 1994; McCormick et al, 1999). 
Models for membrane activity for antimicrobial peptides 
Several models have been described to explain the membrane activity of bacteriocins 
and amphipathic a-helical antimicrobial peptides. Even though sequence and structural 
differences exist between and within these groups, the models are very similar. While 
bacteriocins generally require receptor-mediated access to bacterial cell membranes, 
amphipathic a-helical antimicrobial peptides rely on electrostatic forces to bring them in 
contact. Therefore, amphipathic a-helical antimicrobial peptides tend to be more positively 
charged than bacteriocins and thus are pulled toward the negatively charged membrane. Once 
membrane contact has been established membrane insertion, permeabilization, and pore 
formation appear to proceed in a similar manner between bacteriocins and amphipathic a-
helical antimicrobial peptides. 
Barrel stave model (Figure 1A) 
The 'classical' model to explain pore formation in planar lipid bilayers is the 'barrel 
stave' model (Ehrenstein and Lecar, 1977) also known as the transmembrane helical bundle 
model (Bechinger, 1999). According to this model the peptide monomers bind parallel to the 
membrane in a helical structure, but quickly insert into the membrane core due to 
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hydrophobic interactions with the lipid bilayer. A pore is formed when two or more 
monomers assemble together. As more monomers are recruited, the pore enlarges. It is not 
clear if assembly of monomers is required before insertion or if a single monomer can insert 
by in to the membrane. According to Oren and Shai (1999), it is energetically unfavorable for 
a single amphipathic a-helix to transverse the membrane. The hydrophilic face of the 
peptides forms the inner, water-filled wall of the pore with the outer wall formed by 
hydrophobic sides facing the fatty acyl chains of the lipid membrane (Moll et al., 1999). This 
model appears to apply primarily to strongly hydrophobic peptides that are not highly 
charged and result in pores that are reproducible and well defined (Bechinger, 1999). 
Examples include paradaxin from fish, melittin from insects (Tossi et al., 2000), and 
alamethicin from the fungus Trichoderma viride (Bechinger, 1999). 
Wormhole model (Figure IB) 
The wormhole or toroidal pore model (Ludtke et al, 1996; Matsuzaki et al., 1996) is 
similar to the barrel stave model in many respects. The difference lies in the bending back of 
the lipid on itself forming a toroidal pore that incorporates lipid and peptide into the wall 
lining. This type of pore is more consistent with highly charged antimicrobial peptides such 
as magainin (Bechinger, 1999). These pores form after peptide aggregation causes the 
membrane to thin and cavitate and appears to require a higher concentration of peptide 
compared to the barrel stave model (Tossi et al., 2000). 
Carpet-like model (Figure 1C) 
The carpet-like model (Gazit et al, 1995; Oren and Shai, 1998) describes a situation 
in which amphipathic a-helical peptides initially bind non-cooperatively onto the surface of 
the target membrane and cover it or part of it in a carpet-like manner. After a threshold 
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concentration is reached, the target membrane can be permeated or broken into pieces. This 
model also helps reconcile observations that some small (11-15 residues), synthetic 
amphipathic helices, incapable of crossing the membrane, actually have greater antibiotic 
activity than expected (Bechinger, 1999). This mode, as described by Oren and Shai (1998), 
involves four steps: (a) preferential binding of positively charged monomers to the negatively 
charged phospholipids, (b) laying of amphipathic a-helical monomers on the surface of the 
membrane so that the positive charges of the basic amino acids interact with the negatively 
charged phospholipid headgroups or water molecules, (c) rotation of the molecule leading to 
reorientation of the hydrophobic residues toward the hydrophobic core of the membrane, and 
(d) disintegration of the membrane by disrupting the bilayer curvature. Transient membrane 
holes and micellization of the membrane are expected to precede complete membrane lysis. 
In-plane diffusion model (Figure ID) 
A model that describes pore formation at relatively low peptide-to-lipid ratios is 
called the in-plane diffusion model (Bechinger, 1999). In this model, diffusion of intercalated 
amphipathic peptides non-cooperatively bound within the membrane causes regions of 
instability to overlap, disturbances of the lipid packing to accumulate, and transient small 
openings to occur. The result is a dissipation of the transmembrane ion gradients and loss of 
the transmembrane potential as was shown with low levels of cerocropin A (Silvestro et al., 
1997). 
Lantibiotics are believed to most closely follow the wormhole model for pore 
formation, while class II bacteriocins permeate the membrane by either the barrel stave or 
carpet-like models (Moll et al., 1999). It is likely that the in-plane diffusion, wormhole, and 
carpet-like models are actually describing aspects of the permeabilization process at different 
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peptide concentrations or because of slight peptide differences in structural and 
physicochemical characteristics (Tossi et al., 2000). 
It is unclear if the membrane activity ascribed to many antimicrobial peptides is the 
primary killing mechanism. Experiments show that individual peptides vary widely in their 
ability to depolarize the cytoplasmic membrane of E. coli with some unable to cause 
depolarization even at the minimum inhibitory concentrations (MIC) (Wu et al., 1999). A 
variety of other mechanisms of action have been suggested such as: activation of enzymatic 
degradation of the peptidoglycan (i.e. autolysis) (Chitnis and Prasad, 1990; Chitnis et al., 
1990), interference with bacterial DNA and/or protein synthesis (Boman et al., 1993; 
Subbalakshmi and Sitaram, 1998), binding of DNA and RNA to interfere with cellular 
functions (Park et al., 1998), anti-gyrase activity (Vizan et al., 1991), or endonuclease 
activity (Toba et al., 1988). It may be that the membrane action of many antimicrobial 
peptides is merely a mechanism for passage into the cytoplasm where the primary target 
resides. 
Microcins 
Asensio et al. (1976) were the first to identify microcins as a new class of low 
molecular weight antibiotics. Based on the assumption that most colicins were destroyed in 
the colon by proteases (Kelstrup and Gibbons, 1969), Asensio et al. (1976) screened enteric 
bacteria from newborn infants for products that could inhibit the growth of related organisms 
after passing through a cellophane membrane permeable to molecules smaller than 10 kDa. 
These products were found to be proteinaceous, heat stable, pH resistant, and soluble in 
methanol-water (5:1). The microcins were later classified into groups based on the cross-
resistance of the producer as well as chemical properties and mechanism of action (Baquero 
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et al., 1978; Moreno et al., 1995). At present, there are seven types of microcins that have 
been isolated and studied (Khmel, 1999): A, B, C, D, E, H, and J. The following is an 
overview of microcins starting with colicin V and emphasizing microcin 24 and its 
relationship with other microcins. Mcc is the common abbreviation for microcin preceding 
the letter and/or numerical designation. 
Colicin V 
Colicin V was the first bacteriocin to be identified when Gratia (1925) described a 
biologically active factor produced by E. coli V which inhibited the growth of E. coli <D. The 
inhibitory substance was studied further and given the name "colicin V" (Fredericq et al., 
1949), although later it was found to fit the criteria for a microcin (Fath et al., 1992). Today it 
continues to bear the colicin name for convenience but not for accuracy. ColV is a small 
peptide, not SOS inducible, and is released by a dedicated transport system. The mechanism 
of action is thought to be disruption of membrane potential of the cytoplasmic membrane 
(Yang and Konisky, 1984), but not by the formation of membrane pores (Fath et al., 1991). 
The ColV structural gene, cvaC, and the ColV immunity gene, cvi, were isolated from a 900-
bp Hael\\-Rsa\ fragment from the pColV-B188 plasmid, the smallest piece of DNA with 
killing and immunity characteristics (Frick et al., 1981). Later, it was demonstrated that two 
genes, cvaA and cvaB, were required for export of ColV as mutations in either of these genes 
led to intracellular accumulation of ColV (Gilson et al., 1987). Thus, four genes on two 
converging opérons are required for ColV production, immunity, and export. 
The Cvi protein provides immunity to ColV. This small 78 amino acid inner 
membrane protein (9.1 kDa) is necessary and sufficient for ColV specific immunity as 
subclones containing only the cvi gene are fully immune to ColV (Fath et al., 1992). Cvi is 
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thought to protect cells from ColV molecules interacting with the inner membrane from the 
periplasmic side (Zhang et al., 1995). 
Sequence analysis of the microcin-producing cvaC gene has predicted a 103- amino 
acid peptide with a molecular mass of 10.3 kDa (Gilson et al., 1990). However, the ColV 
toxin, CvaC, has a molecular mass of approximately 6 kDa on SDS-PAGE or 8.7 kDa with 
mass spectroscopy (Fath et al., 1994). The difference appears to lie in the 15 amino-terminal 
amino acids forming the leader sequence. Processing of CvaC involves the cleavage of the 
leader sequence resulting in an 88 amino acid mature peptide with bactericidal activity (Fath 
et al., 1994; Havarstein et al., 1994). Although mature ColV is thought to be composed of 
only natural, unmodified amino acids, modifications involving non-covalent interactions with 
iron (Fath et al., 1994) or formations of disulfide bridges (Havarstein et al., 1994) have been 
suggested. Endogenous cytoplasmic ColV is apparently not toxic since isolates containing 
the intact cvaC gene, but lacking the cvaA, cvaB, and cvi genes were able to grow normally 
(Zhang et al., 1995). Furthermore, lysates from these isolates did retain ColV activity 
indicating that ColV exhibits bactericidal activity only when presented from the outside of 
the inner membrane (Zhang et al., 1995). 
Sequence analysis reveals that cvaB encodes a 698 amino acid (78 kDa) integral inner 
membrane protein with six transmembrane regions and a highly conserved ATP-binding 
domain at the carboxy-terminus of the protein (Gilson et al., 1990). This places CvaB in a 
family of MDR (Multiple Drug Resistance) or ABC transporter (ATP Binding Cassette) 
proteins. These proteins hydrolyze ATP to provide energy for active transport of the substrate 
(Fath and Kolter, 1993; Higgins et al., 1986). CvaB in conjunction with CvaA forms a 
dedicated export apparatus for ColV (Gilson et al., 1990). 
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CvaA is a member of the membrane fusion protein (MPF) family which are accessory 
proteins required in gram- negative bacteria to export substrates across both the inner and 
outer membranes (Dinh et al., 1994). CvaA is an inner membrane protein with the majority 
of the protein located in the periplasmic space and is speculated to form a bridge between the 
inner and outer membranes like the MPF proteins (Skvirsky et al., 1995). Two forms of 
CvaA have been identified, a full-length 413 amino acid protein (47 kDa) and a truncated 
256 amino acid protein (27 kDa) designated CvaA* (Gilson et al., 1990). Since CvaA and 
CvaB are associated with the inner membrane and periplasm, a separate protein is needed to 
translocate the substrate across the outer membrane. TolC, a minor outer membrane protein, 
is suspected to fulfill this role for ColV secretion (Gilson et al., 1990); however, ColV 
secretions can be detected at reduced levels in tolC mutants (Gilson et al., 1990; Zhang et al., 
1995). 
Although ColV is exported through a dedicated transport system, replacement of the 
natural leader sequence with a general protein secretion leader sequence (sec-dependent) has 
allowed the expression of active ColV (McCormick et al., 1999; Zhang et al., 1995). Export 
of ColV into the periplasmic space was demonstrated by fusion of the OmpA sec-dependent 
leader sequence upstream of the mature structural gene for ColV (Zhang et al., 1995). Later, 
extracellular secretion of ColV was accomplished by replacement of the dedicated leader 
with a sec-dependent leader from divergicin, a bacteriocin produced by Carnobacterium 
divergens (McCormick et al., 1999). 
Type A microcins 
The only studied microcin of this type is microcin A15. It is a very small protein (240 
Da) and is suggested to be a derivative of L-methionine. The target for this microcin is 
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homoserine-O-succinyltransferase, the first enzyme of methionine synthesis, and the effect is 
bacteriostatic. Its activity is antagonized in the presence of L-methionine and is the only 
nonpeptidic microcin presently known (Aguilar et al., 1982). 
Type B microcins 
Microcin B17 is the most studied microcin and represents the type B microcins. Of all 
the microcins, MccB17 was the first to be biochemically defined (Bayer et al., 1995; Yorgey 
et al., 1994). MccB17 works by interacting with subunit B of type II DNA topoisomerase 
(DNA gyrase), trapping a gyrase-DNA-DNA intermediate and inhibiting DNA elongation in 
a manner similar to the quinolone antibiotics (Couturier et al., 1998; Hernandez-Chico et al., 
1992; Vizan et al., 1991). The result is double stranded cleavage of the DNA, SOS induction, 
and massive DNA fragmentation in susceptible cells (Herrero et al., 1986; Vizan et al., 
1991). 
Genetic control of MccB17 synthesis and immunity is conferred by a group of seven 
genes. Four genes (mcbA, mcbB, mcbC, and mcbD) are involved in microcin production, 
while three genes (mcbE, mcbF, and mcbG) confer immunity to host cells (Davagnino et al., 
1986; Garrido et al., 1988; Genilloud et al., 1989). The structural gene, mcbA, encodes a 69 
amino acid microcin B17 precursor (Davagnino et al., 1986; Yorgey et al., 1993). The mcbB, 
mcbC, and mcbD genes are involved in post-translational modifications of the precursor. 
These genes form a complex which causes precursor MccB17 to undergo a series of 
cyclization and dehydration reactions forming four thiazole and four oxazole rings which in 
turn fold to produce two aromatic heterocycles (Bayer et al., 1995; Jack and Jung, 2000; 
Yorgey et al., 1994). A chromosomal gene,pmbA, further processes the proMccB17 by 
cleaving the amino-terminal 26 amino acids to form the mature MccB17 (Jack and Jung, 
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2000; Rodriguez-Sainz et al, 1990; Yorgey et al., 1993). Genes mcbE and mcbF are 
involved in exporting the mature peptide out of the cell. The sequence of McbE suggests it is 
a membrane protein and McbF appears to be a member of the ABC family of transport 
proteins (Higgins et al., 1986). Apparently this export complex affords protection from 
MccB17 along with the mcbG immunity gene (Garrido et al., 1988). The mechanism of 
McbG appears to be the prevention of DNA degradation after the microcin-gyrase-DNA 
complex has formed (Herrero et al., 1986). A chromosomal gene, sbmC, may also be 
involved with MccB17 immunity by affecting sequestration of microcin (Baquero et al., 
1995; Lavina et al., 1986). 
Other B type microcin genes are described based on their cross immunity and 
homology to microcin B17 DNA. They have been named microcins B2 and B27 (Basiuk et 
al, 1994), although the relationship to microcin B17 has not been resolved (Khmel, 1999). 
Type C microcins 
Two type C microcins have been characterized, MccC7 and MccCSl (Garcia-Bustos 
et al., 1984; Kurepina et al, 1990). They are both heptapeptides with the same amino acid 
sequence (Met-Arg-Thr-Gly-Asn-Ala-Asn), and are encoded by the smallest prokaryotic or 
eukaryotic genes known (Gonzalez-Pastor et al., 1994). Both have a modified adenine 
monophosphate at the carboxy-terminus, while MccC7 is reported to also have a formyl 
group attached to the amino-terminal methionine (Khmel, 1999). Both are reported to have a 
rather broad spectrum of activity, which includes some gram- negative bacteria (E. coli, 
Salmonella, Shigella, Klebsiella pneumoniae, and Proteus mirabilis for MccC7, and, 
additionally, Citrobacter freundii, Serratia marcesens, Yersina enterocolitica, Y. 
pseudotuberculosis, Providencia rettgerij Bacillus subtilis, and B. megaterium for MccC51). 
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Both act bacteriostatically by inhibiting protein synthesis while MccC51 reportedly inhibits 
DNA and RNA synthesis as well (Khmel, 1999). Genetically, Mcc7 and Mcc51 biosynthesis 
differ. MccC7 has six genes responsible for synthesis and immunity (mccABCDEF) 
(Gonzalez-Pastor et al., 1995), but MccC51 has only four (Kurepina et al., 1993). Cross 
immunity is identical for both MccC7 and MccC51 (Guijarro et al., 1995). 
Type D microcins 
Microcin D93 is the prototypical of the type D microcins. It is a small (<lkDa), 
hydrophilic, basic peptide with activity against E. coli, Pseudomonas, Proteus, and 
Citrobacter species (Martinez and Perez-Diaz, 1986). DNA synthesis rapidly decreases in 
cells treated with microcin D93; recA positive strains are highly sensitive to MccD93 
mediated inhibition of DNA (Martinez and Perez-Diaz, 1986) while rates of protein and 
RNA synthesis are unchanged (Martinez and Perez-Diaz, 1986). Microcin D93 genes are 
found on plasmids of different sizes depending on the producing strain (Martinez and Perez-
Diaz, 1990). MccD15 and MccD140 are suggested to be similar or the same as MccD93, 
although differences in their reported mechanisms of action have made this unclear. 
MccD140 was shown to attack the inner membrane causing disruption of the proton motive 
force (Duro et al., 1979) while MccD15 is suspected to inhibit homoserine-O-
succinyltransferase and was previously classified as an type A microcin (Aguilar et al., 
1982). 
Type E microcins 
Microcin E492 (MccE492) is the only type E microcin known. It is unusual in that it 
is produced by Klebsiella pneumoniae (de Lorenzo, 1984) from genes located on the 
chromosome (de Lorenzo and Pugsley, 1985; Wilkens et al., 1997). All previously described 
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microcins are E. coli derived products and encoded on plasmids. MccE492 is a basic, 
hydrophobic peptide with a molecular mass of approximately 7.9 kDa. It is acid- and heat-
resistant and more active on when target bacteria are grown on minimal medium (de 
Lorenzo, 1984). MccE492 causes depolarization of the inner membrane in sensitive cells (de 
Lorenzo and Pugsley, 1985) and has been shown to form ion channels in phospholipid 
membranes (Lagos et al., 1993). MccE492 has activity against E. coli, Klebsiella, 
Salmonella, Citrobacter, Enterobacter, and Erwinia species (de Lorenzo, 1984). 
The genes involved with MccE492 production and immunity are located in a 13 kb 
segment of DNA on the chromosome of Klebsiella pneumoniae RYC492 (Wilkens et al., 
1997). Random Tn5 mutagenesis and DNA sequencing has revealed that up to 10 genes may 
be involved in the production of active microcin and its immunity protein (Lagos et al., 
2001). The MccE492 system appears to be a mosaic system acquired from horizontal gene 
transfer. The structural and immunity genes (mceA and mceB, respectively) are homologues 
of the same functional genes in the Mcc24 system (Lagos et al., 1999), and the exporter 
genes (mceG and mceH) are nearly identical to the transport system in ColV (Lagos et al., 
2001). MceG appears to function as the ABC export protein with 87% identity to CvaB in the 
ColV system and MceH appears to function as an inner membrane protein with 91% identity 
to CvaA (Lagos et al, 2001). MccE492, however, requires the gene product from mceF in 
order for the export activity and this protein appears to be a membrane protein with 
homology to a protease gene from Drosophila melanogaster (Lagos et al., 2001). Although 
genes mceC, mcel, and mceJ are required for active MccE492, they do not appear to act by 
directing covalent modifications of the microcin (Lagos et al., 2001). It is postulated that 
these genes affect the secondary structure of MccE492, allowing it to fold into an active 
form, although the mechanism is unclear (Lagos et al., 2001). mceC encodes for a 
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homologue of iroB, a putative glycosyl transferase from Salmonella enterica serotype Typhi 
(Lagos et al., 2001). mcel has significant homology with acyltransferases from 
Actinobacilluspleuropneumoniae and Pasteurella haemolytica (Lagos et al., 2001). No 
homologues of mceJ were found in the NCBI database (Lagos et al., 2001). mceD and mceE 
genes were also found the MccE492 gene cluster, but their functions are unknown. Although 
mceD encodes a homologue of IroD, a putative enterochelin esterase from S. enterica 
serotype Typhi (Lagos et al., 2001). Enterochelin has been reported to be an antagonist of 
MccE492 (Orellana and Lagos, 1996). It is, therefore, likely that MceD is involved in the 
interaction of MccE492 and enterochelin. No mutants or homologues of mceE have been 
found and its role in the MccE492 remains undetermined (Lagos et al., 2001). 
Type H microcins 
Microcin H47 was isolated from a strain of E. coli recovered from human feces and 
was shown to have activity against isolates of E. coli, Salmonella, Enterobacter, Shigella, 
Klebsiella, and Proteus spp. (Lavina et al., 1990). It is the only other chromosomally 
encoded microcin besides microcin E492. The genes for synthesis, secretion and immunity 
lie on a 10 kb DNA fragment and involve at least seven genes (Gaggero et al., 1993; Lavina 
and Gaggero, 1992). Four of these genes (mchABCD) are devoted to synthesis of the 
microcin with mchB serving as the structural gene (Gaggero et al., 1993). mchEF codes for 
proteins that form a dedicated ABC export apparatus very similar to the ColV system 
(Azpiroz et al., 2001; Gaggero et al., 1993). Immunity to MccH47 is controlled by the mchl 
gene, which codes for a small hydrophobic integral membrane protein. This data suggests 
that the membrane is the site of action for MccH47 (Rodriguez and Lavina, 1998). An eighth 
gene, mchX, is located upstream of mchl and may be involved in activation of the immunity 
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gene and the downstream genes associated with production of MccH47 (Rodriguez and 
Lavina, 1998). Precursor MccH47 is has a characteristic double-glycine motif forming part of 
the leader sequence and possesses antibiotic activity (Rodriguez et al., 1999). The mode of 
action is unclear, but is thought to involve the ATP synthase complex as atp mutants were 
resistant to MccH47 (Rodriguez et al., 1999). 
Type J microcins 
Microcin J25, produced by an E. coli strain isolated from human feces, has activity 
against E. coli, Salmonella and Shigella spp (Salomon and Farias, 1992). It is a peptide of 21 
unmodified amino acid residues cyclized in a head-tail linkage (Blond et al., 1999). The 
mode of action of MccJ25 is unclear. It induces cell filamentation in a non-SOS-dependent 
way suggesting that its molecular target is involved in cell division (Salomon and Farias, 
1992). Supporting evidence shows a mutation in the gene for the beta subunit of E. coli RNA 
polymerase, rpoC, confers complete immunity to MccJ25 presumably by impaired 
transcription of genes encoding cell division proteins (Duarte et al., 2001). However, other 
evidence indicates that MccJ25 leads to disruption of the cytoplasmic membrane in S. 
newport suggesting that the membrane is the site of activity (Rintoul et al., 2001). Four genes 
located on a 4.8-kb region of 50 kb plasmid are responsible for MccJ25 synthesis, export, and 
immunity (Solbiati et al., 1999). mcjA encodes the microcin precursor that contains a 37 
amino acid leader sequence and a double glycine adjacent to the cleavage site; however, 
cleavage occurs on the amino side of the double glycine incorporating it into the microcin 
(Solbiati et al., 1999). The mcjB and mcjC gene products are required for the conversion of 
the precursor to the mature microcin and are thought to be involved in cleavage and 
cyclization (Solbiati et al., 1999). The mcjD gene appears to code for an ABC exporter and, 
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therefore, is involved in pumping the microcin from the cell and conferring immunity 
(Solbiati et al, 1999). Mutational studies indicated the involvement of the fhuA, exb, tonB, 
and sbmA genes in MccJ25 resistance (Salomon and Farias, 1995). FhuA is thought to be the 
receptor for MccJ25 and together with TonB and ExbBD form an import complex into the 
periplasmic space, whereupon it is translocated into the cytoplasm by the SbmA protein 
(Salomon and Farias, 1995). 
Microcin 24 
In 1994 a new colicin was identified from a human uropathogenic strain of E. coli and 
given the designation Colicin 24 (O'Brien and Mahanty, 1994). Later, it was reclassified as a 
microcin when it was shown to pass through cellophane, and otherwise fit the definition of a 
microcin (O'Brien, 1996). A letter designation has not yet been assigned. Mcc24 has strong 
activity against Salmonella typhimurium strains in addition to activity against E. coli and 
Shigella spp. (1996) The anti-Salmonella activity of Mcc24 has made it an attractive 
molecule for possible use in Salmonella pathogen control (Wooley et al., 1999; Wooley et 
al., 2001). When given continuously in water, Mcc24 significantly reduced the level of S. 
typhimurium found in the feces of broilers after challenge (Wooley et al., 1999). Microcin 24 
was also shown to have strong in vitro activity against 44 of 57 reptilian Salmonella isolates 
(Wooley et al., 2001). 
The genes for microcin 24 production were found on a plasmid and restriction 
digestion isolated a 5.25 kb insert that conferred Mcc24 production and immunity when 
cloned into pBR322 (O'Brien, 1996). Five genes (mdbA, mtfl, mtfS, mtfA, and mtfB) 
comprising three opérons were shown to be involved (O'Brien, 1996). The structural gene, 
mtfS, encodes a 90 amino acid precursor that is modified to form the 74 amino acid mature 
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MtfS protein. The apparent modification is the loss of a leader sequence with a double-
glycine motif at the cleavage site. The active microcin is visualized as a band on SDS-PAGE 
corresponding to a molecular mass of 7.75 kDa. The mode of action of microcin 24 is not 
clearly understood. It is thought to share a common ancestor with MccE492 (Lagos et al., 
1999) which suggests that it has membrane activity; although, it has been shown to have 
nonspecific endonuclease activity (O'Brien, 1996). 
Immunity to Mcc24 is conferred by mtfl, a gene that encodes a 93 amino acid peptide 
with a molecular mass of 11.43 kDa. mtfl and mtfS form an operon in which the immunity 
gene is transcribed first and overlaps with the structural gene. The mechanism for Mcc24 
immunity is not known, but the predicted structure of Mtfl shows three hydrophobic domains 
and suggests an integral membrane protein. This would imply that Mtfl acts by sequestering 
or blocking entry of active Mcc24, although inhibition of nuclease activity remains a 
possibility (O'Brien, 1996). 
Export of Mcc24 is accomplished by the products of genes mtfA and mtfB. Together 
these proteins form an ABC transport complex that is dedicated to Mcc24 export (O'Brien 
and Mahanty, 1994). This complex is homologous to the transport complex for ColV 
(O'Brien, 1996). MtfA has a predicted size of 414 amino acids and molecular mass of 47 
kDa. It is 71% identical to CvaA, the MFP protein involved in ColV export and functions as 
an accessory transport protein (O'Brien, 1996). MtfB belongs to the ATP-binding cassette 
(ABC) transporter family of proteins, is predicted to have 707 amino acids, and is 73% 
identical to CvaB from the ColV export system. This family of exporters recognizes a double 
glycine motif in the leader sequence (Havarstein et al., 1995). Similar to ColV, Mcc24 
requires TolC, an outer membrane protein, for export across the outer membrane (O'Brien, 
1996). However, Mcc24 does not appear to "leak out" in tolC mutants which contrasts with 
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ColV (Gilson et al., 1990; O'Brien, 1996). Uptake of Mcc24 appears to involve the outer 
membrane receptor protein SemA (O'Brien, 1996). SemA was also found to be one of the 
receptors that bind MccE492 (Pugsley et al., 1986). 
A fifth gene included in the Mcc24 system is mdbA. It appears to function as a re­
acting element to positively regulate the production of Mcc24 (O'Brien, 1996). No other 
microcin producing system is known to include a gene with this type of function. It is located 
upstream of the rest of the Mcc24 gene and has significant identity to DNA binding proteins 
of the histone-like nucleoid structural (H-NS) family (O'Brien, 1996). MdbA production in 
stationary phase is thought to involve as, the stationary phase sigma factor (O'Brien, 1996). 
Putative consensus sequences for os are located within the promoter for mdbA (PmdbA) 
(O'Brien, 1996). Although the mechanism of MdbA regulation is not known, miniTniO 
insertion into mdbA abolished activity of Mcc24 (O'Brien, 1996). 
Regulation of Mcc24 production also involves the Fur repressor, a global regulatory 
protein related to environmental iron levels and a strong regulator of ColV expression 
(Chehade and Braun, 1988). A Fur-box is located upstream of mtfl (O'Brien, 1996), similar 
to that found in the ColV system (Gilson et al., 1990). However, the increased expression of 
Mcc24 is slight in iron limited media (O'Brien, 1996). 
Bacterial secretion systems 
A wide variety of cytoplasmically-derived bacterial products must cross one or more 
cellular membranes in order to reach their final destination. This generally involves the aid of 
transport systems. Up to six different types of membrane transport systems have been 
described, although a generally agreed classification system has not been established for all 
of these (de Lima Pimenta et al, 1997). Two systems, both requiring energy from ATP 
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hydrolysis, have been shown to transport bacteriocins to the extracellular medium. 
Manipulation of Mcc24 export was a part of an objective to produce Mcc24 in lactic acid 
bacteria for this study. 
ABC exporters 
ABC protein exporters secrete substrates in a manner that is independent of the 
general secretory proteins or Sec proteins used in several other secretion systems. The ABC 
exporters form a dedicated, Type I secretion pathway, that is able to transport a wide variety 
of substrates such as ions, amino acids, sugars, polysaccharides, peptides and proteins 
(Gilson et al, 1988; Higgins, 1992). ABC exporters are part of a superfamily of prokaryotic 
and eukaryotic ATP-binding cassette proteins that bind and hydrolyze ATP for energy. 
Some, but not all of the proteins in this superfamily, are involved in transport. Therefore, a 
distinction is made between an ABC protein and an ABC transporter with the latter 
sometimes referred to as an ABC traffic ATPase (Young and Holland, 1999). Also, a 
distinction is made between export and import (i.e. permeases). 
The common feature of ABC proteins is a highly conserved cytoplasmic carboxy-
terminal 215-amino acid domain located at the end of an a-helix. This domain contains the 
ATP-binding site. An important structural feature of the ATP binding domain is the presence 
of a motif that forms the pocket that binds ATP. This motif is commonly referred to as the 
Walker motif (Walker et al., 1982), but may also be called the Rossmann fold (Rossmann et 
al., 1975) or the Doolittle motif (Doolittle et al., 1986). It contains two conserved sites (A 
and B) that border a central helical domain (Walker et al., 1982). The domain's core is highly 
folded with loops that interact with other components of the protein. Thus, the 
conformational change resulting from ATP hydrolysis is spread to other parts of the protein 
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and results in transport of the substrate (Walker et al., 1982). A linker peptide or signature 
sequence, LSGGQ, is found between the Walker A and B sites and is important to the 
transmission of the ATP-dependent conformational change as changes result in disrupted 
energy translocation but not ATP binding (Koronakis et al., 1995). 
The common general structure of ABC transporters consists of two ATP-binding 
domains and two membrane spanning domains (MSD). The hydrophobic MSD usually has 
six transmembrane segments giving each ABC transporter twelve membrane spanning 
segments. The four domains can be combined as part of single polypeptide, or as separate, 
independent polypeptides (Wandersman, 1998). Some exceptions to this general structure are 
the antibiotic resistance proteins CarA (Schoner et al., 1992), MsrA (Ross et al., 1990), 
SrmB (Schoner et al., 1992), and TlrC (Schoner et al., 1992). These transporters have two 
ABC cassettes but no MSD has been identified. 
Depending on the final destination of the substrate and type of bacteria, additional 
proteins may be needed for ABC exporters. These are termed accessory proteins. In gram-
negative bacteria, secretion across the outer membrane requires the aid of a protein that 
connects the exporter to the outer membrane. These proteins have been classified into the 
membrane fusion protein family (MFP) (Dinh et al., 1994). The MFP is anchored to the inner 
membrane with a small hydrophobic domain and has a large, hydrophilic periplasmic 
domain. The carboxy-terminal domain interacts with an outer membrane protein (OMP) 
which is regarded as an accessory protein as well (Wandersman and Delepelaire, 1990). TolC 
is an important OMP recruited for use in a variety of Type I systems (Benz et al., 1993; 
Koronakis et al., 1997). A TolC box in MFPs has been suggested as the common motif 
allowing interactions between these two accessory proteins (Marugg et al., 1992). An 
ordered assemblage occurs, beginning with the substrate recognition by the ABC protein and 
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triggering a chemical or conformational change in the exporter. Interaction then occurs 
between the ABC exporter and the MFP that in turn binds to the OMP (Binet et al., 1997; 
Letoffe et al, 1996). The apparatus is then referred to as the ABC protein-mediated exporter 
(Binet et al., 1997) and is shown in Figure 2. 
The genes encoding the MFP accessory protein are linked to the genes for the ABC 
exporter protein (Letoffe et al., 1990). The gene for the OMP may be linked or reside 
elsewhere (Wandersman and Delepelaire, 1990). Nonprotein substrates such as 
polysaccharides, antibiotics, and lipophilic drugs may not require accessory proteins since 
these products are transported only in to the periplasm (Fath and Kolter, 1993). Gram-
positive bacteria secretion systems may have MFP-like sequences linked to ABC exporter 
genes and these MFP-like sequences have some homology to gram- negative accessory 
factors. However, their role is unclear since there is no outer membrane to cross (Chung et 
al., 1992; Klein et al., 1992). 
Secretion signals 
Large proteins secreted by the Type I pathway include toxins, metalloproteases, 
lipases, hemo-proteins, and S layers. These proteins generally have a non-cleaved secretion 
signal located in the last 60 to 150 amino acids of the carboxy-terminus (Fath and Kolter, 
1993). Secretion signals were first identified on the ^-hemolysin from E. coli. (Mackman et 
al, 1986). Specific ABC transporters recognize these signals and there is little conservation 
among them except for the carboxy-terminal end. Here, a motif consisting of a negatively 
charged amino acid followed by several hydrophobic amino acids is found (Binet et al., 
1997). There is, however, homology among secretion signals for different groups of 
exoproteins. Homologous toxins tend to have similar signals and metalloproteases share a 
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common secretion signal with lipases. Heterologous complementation within these groups 
generally results in efficient expression (Wandersman, 1998). However, functional 
complementation using a secretion signal and a Type I exporter from a different group is 
very infrequent (Wandersman, 1998). Foreign proteins can be expressed when hybridized to 
a secretion signal in the presence of its dedicated transporter (Gray et al, 1989). This 
indicates that specificity is maintained at the secretion signal-exporter level. 
Proteins transported by Type I exporters are secreted directly to the extracellular 
medium without a periplasmic intermediate. Evidence for this comes from observations that 
periplasmic intermediates are not found in strains without the accessory OMP (Wandersman 
and Delepelaire, 1990) and that the OMP is required for secretion from E. coli spheroplasts 
(Koronakis et al., 1997). 
Type I secretion of peptides such as bacteriocins differs somewhat from the secretion 
of large proteins. The most striking difference is the absence of a carboxy-terminal signal 
sequence. This is instead replaced by an amino-terminal leader peptide. The leader peptide is 
cleaved to produce the mature bacteriocin. In the case of most lantibiotics, cleavage occurs 
externally after transport through the ABC export apparatus and is accomplished by 
peptidases belonging to the subtilisin family (Wandersman, 1998). For most non-lantibiotics 
and certain lantibiotics such as lactococcin DR, salvaricin A, and streptococcin A-FF22, the 
leader is cleaved concomitantly with export (Havarstein et al., 1995). The leader peptide for 
these bacteriocins shares a consensus sequence of L(-12)S(-11 )XXE(-8)L(-7)XXI(-4)XG(-
2)G(-1) with the carboxy-terminal two glycine residues serving as a conserved cleavage site. 
These leaders have thus been termed double-glycine-type leader peptides (Havarstein et al., 
1994). It has also been shown that removal of the leader peptide is accomplished by an 
amino-terminal extension of 100-150 residues of the ABC transporter, which has proteolytic 
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activity (Havarstein et al, 1995). No significant similarity was found between this 
proteolytic domain and other proteases and a dual role of processing and transport was 
demonstrated for this family of ABC transporters (Havarstein et al., 1995). Microcins such as 
ColV (Havarstein et al, 1994), MccE492 (Lagos et al., 1999b), MccH4 (Rodriguez et al., 
1999), MccJ25 (Solbiati et al., 1999)and Mcc24 (1996) all appear to have leader peptides 
with the double-glycine motif. 
Sec system 
The general export pathway (GEP) or Sec pathway is the primary system for export 
of proteins across the cytosolic membrane. It is a universally conserved system in 
prokaryotes and eukaryotes and essential for cell viability. It has been most extensively 
studied in E. coli (Driessen et al., 1998; Economou, 1999; Mori and Ito, 2001; Wandersman, 
1993). In gram- negative bacteria, it contributes to at least four types of secretion systems 
and these systems are referred to as Sec-dependent (Thanassi and Hultgren, 2000). In gram-
positive lactic acid bacteria, the Sec pathway is responsible for secretion of S-layer proteins, 
proteases, amylases, and some bacteriocins. Both divergicin A from Carnobacterium 
divergens LV13 (Worobo et al., 1995) and acidocin B from Lactobacillus acidophilus strain 
M46 (Leer et al., 1995) are secreted in a Sec-dependent manner. 
Sec-dependent translocation occurs in a stepwise manner with three stages: targeting, 
translocation, and release. Two distinct targeting routes are described and appear dependent 
on the localization the final protein. The signal recognition particle (SRP) composed of the 
Ffh protein and a 4.5S-RNA species mainly targets ribosome-bound nascent membrane 
proteins, whereas SecB facilitates targeting of periplasmic and outermembrane proteins 
(Dreiessen et al., 2001). These routes converge at the translocase which consists of a protein-
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conducting channel, the SecYEG complex, associated with an ATPase, Sec A (Valent et al., 
1998; Driessen et al., 2001). Therefore in proteins destined to be secreted, SecB recognizes 
sequence motifs on the preprotein and prevent it from folding prior to translocation (Driessen 
et al., 2001). Sec B also channels the secretory proteins to SecYEG-bound SecA protein A 
(Driessen et al., 2001). SecA is essential for moving the protein into and across the 
membrane, thus providing a physical link and energy for the translocase (Cunningham et al., 
1989; Economou, 1999). Sec Y and SecE dimers assemble into a ring-shaped structure that 
forms the translocation pore (Meyer et al., 1999). SecG a membrane protein that co-purifies 
with Sec Y and SecE (Joly et al., 1994) but is not essential for viability in E. coli (Bost and 
Belin, 1997). Additional Sec proteins include SecD, SecE and yajC which are thought to 
regulate SecA membrane cycling (Duong and Wickner, 1997; Economou, 1998). The energy 
for translocation comes primarily from ATP although electrochemical energy from the 
proton motive force (PMF) enhances translocation rates (Duong and Wickner, 1997; 
Economou, 1998). The final stage in the secretion process is release of the preprotein from 
the signal peptide to form the mature protein. In E. coli, the serine peptidase LepB appears 
primarily responsible for this enzymatic reaction (Dalbey, 1991; Dalbey and Wickner, 1985). 
The signal peptide, responsible for directing a protein into the Sec pathway, has three 
domains (von Heijne, 1985). The amino terminal domain is short and positively charged, 
followed by a hydrophobic core of ten or more residues and a hydrophilic carboxy-terminal 
region that contains a consensus sequence for leader peptidase cleavage (Mori and Ito, 2001). 
The positively charged amino-terminal domain is drawn to the negatively charged inner 
membrane and helps to orient the protein within the translocase. The "positive-inside rule" 
states that the positively charged side of a hydrophobic segment is oriented towards the 
cytoplasm (Mori and Ito, 2001; von Heijne, 1986). Thus, with regards to the membrane, the 
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signal peptide is oriented with the amino domain on the cytoplasmic side while the 
hydrophobic domain spans the membrane and the carboxy hydrophilic domain remains in the 
periplasm with the rest of the polypeptide. The cleavage site of the carboxy terminus is 
characterized by small side chain amino acids at -3 and -1 (von Heijne, 1984). As stated 
above in E. coli, LepB acts as the signal peptidase and is essential for processing (Dalbey and 
Wickner, 1985). In Bacillus spp., at least three signal peptidases exist with SipS appearing 
the most important (van Dijl et al., 1992). 
Multiple antibiotic resistance and the mar system 
Microorganisms have the ability to resist the effects of antimicrobial agents or drugs 
through a variety of mechanisms. Resistance may come in the form of genes or mutations, 
that ultimately alter the target of the drug or the drug itself, induce overproduction of the 
target, or extrude the drug from the microorganism. Some of these resistance mechanisms are 
acquired as a result of mutations in existing genes or genetic exchange between 
microorganisms. Other mechanisms are intrinsic and only require the activation of existing 
genes. One such example is the mar system, mar is an acronym for multiple antibiotic 
resistance. This system was discovered in the early 1980's when researchers found that 
passage of E. coli in media containing subinhibitory levels of tetracycline or chloramphenicol 
gave rise to mutants that were resistant to a variety of non-related antibiotics (George and 
Levy, 1983). In addition to tetracycline and chloramphenicol, the mar mutants have 
increased resistance to penicillin, cephalosporins, puromycin, rifampin, nalidixic acid, 
fluoroquinolones, oxidative stress agents, and organic solvents (Ariza et al., 1994; Asako et 
al., 1997; Cohen et al, 1989; George and Levy, 1983; Greenberg et al., 1991; White et al, 
1997). Collectively, this is referred to as the mar phenotype. Resistance was mapped to a 
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locus at the 34 min region of the chromosome (George and Levy, 1983). Homologues to the 
mar system have been found in a variety of bacteria including Salmonella, Shigella, 
Klebsiella, Citrobacter, Hafnia, and Enterobacter (Cohen et al., 1993). 
In E. coli, the mar locus features two divergently positioned opérons on either side of 
the operator, marO as shown in Figure 3. One operon, containing marC, encodes a putative 
inner membrane protein that may contribute to the mar phenotype in some strains (Alekshun 
and Levy, 1997). The other operon is composed of marRAB, which encodes MarR, (the 
repressor), MarA (the activator), and MarB (a protein with unknown function) (Alekshun and 
Levy, 1997). MarR negatively regulates the transcription of marRAB by binding two 
promoters, Pmart and Pmarn, located within marO (Cohen et al, 1993; Martin and Rosner, 
1995; Seoane and Levy, 1995). Binding is highly specific, although a DNA binding motif has 
not been identified (Alekshun and Levy, 1997). The mar phenotype can by induced by 
exposure to salicylate (Rosner, 1985) that results from the direct binding of salicylate to 
MarR (Martin and Rosner, 1995). Similarly, exposure to compounds such as dinitrophenol 
(uncoupling agent), plumbagin (redox-cycling agent), and sodium benzoate has shown to 
relieve MarR repression in marO-LacZ fusions (Seoane and Levy, 1995). Additionally, 
experimentally produced marR mutants display the typical mar phenotype (Ariza et al., 
1994) and marR mutations have been found in clinical E. coli isolates resistant to 
fluoroquinolones (Maneewannakul and Levy, 1996). 
Once relieved of MarR repression, Pmarn is able to promote the transcription of 
MarA, which activates the mar regulon. This is a global stress response regulon involving 
over 60 genes which function in DNA repair, metabolism, translation, superoxide stress 
response, pH response, as well as antibiotic resistance (Barbosa and Levy, 2000) (see Figure 
3). Important in this multiple antibiotic resistance phenotype are acrAB (Ma et al., 1996; Ma 
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et al., 1993; Ma et al., 1995) and micF (Andersen and Delihas, 1990; Chou et al., 1993; 
Cohen et al., 1988; Hall and Silhavy, 1981; Mizuno et al., 1984). The gene products of 
acrAB encode an efflux system of the resistance/nodulation/cell division (RND) family (Dinh 
et al., 1994; Saier, 1994). RND systems mediate proton-dependent export of a wide range of 
substrates (Paulsen et al., 1996). In E. coli, the AcrAB system exports a variety of lipophilic 
and amphiphilic substances such as bile salts, short-chain fatty acids that are important in the 
gut and the AcrAB system may be an evolutionary component of enteric habitation (Ma et 
al., 1995). Other compounds exported by the AcrAB system include acriflavine, crystal 
violet, ethidium bromide and pine oil (Poole, 2001). Additionally, antibiotics such as beta-
lactams, chloramphenicol, erythromycin, novobiocin, and tetracycline are known substrates 
(Poole, 2001). AcrB is an inner membrane protein that acts as the transporter through TolC 
with AcrA acting as the membrane fusion protein (Nikaido and Zgurskaya, 2001). The micF 
gene acts to decrease expression of OmpF, an outer membrane protein involved in osmotic 
regulation (Mizuno et al., 1984). When micF is activated it produces antisense RNA to a 
portion of the mRNA for OmpF and thereby prevents translation (Mizuno et al., 1984). 
The clinical importance of mar activation is variable. Most first-step mar mutants are 
still susceptible to most currently used antibiotics (Alekshun and Levy, 1999). However, 
clinical resistance is seen with some drugs such as tetracycline, rifampin, and nalidixic acid 
(Alekshun and Levy, 1999). MarR mutants that constitutively expressed the mar operon have 
been found in clinical isolates resistant to fluoroquinolones (Maneewannakul and Levy, 
1996; Oethinger et al., 1998). Of concern is that low-level resistance conferred by mar 
activation may allow higher levels of resistance to develop through further mutations. This 
apparently occurs as first-step E. coli mar mutants selected by low-level exposure to 
tetracycline or chloramphenicol mutate more readily to high-level fluoroquinolone resistance 
31 
as compared to wild type (Cohen et al., 1989). Another important finding is that the absence 
of a functional AcrAB efflux pump prevents gyrase target mutations from producing 
clinically relevant fluoroquinolone resistance (Oethinger et al., 2000). 
Aims of this study 
Microcins belong to a group of low molecular mass antimicrobial peptides produced 
by strains in the family Enterobacteriaceae. They can exhibit strong inhibitory activity 
against related strains including pathogenic bacteria such as Salmonella. Some microcins 
hold promise for use in food safety interventions and may provide a model for the 
development of new antimicrobials. 
The use of Mcc24 to reduce shedding of S. typhimurium in chickens demonstrated a 
food safety application of this microcin (Wooley et al., 1999). Additionally the production of 
a microcin, ColV, from lactic acid bacteria (McCormick et al., 1999) offers the possibility 
that Mcc24 could be produced from similar beneficial bacteria used as probiotics. The 
specific objectives of this study were: 
1. To fuse a sec leader sequence to the Mcc24 gene and express active Mcc24 from lactic 
acid bacteria. 
2. To investigate the use of Mcc24-producing bacteria to reduce the level of S. typhimurium 
shedding in swine. 
3. To investigate S. typhimurium resistance development to Mcc24 and the role of the mar 
system in Mcc24 resistance. 
4. To investigate structure/function aspects of the Mcc24 gene and the mechanism of action 
of Mcc24. 
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3* f 
Figure 1. Models of membrane activity for antimicrobial peptides. (A) Barrel stave model. 
(B) Wormhole model. (C) Carpet model (D) In-plane diffusion model. See text for details on 
these models (Reproduced from Bechinger, 1999). 
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Periplasm 
Figure 2. Model for secretion by the type I pathway. Most type I substrates possess a 
carboxy-terminal signal sequence. Exceptions to this include peptides such as bacterocins, 
which instead possess an amino-terminal leader peptide. See text for details (Reproduced 
from Thanassi and Hultgren, 2000) 
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Figure 3. Genetic organization of the mar locus in E. coli. The repressor, MarR, negatively 
controls the expression of marRAB and marC. MarA is the primary activator of the mar 
regulon. MarB and MarC have unknown functions. Genes that respond to MarA include: 
acrAB (a stress-induced efflux pump), micF (antisense RNA controlling OmpF expression), 
mlrl, -2, and -3 (mar locus regulated genes), sip (a carbon starvation- and stationary phase-
inducible lipoprotein), inaA ( a weak acid-inducible geno),fpr (ferredoxin reductase), sodA 
(Mn-containing superoxide dismutase), soi-17,19 (superoxide-inducible genes), zwf (glucose-
6-phosphate dehydrogenase), fumC (fumarase C), and rpsF (small ribosomal protein S6) 
(reproduced from Alekshun and Levy, 1999). 
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CHAPTER 2 
ATTEMPT TO PRODUCE MICROCIN 24 IN LACTIC ACID 
BACTERIA 
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Abstract 
Microcin 24 (Mcc24) is an antimicrobial peptide produced by Escherichia coli with 
activity against Salmonella enterica serotype Typhimurium (S. typhimurium). A double-
glycine-type leader peptide is present on the immature Mcc24 based on the translated 
nucleotide sequence of the structural gene, mtfS. Export of peptides with this type of leader 
peptide is known to be dependent on dedicated transport systems involving ABC (ATP-
binding cassette) secretion proteins. However, replacement of a similar leader peptide in 
colicin V with a general secretion pathway signal peptide from divergicin A led to expression 
of active microcin in lactic acid bacteria. A similar approach was attempted to allow 
expression of Mcc24 in lactic acid bacteria, which could then be used to decrease S. 
typhimurium in the intestine of animals. The nucleotide sequence for the divergicin A signal 
peptide was fused to the nucleotide sequence encoding the mature Mcc24 peptide and cloned 
into a lactic acid bacteria expression vector. Mcc24 RNA transcripts could be recovered from 
lactic acid bacteria, but no Mcc24 activity was observed. Possible causes for the lack of 
Mcc24 activity are discussed. This study indicates a system successfully expressing colicin V 
in lactic acid bacteria did not express microcin 24 under similar conditions. 
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Introduction 
Microcin 24 (Mcc24) is a small antimicrobial peptide produced by a uropathogenic 
strain of Escherichia coli (O'Brien and Mahanty, 1994). Salmonella organisms are sensitive 
to the effects of Mcc24 (O'Brien and Mahanty, 1994; O'Brien, 1996; Wooley et al., 1999; 
Wooley et al., 2001) and chickens fed avirulent Mcc24-producing E. coli shed less S. 
typhimurium after challenge (Wooley et al., 1999). 
Mcc24 is produced by ribosomes, less than lOkDa, heat resistant, and is not SOS 
inducible. Therefore, it meets the criteria established for a microcin and was reclassified from 
colicin 24 to Mcc24 (O'Brien, 1996). A 5.25 kb insert was isolated from a plasmid and 
contained all the genes necessary for production, immunity, and transport (O'Brien, 1996). 
Five genes (mdbA, mtfl, mtfS, mtfA, and mtfB) forming three opérons were characterized 
from the insert (O'Brien, 1996). mtfl and mtfS encode Mcc24 immunity and structural genes, 
respectively, and compose an operon transcribed in the same direction with mtfl overlapping 
mtfS (O'Brien, 1996). The gene products of mtfA and mtfB form a dedicated Mcc24 transport 
system that is homologous to colicin V (ColV) transporters (O'Brien, 1996). MtfB belongs to 
a family of ATP-binding (ABC) bacterial transporters and MtfA has a recognized pattern for 
a membrane fusion protein (MFP) or accessory protein (O'Brien, 1996). TolC, an outer 
membrane protein, is also required for transport (O'Brien, 1996). mdbA appears to be a ex­
acting positive regulatory gene with sequence similarity to histone-like proteins (O'Brien, 
1996). 
Precursor Mcc24 is composed of 103 amino acids of which 15 residues comprise the 
N-terminal leader peptide that is subsequently cleaved to form the mature microcin (O'Brien, 
1996). The leader peptide contains a double-glycine motif characteristic of several microcins 
including ColV and non-lanthionine bacteriocins (Path et al., 1994; Havarstein et al, 1994; 
Klaenhammer, 1993; Lagos et al, 1999; O'Brien, 1996; Rodriguez et al, 1999; Solbiati et 
al, 1999). Replacement of the leader peptide with a Sec-dependent signal sequence from 
divergicin A has resulted in the secretion of active ColV in lactic acid bacteria (LAB) 
(McCormick et al., 1999). Lactobacillus is a lactic acid bacterium which can reduce the 
numbers of Salmonella in swine feces (van Winsen et al. 2002). Additionally Lactobacillus 
acts synergistically with fructooligosaccharide (FOS), a digestive enzyme resistant starch, in 
reducing levels of Enterobacteriaceae in pigs (Nemcova et al. 1999). The goal of this 
experiment is to express Mcc24 from Lactobacillus and use the resultant Mcc24-producing 
Lactobacillus in conjunction with FOS to reduce shedding of S. typhimurium in swine. 
Materials and Methods 
Plasmids, Bacterial strains and media 
Bacterial strains and plasmids used in this study are listed in Table 1. Carnobacteria 
was grown in All Purpose Tween (APT, Difco) broth at 37° C without agitation. 
Lactobacillus was grown in Mann Rogosa Sharpe (MRS, Difco) broth at 37° C without 
agitation. E. coli was grown in Luria-Bertani (LB, Gibco) broth at 37° C on a rotary shaker. 
Agar plates for the above media were made with 1.5% agar (w/v) added. Antibiotics were 
added as needed in the following concentrations: ampicillin (100 jig ml"1), erythromycin (200 
Hg ml"1), kanamycin (64 jug ml"1), and Zeocin (25 pg ml"1) for E. coli, and erythromycin (5 
jag ml"1) for Carnobacteria and Lactobacillus. Stock cultures of the bacterial strains were 
stored in the appropriate broth containing 20% (v/v) glycerol at -70° C. 
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Oligonucleotide primer synthesis and amplification 
All primers used in this study are listed in Table 2. 
Construction of mtfS with Divergicin A leader peptide (Figure 1) 
The plasmid that was to harbor the divergicin A leader was a derivative of pCR-Blunt 
II-TOPO (Invitrogen). The portion of C. divergens containing the divergicin A leader peptide 
(Worobo et al., 1995) was synthesized in two complementary strands (Genemed, San 
Francisco, CA) with the following sequence: 5 '-
CCCGGGTT GGT AT C AC A A ACT AATT GGA G GIT GGT ATAT ATG A AAAAAC AAATT 
TTAAAAGGGTTGGTTATAGTTGTTTGTTTATCTGGGGCAACATTTTTCTCAA 
CACCACAACAAGCTTCTGCT-3'. Features include a 5' Xma I restriction site 
(underlined), the native RBS (italics, bold) and associated nucleotides, and the sequence for 
the divergicin A leader peptide (bold) with 3 ' Hind III restriction site (double underlined). 
The leader sequence was cloned into pCR-Blunt II-TOPO and confirmed by sequencing 
producing pBTLD2. It was then necessary to modify the plasmid in order to facilitate 
subsequent manipulations involving fusion of the mtfS gene. Therefore mutagenesis of the 
Hind III restriction site upstream of the insertion site for the leader sequence was 
accomplished as described in mutagenesis methods section using HindF and HindR as 
forward and reverse primers, respectively. The result was alteration of the Hind III site from 
AAGCTT to AATATT creating pBTLD2a. This was confirmed by sequencing. pBTLD2a 
was subsequently modified by deletion of the Xma I restriction site contain within the Zeocin 
resistance gene. This was accomplished by double digesting using Aat II and Dr a III 
restriction enzymes, which flank the Xma I site, treating with Mung Bean enzyme to remove 
the overhang ends, dilute ligation, and transformation into E. coli TOP 10. The transformants 
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were screened for loss of Zeocin resistance and a single colony picked for DNA isolation. 
The resulting plasmid, pBTLD12, was used as template for ligation of the leader sequence to 
a leaderless mtfS. 
A plasmid containing a leaderless mtfS gene with compatible restriction enzyme sites 
for pBTLDR was constructed using methods similar to those described for ColV 
(McCormick et al. 1999). Amplification of the mtfS gene from pGOBIS lacking the double-
glycine leader peptide was accomplished with the following two PCR primers: Mcc24F (5'-
CCCGGGCCCAAGCTTCTGCTGCTGGAGATCCGCYTG-y) ' and Mcc24R (5'-
CCCGGTACCACTTATCCTTTACTTCCGTTCCATGAG-3 ) using a PCR protocol 
described in PCR methods section. Features of Mcc24F forward primer include a 5 ' Xmal 
restriction site (underlined), the carboxy-terminus of divergicin A leader peptide (italics) with 
the Hindlll restriction site (underlined), and the amino-terminus of the leaderless mtfS gene 
(bold). Features of Mcc24R reverse primer include a Kpnl restriction site (underlined) and 
the carboxy-terminus of the mtfS gene (bold). The PCR product was cloned into pBAD-
TOPO (Invitrogen), transformed into TOP 10 cells and grown on LB agar plus ampicillin. 
Single colonies were picked and screened for the leaderless mtfS gene in pBAD using PCR 
and potential recombinant plasmids sequenced. The resulting plasmid was designated 
pBDMC25. 
Ligation of the divergicin leader to the mtfS gene was attempted by co-digesting 
pBTLD12 and pBDMC25 with Xmal and Hindlll, T4 ligation and transformation into 
TOP 10 cells. Single colonies were picked and screened for the fused construct. After 
repeated attempts to combine the divergicin leader to the mtfS gene, no constructs with the 
correct sequence could be found. It was presumed that this construct was lethal in E. coli 
even at basal levels from the uninduced araBAD promoter on pBAD-TOPO. This is similar 
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to what occurred during the divergicin A-ColV fusion attempt (McCormick et al., 1999). 
However, one isolate was found to harbor the divergicin leader separated from the leaderless 
mtfS gene by a 192 base insert and was designated pBDLIM6. The inserted sequence was 
found to match the sequence adjacent to the cloning site in pCR-Blunt II-TOPO and contain 
a 3"-AAGCCT sequence at the fusion site with mtflS. This appeared to function as a 
secondary Hind III restriction site allowing the divergicin leader and mtfS gene to be 
harbored on the same plasmid. The secondary Hind III was mutagenized as described above 
using IHindF and IHindR as forward and reverse primers, respectively. Subsequently a Kpnl 
site located within the 192-base insert was mutagenized as described above with IKpnF and 
IKpnR as forward and reverse primers, respectively. The resulting plasmid was designated 
pBDLIMl? and was cloned into pMG36e, an LAB expression vector, by co-digestion with 
Xmal and Kpnl and resulted in pMGLIM27. Following Hindlll digestion and T4 ligation 
pMGLIM27 became pMGLM14 and was transformed directly into C. diver gens. Re-isolation 
and sequencing of pMGLM14 from C. diver gens indicated that the divergicin leader had 
successfully been fused in-frame to the mtfS gene. Figure 2 contains the relevant sequence 
results for pMGLM14. 
Polymerase chain reaction (PCR) 
Typical reactions were performed in 0.2 ml tubes with 20 (xl of reaction mix 
containing 300 pM dATP, dTTP, dCTP and dGTP, 2.5 mM magnesium chloride, 4 pmoles 
of each primer, 10 mM Tris-HCl, 50mM KC1, 0.5 units of AmpliTaq Gold (Perkin Elmer, 
Foster City, CA), 100-250 ng bacterial template, and ddH^O. Typically PCR was performed 
in an automated thermocycler with a hot bonnet (Hybaid, Teddington, UK) utilizing the 
following program: one cycle (95° C, 12 min), 40 cycles (denaturation, 94°C, lmin; 
57 
annealing, 40° C, 1min; extension, 72° C, 1.5 min), final extension (60° C, 5 min and 72° C, 
5 min). 
Site-directed mutagenesis 
Mcc24 mutants were produced using the QuikChange™ Site-Directed mutagenesis 
kit (Stratagene). A 50 pi reaction was prepared with 5 |il of lOx reaction buffer, 1 jol dNTP 
mix, 1 gl of each forward and reverse primer containing the mutational site (125 ng/gl), 41 pi 
of ddH]0 and 1 pi of dsDNA template (10 ng/pl). Then 1 (il of Pfu turbo DNA polymerase 
(2.5 U/(j,l) was added and the reaction placed in the thermocycler. PCR was performed in an 
automated thermocycler with a hot bonnet (Hybaid, Teddington, UK) utilizing the following 
program: one cycle (95° C, 30sec), 16 cycles (denaturation, 95°C, lmin; annealing, 55° C, 
lmin; extension, 68° C, 16min). Following the temperature cycling, the reactions were 
cooled and 1 |xl of Dpn I restriction enzyme (10 U/p.1) added and then incubated for 1 hour at 
37° C to digest the parental DNA. A 1 pi sample of the Dpn I treated DNA was 
electroporated into approximately 1010 E. coli MC4100 or E. coli TOPIO cells using 0.2-cm 
cuvettes (BioRad Laboratories, Hercules, CA) at 2.5 kV and 25 jiF (GenePulser, BioRad). 
The cells were plated on LB agar with the appropriate antibiotic. Plasmid DNA was prepared 
from 5 selected colonies for each mutagenesis reaction and submitted for automated 
dideoxynucleotide sequencing. 
Reverse-transcriptase polymerase chain reaction (RT-PCR) 
Preparation of mRNA (QIAGEN) 
Preparation of mRNA for RT-PCR was accomplished using QIAGEN's RNeasy mini 
protocol in combination with QIAGEN's RNase Free DNase free protocol. In summary, 1ml 
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of overnight culture (lx 109 CFU) was harvested by centrifugation (5000 x g, 5min, 4°C). 
Supernatant was removed and the pellet resuspended in lysozyme-containing TE buffer and 
incubated at room temperature. For gram- positive bacteria the lysozyme concentration and 
incubation time was 3mg/ml and 10min, respectively. For gram- negative bacteria the 
lysozyme and incubation time was 400|ig/ml and 5min, respectively. Then 350(d Buffer RLT 
was added to the suspension, vortexed, centrifuged (14,000 rpm, 2min), and supernatant 
removed. This was followed by the addition of 250(11 ethanol (96-100%) and mixing. The 
sample was then applied to the RNeasy mini-spin column and centrifuged (14,000 rpm, 
15sec). The column was washed by adding 350|il Buffer RW1 to the column followed by 
centrifugation (14,000 rpm, 15sec). DNase I incubation mix (DNasel stock 10p.l with 70(4.1 
Buffer RDD) was added to the column, mixed gently, and incubated for lhr. The column was 
washed a second time with 350jo,l Buffer RWland centrifuged (14,000 rpm, 15sec). 
Subsequently 500(xl of Buffer RPE was added to the column, centrifuged (14,000 rpm, 
15sec), and followed by adding a second 500|il of Buffer RPE with centrifugation (14,000 
rpm, 2min). RNA was eluted by adding 30(1.1 of RNase-free water to the column and 
centrifuging (14,000 rpm, lmin). Prior to RT-PCR, RNA fractions were treated with 
restriction endonuclease enzymes to further degrade any residual DNA. 
RT-PCR (QIAGEN) 
Reverse-transcriptase polymerase chain reaction was performed using QIAGEN's 
OneStep RT-PCR kit. This kit contains a reverse-transcriptase in combination with HotStart 
Taq DNA polymerase. After the initial reverse-transcriptase reaction, the reverse-
transcriptase enzyme was inactivated by the activation cycle of the HotStar Taq DNA 
polymerase at 95°. Briefly, 50fil reactions were mixed using the following formula: lOpl 5x 
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QIAGEN OneStep RT-PCR Buffer, 2pi dNTP mix (containing lOmM of each dNTP), lpl 
Primer 1 (50pmol/ pi), lpl Primer (50pmol/ pi), 2pi QIAGEN OneStep RT-PCR Enzyme 
mix, 33pl RNase-free water, and lpl template (100pg-lpg/pl). The order of thermocycler 
conditions included: reverse transcription (30min, 50°C), initial PCR activation (15min, 
95°C), 3-step cycling for 35 cycles ( denaturation lmin, 94°C, annealing lmin, 50-68°C, 
extension lmin, 72°C), final extension (10min, 72°C). As a control, duplicate reactions were 
performed by preheating one of reactions to 95°C for 5min prior to the reverse-transcriptase 
reaction. This inactivated the reverse-transcriptase enzyme and ensured that no DNA 
contamination occurred if no products were found. 
DNA manipulation and cloning techniques 
Small scale plasmid preparation 
Small scale extraction of plasmid DNA from gram- negative bacteria was performed 
using a miniprep kit (Perfectprep, Eppendorf). A l-3ml aliquot of overnight bacterial culture 
was poured into a 1.5 ml microfuge tube and the cells pelleted by centrifugation (12,000rpm, 
2min). The supernatant was aspirated and 100 pi of Solution I (Buffered RNase A solution) 
was added and the pellet resuspended by vigorous vortexing. Then 100 pi of Solution II 
(Alkaline lysis solution) was added and gently mixed by repeated inversion. Then 100 p,l of 
Solution III (Potassium acetate solution) was added and mixed well by repeated inversion. 
The lysate was centrifuged (12,000 rpm, 10 min) and the supernatant transferred to a spin 
column to which 450 pi of DNA Binding Matrix Suspension in guanidine was added. After 
mixing, the column was centrifuged (12,000 rpm, 2 min) and the filtrate removed from the 
collection tube. Then 400 pi of diluted Purification solution (Buffered salt solution) was 
added to the spin column and centrifuged (12,000 rpm, 2 min). The spin column was 
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transferred to a fresh collection tube and 30-50 p.1 65 °C of sterile ddH20 water was added 
and vortexed briefly. The column was centrifuged (12,000 rpm, 2 min) and the eluted DNA 
stored at -20°C. 
Large scale plasmid preparation 
Large scale extraction of plasmid DNA from gram- negative bacteria was performed 
using a maxiprep kit (Maxiprep, Qiagen). A 500ml aliquot of overnight bacterial culture was 
harvested by centrifugation (7000rpm, 5min), and the supernatant removed. The pellet was 
resuspended in 10ml Buffer PI (Buffered RNase solution) by thoroughly pipetting up and 
down. Then 10ml Buffer P2 (Lysis buffer) was added and mixed by gentle inversion. Then 
10ml Buffer P3 was added and mixed thoroughly by inversion. The mixture was transferred 
to a polypropylene tube and centrifuged (17,000 rpm, 30 min, 4°C). The supernatant was 
transferred to a fresh polypropylene tube and centrifuged (17,000 rpm, 15 min, 4°C). The 
supernatant was then transferred to a QIAGEN-tip column previously equilibrated with 
Buffer QBT (Equilibration buffer) and allowed to enter the resin by gravity flow. The 
column was washed twice with 30ml Buffer QC (Wash buffer) and the column transferred to 
a polycarbonate tube. The plasmid DNA was eluted with 15ml Buffer QN (Elution buffer) 
and precipitated with 10.5 ml isopropranolol and centrifugation (17,000 rpm, 30 min, 4°C). 
The resulting pellet was washed with 70% ethanol and allowed to air-dry. The DNA pellet 
was resuspended in 100-500ml of sterile ddL^O water according to pellet size. 
Modified procedure for extraction of plasmid DNA from gram- positive bacteria 
Due to the thick peptidoglycan layer surrounding gram- positive bacteria 
modifications to the plasmid DNA extraction procedure were required. Aliquots were 
obtained from overnight bacterial cultures for either small scale or large scale extraction and 
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centrifuged as described above. The cells were harvested by centrifugation and washed in 
STE buffer (6.7% sucrose; 50nM Tris-HCL, pH 8.0; 1 mM EDTA). The pellets were 
resuspended in a 50:50 combination of lysozyme (Sigma, 10mg/ml final concentration) and 
mutanolysin (Sigma, 0.5U/(il final concentration) in STE and incubated for lhr at 37°C. 100 
|j,l and 2ml of lysozyme-mutanolysin mixture were used for small and large scale 
preparations, respectively. The suspensions were centrifuged and the pellet prepared as 
described above for small or large scale extraction of plasmid DNA from gram- negative 
bacteria. 
Ethanol precipitation of DNA 
1/10 volume of 3M sodium acetate (pH 5.5) was added to the sample followed by 2.5 
volumes of ice cold EtOH (95%). The DNA was pelleted by centrifugation (12,000rpm, 
15min, 4°C) and the supernatant removed. The pellet was resdissolved in appropriate amount 
ofddHzO. 
Restriction digestion of DNA 
Restriction digestions were carried out using the manufacturers' (New England 
Biolabs) recommended conditions and buffers. Typically the reactions were carried out in 20 
|il volumes and incubated for 4 hours or overnight. For double digestions, the most suitable 
buffer for the two enzymes was used. Mung Bean (New England Biolabs) digestion was 
carried out at 30°C for 30 min. 
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Ligation of DNA 
Typical ligations were performed following ethanol precipitation of DNA using T4 
ligase in a total volume of 20 jxl. This included 2 (il lOx T4 ligase buffer, 1 (il T4 ligase, and 
17 |xl sterile ddHaO. The reaction was incubated overnight at 14°C. 
Gel electrophoresis 
Agarose dissolved in lx TAB buffer was used for electrophoresis. The agarose 
(Perkin Elmer) content varied between 0.6-1.5% depending on the size of the fragment of 
interest. Ethidium bromide-stained DNA bands were visualized on a UV transilluminator 
using the BioRad GelDoc System. 
PCR purification 
PCR products to be sequenced were purified beforehand using the Wizard® PCR 
Preps DNA Purification System (Promega, Madison, WI). A 200 pi aliquot of completed 
PCR amplification was added to 1 ml of resin (supplied by kit) and vortexed briefly. The 
resin/DNA mix was pushed through a mini-column attached to a syringe. The mini-column 
was then washed with 2 ml of 80% isopropanol and centrifuged (10,000 x g, 2 min) to dry. 
The DNA was eluted with 50 pi of water and centrifugation (10,00 x g, 20 sec). 
Transformation 
Preparation of competent gram-negative bacterial cells 
An exponential culture of E. coli MC4100 was grown in 100ml of LB broth from an 
overnight culture after inoculation (1:100). The culture was shaken at 37°C until cells 
reached an O.D.eoo of 0.4-0.5. The culture was divided into two 50ml aliquots and 
centrifuged (7000rpm, 5min, 4°C), supernatant removed, and resuspended in 100ml cold, 
sterile, nanopure water. The washing procedure was repeated twice in Vi volume of water. 
The final pellet was resuspended in lOOpl aliquots of 40% sterile glycerol and water, which 
were either used immediately or frozen at -70°C. 
Preparation of competent gram-positive bacterial cells (Walker et al., 1996; Worobo et 
al., 1995) 
C. divergens was transferred from -70° C stock cultures to APT, incubated overnight, 
and transferred to fresh APT with 1% glycine and incubated again overnight. A 1% inoculum 
was then made to 200 ml of APT with 1% glycine and the cells propagated to an OD590 of 
0.25-0.30. The cells were placed on ice for 5 min and centrifuged (6,000 x g, 5 min, 4°C). 
The pellet was held on ice and washed twice with cold electroporation buffer (0.5M sucrose, 
2.5 mM CaCli pH 7.0). The pellet was resuspended in 1.6-ml cold electroporation buffer, 
divided into 800 pi aliquots and kept on ice. If not used immediately the cells were frozen at -
70°C in 20% sterile glycerol and water. 
Chemical transformation of gram-negative bacterial cells 
Typically approximately 100-200ng of plasmid DNA was added to thawed competent 
cells and gently mixed in a 0.5ml microfuge tube. After incubation on ice for 30min, the 
mixture was placed in a water bath at 42°C for 30sec and then placed on ice for 2min. 250pl 
of SOC media was then added to the tube and the mixture incubated for 1 hour at 37° C with 
vigorous shaking. The mixture was then plated on LB plus the appropriate antibiotic(s). 
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Electroporation of gram-negative bacterial cells 
Sterile electroporation cuvettes (0.2cm gap) were chilled on ice and approximately 
lOOng of plasmid DNA added to thawed, competent cells (1010 bacteria) and the mixture left 
on ice for one minute. The mixture was transferred to the cuvette and electropulsed once at 
25jj,F, 2.5kV, 200Q (BioRad Laboratories, Hercules, CA,). A 250(4,1 aliquot of SOC media 
was immediately added to the sample and the suspension transferred to 0.5ml tube and 
incubated for 1 hour at 37°C with vigorous shaking. The suspension was then plated onto 
appropriate media plus antibiotic. 
Electroporation of gram-positive bacterial cells (Luchansky et al., 1988) 
Transformation was accomplished by mixing 5-10 pg of plasmid DNA with 800 pi of 
electrocompetent cells in a chilled cuvette (0.4-cm electrode gap). After 5 min on ice, the 
suspension was electroporated at 2.5 kV, 200 Q and 25 /uF (GenePulser™, Biorad 
Laboratories, Hercules, CA). The cuvette was placed on ice for 5 min and then transferred to 
5 ml of recovery medium (APT broth containing 0.5 M sucrose and 10.0 mM CaCh), 
incubated without shaking at 37° C for 3 hours, and plated on APT agar containing 
erythromycin. 
Microcin extraction, concentration and detection of activity 
Protein extraction of Mcc24 
Extraction of soluble proteins was accomplished using a detergent formulation in Y-
PER™ Yeast Protein Extraction Reagent (Pierce, Rockford, IL), which is also suitable for E. 
coli and gram-positive bacteria. An overnight culture of bacteria was pelleted by 
centrifugation (3000 x g, 5 min, 4° C). The pellet was resuspended in the appropriate amount 
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of Y-PER™ into a homogeneous mixture. The mixture was agitated for 20 minutes at room 
temperature and then centrifuged (13,000 xg, 10 min, room temperature) to remove the cell 
debris. The lysate was collected and checked for Mcc24 activity. 
TCA concentration (Fath et al., 1994) 
Microcin producing strains were grown overnight under appropriate conditions as 
described above. The cultures were centrifuged (6000 x g for 5 min) and the supernatant or 
lysate were filtered sterilized (0.45 pm). Trichloroacetic acid (TCA) was added at 10% (v/v). 
The mixture was held on ice for 45 min and centrifuged (30,000 x g for 15 min). The 
supernatant was discarded and the pellet reconstituted with 3.5M Tris base (pH 9.5) at 1/250 
of the original volume. 
Co-culture test 
LB plates were flooded with indicator strain (approximately 2 x 108 bacteria) in broth 
and allowed to absorb the liquid (2-5 min). Sterile blank discs (Bacto concentration discs, 
sterile blanks, DIFCO) were placed on the plate surface and soaked with tester strain or 
Mcc24-containing extract (10-15 pi). The plates were incubated overnight (18-24 hours) and 
observed for zones of inhibition. 
Overlay test 
The tester strain was inoculated onto APT or LB plates and grown overnight under 
appropriate conditions as described above. A 5ml aliquot of molten 0.6% LB agar inoculated 
with an overnight culture of an indicator strain (500pi) was overlayed and incubated 
overnight. 
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Results 
Mcc24 in lactic acid bacteria 
To test the potential of using Lactobacillus for the expression of Mcc24, we 
introduced an expression vector harboring mtfS (Mcc24 production) devoid of its natural 
leader peptide but fused to a sec leader signal into Carnobacterium. C. divergens containing 
pMGLM1414 were tested for activity by spotting on APT agar containing erythromycin, 
allowing overnight growth and then overlaying a microcin sensitive strain of E. coli (TOP 10 
or MC4100) in soft LB agar (0.6%). No zone of inhibition was observed using this method. 
Alternatively, C. divergens containing pMGLM14 were grown in APT broth to stationary 
phase and the supernatant harvested and concentrated with TCA as described above. This 
concentrated supernatant was tested for Mcc24 activity by soaking a sterile disc on a plate 
with a lawn of sensitive E. coli (TOP 10). Additionally, soluble proteins were extracted from 
a pellet derived from an overnight growth of C. divergens containing pMGLM14. The extract 
was tested with and without TCA concentration. No zone of inhibition could be detected by 
any of these methods. Additionally no differences in growth characteristics were observed 
between strains of C. divergens harboring pMGLM14 or pMG36e. RT-PCR of 
Carnobacterium containing pMGLM14 did produce bands of correct size for the mtfS gene, 
indicating RNA transcript production from the mtfS containing plasmid as shown in Figure 3. 
Discussion 
Previously, active ColV was produced from lactic acid bacteria by replacing the 
double-glycine leader peptide with the sec-leader from divergicin A (McCormick et al., 
1999). In this study using similar methods with Mcc24, no active microcin was detected. 
However, using primers specific for mtfS, RT-PCR was able to amplify RNA products from a 
67 
transformed strain of C. divergens. This indicates that transcription of the Mcc24 gene did 
occur in C. divergens. There are several possibilities why active Mcc24 was not produced or 
could not be detected. 
The first possibility is an inadequate level of production of Mcc24. Earlier work 
suggests that Mcc24 needs to achieve a threshold level of production in order to be active. 
When E. coli ZK762, a strain carrying the plasmid copy number reducing mutation pcnB 
(Lopilato et al., 1986), was used as the host for pGOBIS, negligible activity of Mcc24was 
observed (O'Brien, 1996). This indicates the Mcc24 activity threshold was not reached and is 
due to the reduction in pGOBIS. The vector used in this present study, pMG36e, contains the 
origin of replication derived from pWVOl (van de Guchte et al., 1989) and is estimated to 
have a copy number of 3 to 5 in gram-positive bacteria such as Streptococcus lactis and 
Bacillus subtilis (Kok et al., 1984). Additionally, the P32 promoter in pMG36e differs in two 
nucleotides from the hexanucleotide consensus promoter in E. coli and B. subtilis and this is 
thought to explain the decreased cat-86 gene expression when compared to similar promoters 
(van der Vossen et al., 1987). Thus, it is possible that even though a pMG36e-derived 
plasmid could produce sufficient ColV for antimicrobial activity, under similar conditions 
Mcc24 production levels were not adequate to detect E. coli growth inhibition. 
The second possibility is incorrect processing of pre-Mcc24. Although Mcc24 is 
considered to be grouped with microcins that do not undergo post-translational modifications 
(Pons et al., 2002a) and it is considered to be a relative of MccE492 which has been shown to 
be an unmodified peptide (Pons et al., 2002b), it is possible that Mcc24 requires modified 
amino acids for activity. If this were true, Mcc24 may require genes not present on 
pMGLM14 or in C. divergens in order to become fully functional. Additionally, although 
MccE492 is considered to be unmodified it has been shown that accessory genes are thought 
to be involved in conformation maturation of MccE492 (Lagos et al., 2001). In the absence 
of these gene products, inactive forms of the microcin are secreted. This is an apparent 
difference with the ColV system where microcin activity was detected in lysates recovered 
from E. coli strains harboring a plasmid with only cvaC (ColV production gene) (Zhang et 
al., 1995). The opposing possibility that Mcc24 was unnecessarily modified in the C. 
divergens environment also exists. 
The third possibility is lack of Mcc24 secretion. Although replacement of the double-
glycine leader with a sec-pathway leader resulted in the secretion from lactic acid bacteria for 
ColV (McCormick el al., 1999) and camobacteriocin B2 (McCormick et al., 1996), this may 
not be true for Mcc24. Mesentericin Y105 with the divergicin A leader was detected when 
heterologously expressed in strains of Leuconostoc, but not in Lactococcal strains (Biet et al., 
1998). This demonstrated the importance of LAB host in heterologous bacteriocin 
expression. It was postulated that the difference in expression was due to either peptide 
degradation or trapping in the different bacterial systems (Biet et al., 1998). These 
explanations could certainly have been involved in the lack of Mcc24 expression in this study 
as well. 
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Table 1. Plasmids and bacterial strains used in this study. 
Plasmids or 
Bacterial 
Strain 
Relevant Features Source 
pBAD-TOPO Expression vector under AraBAD inducible promoter; AmpR Invitrogen 
pBDLIMl? 
555 bp fragment on pBAD TOPO containing dvn leader and 
leaderless mtfS separated by 192 bp insert, double Hind III 
sites, Kpn I site absent 
This study 
pBDLIM6 
555 bp fragment on pBAD TOPO containing dvn, leader and 
l e a d e r l e s s  m t f S  s e p a r a t e d  b y  1 9 2  b p  i n s e r t ,  s i n g l e  H i n d  I I I  
site, Kpn I site present 
This study 
pBDMC25 pBAD-TOPO containing leaderless mtfS, structural gene for Mcc24 This study 
pBTLD12 pCR-Bluntll-TOPO containing dvn leader with Hind III and Xma I modifications This study 
pBTLD2 pCR-Bluntll-TOPO containing dvn leader This study 
pCR-Blunt II-
TOPO Expression vector under Plac promoter; KnR; ZeoR; 3.5 kb Invitrogen 
pGOBIS 5.25 kb Sau2Al fragment in pBR322 with mtfl, mtfS, mtfA, 
mtfB & mdbA; AmpR; 9.8 kb O'Brien, 1996 
pMG36e Expression vector under P32 promoter; EmR; 3.6 kb Kok et al., 1984 
pMGLIM27 
555 bp fragment on pMG36e containing dvn leader and 
leaderless mtfS separated by 192 bp double Hind III insert; 
EmR; 3.6 kb 
This study 
pMGLM14 355 bp fragment containing dvn leader and leaderless mtfS; EmR; 3.6 kb This study 
E. coli MC4100 F~ ara DI39 A (lacl PO ZYA-argF), U169 rpsL thi recA-56 
Casadaban, 1976 
Escherichia coli 
TOP 10 
F~ mcrA A(mrr-hsdRMS-merBC) 080/acZ,AM 15 AlacX74 
recAl deoR araD139,A(ara-leu)7697 galU galK rpsL (StrR) 
endAl nupG 
Invitrogen 
Carnobacterium 
divergens LV13 Contains pCD3.4, dvn, dvi, resistant to microcin 24 
NCIMB (National 
Collection of Industrial 
and Marine Bacteria, 
Aberdeen, UK) 
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Table 2. Primers and oligonucleotides used in this study. 
Primer 
ID Sequence Used for Source 
24GeneF GCTGGAGATCCGCTTGCAGAT sequencing ISU 
24GeneR TTATCCTTTACTTCCGTTCCA sequencing ISU 
HINDF 
AATACTCAAGCTATGCATCAATATTGGTACCGAGCT 
CGGA mutagenesis IDT 
HINDR 
TCCGAGCTCGGTACCAATATTGATGCATAGCTTGAG 
TATT mutagenesis IDT 
IHINF CATAAAGTGTAAAGCTTCTGCTGCTGGAGAT mutagenesis ISU 
IHINR ATCTCCAGCAGCAGAAGCTTTACACTTTATG mutagenesis ISU 
IKNPR CTATGCATCAATATTTGTACCGAGCTCGGTA mutagenesis ISU 
IKPNF ATCCGAGCTCGGTACAAATATTGATGCATAG mutagenesis ISU 
IMMF ATGAGTTTTCTTAATTTTGCA PCR cloning ISU 
IMMR TCATATACATCTCCTGTATAA PCR cloning ISU 
LDRF CCCGGGTTGCTATCACAAACT sequencing Genemed 
LDRR ACGAGAAGCTTGTTGTCCTCT sequencing Genemed 
MCC24F CCCGGGCCCAAGCTTCTGCTGCTGGAGATCCGCTTG PCR cloning ISU 
MCC24R CCCGGTACCACTTATCCTTTACTTCCGTTCCATGAG PCR cloning ISU 
MCC24Ra GGTACCACTTATCCTTTACTT sequencing ISU 
MG36F CACAAAATGCTATACTAGGTAGGT sequencing ISU 
MG36Fa CGGTTACTTTGGATTTTTGTG sequencing ISU 
MG36R GTCAGCTGCCTAAGCAAGGTT sequencing ISU 
PBADF ATGCCATAGCATTTTTATC sequencing ISU 
PBADR GATTTAATCTGTATCAGG sequencing ISU 
Leader 
CCCGGGTTGGTATCACAAACTAATTGGAGGTTGGTA 
TATATGAAAAAACAAATTTTAAAAGGGTTGGTTAT 
AGTTGTTTGTTTATCTGGGGCAACATTTTTCTCAAC 
ACCACAACAAGCTTCTGCT 
Fusion of leader 
signal to mtfS Genemed 
Leader 
Comp 
AGCAGAAGCTTGTTGTGGTGTTGAGAAAAATGTTGT 
CCC AG AT A A AC AAAC A ACT AT A ACC A ACCCTTTTA 
AAATTTGTTTTTTCATATATACCAACCTCCAATTAGT 
TGGTGATACCAACCCGGG 
Complement to 
Leader Genemed 
Xma I Hind III 
leaderless mtfS PCR 
product from PG0B18 
pBAD- TOPO with 
leaderless mtfS 
pBAD-TOPO 
pBDMC25 
/ PMGLM14 % 
t 
Digest with Hind III 
^Transform into 
LAB 
dvn leader and mtfS 
separated by 192 
bp fragment 
on pMG36e PMGLIM27 pMG36e 
Co-digest with 
Xma I and Hind III 
Co-digest with 
Xma I and Kpn I 
\ 
pCR-Blunt I 
TOPO 
with dvn / \ 
leader I pBTLD12 I 
(modified) X J 
Xma I deletion 
in Zeocin gene 
Hind III 
PBDLIM6 Hind III 
mutagenesis 
Kpn I 
mutagenesis O dvn leader and mtfS separated by 192 bp fragment on pBAD-TOPO (modified) 
dvn leader and mtfS 
separated by 192 bp fragment 
on pBAD-TOPO 
Hind III Xma I 
pBTLD2a 
dvn leader signal 
(synthesized) 
Hind III 
mutagenesis 
PBTLD2 
pCR-Blunt II 
TOPO pCR-Blunt ll-TOPO 
with dvn leader 
pCR-Blunt ll-TOPO 
with dvn leader 
Figure 1. Cloning strategy for the construction of pMGLMH. See text for details 
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Xma I 
5 ' GTTTCAGCAGAAAAATTCGTAATTCGAGCTCCCCCGGGTTGGTATCACAAACT 
RBS 
AATTTGGAGGTTGGTATAT AT G AAA AAA CAA ATT TTA AAA GGG TTG GTT ATA GTT GTT 
M K K Q I  L K G L V I V V  
Divergicin A signal peptide 
HindiII 
TGT TTA TCT GGG GCA ACA TTT TTC TCA ACA CCA CAACAA GCT TCT GCT GCT GGA 
C L S G A T F F S T P Q Q A S R î  |A Gl 
GAT CCG CTT GCA GAT CCT AAT TCC CAA ATT GTA AGA CAG ATA AT G 
1 
TCT AAT GCG 
|D P L A D P N S Q I V R Q I M S N a| 
GCA TGG GGC GCC GCC TTT GGT GCC AGA GGC GGT TTA GGG GGA AT G GCT GTT GGA 
K W G A A F G A R G G L G G M A V G| 
GCC GCA GGT GGG GTT ACG CAG ACA GTT CTT CAA GGA GCA GCA GCT CAT ATG CCG 
K A G G V T Q T V L Q G A A A H M P 
GTT AAT GTC CCT ATA CCT AAA GTT CCG AT G GGA CCC TCA TGG AAC GGA AGT AAA 
N V P I P K V P M G p S W N G S 
Kpn I 
GGA TAA GTGGTACCCCGGCGCTACGATATTTGGAGTTGAGGTTCAAAGTCmAT 3 ' 
|G *| 
Figure 2. Nucleotide and amino acid sequences of the divergicin A signal peptide fused to the 
product of the structural gene of microcin 24 (Mcc24) devoid of its natural leader peptide 
using methods similar to divergicin A-ColV fusion (McCormick et al. 1999). The sequence 
for mature Mcc24 is boxed. The location of the forward primer (Mcc24F) used for PCR and 
the Hind III restriction enzyme site are shown and signal peptide cleavage site is marked (Î). 
RBS, ribosome binding site. 
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Figure 3. Agarose gel electrophoresis of amplicons observed following RT-PCR for mtfS 
transcripts in C. divergens LV17 and C. divergens LV17 harboring pMGLMH. Lanes 
designated as "M" or "m" represent 100 or 50 bp, respectively, molecular size standards 
(GIBCO BRL). Lane 1 represents C. divergens LV17 devoid of pMGLMH. Lanes 2 
represents C. divergens LV17 devoid of pMGLMH and initially heated to inactivate the 
reverse-transcriptase. Lane 3 represents C. divergens LV17 harboring pMGLMH. Lane 4 
represents C. divergens LV17 harboring pMGLMH and initially heated to inactivate the 
reverse-transcriptase. Lane 5 represents a no template reaction. Specific molecular size 
standards and amplicon sizes (bp) are indicated on both sides. 
74 
References 
Biet, F., J. M. Berjeaud, R. W. Worobo, Y. Cenatiempo, and C. Fremaux. 1998. 
Heterologous expression of the bacteriocin mesentericin Y105 using the dedicated 
transport system and the general secretion pathway. Microbiology 144 ( Pt 10):2845-
54. 
Casadaban, M. J. 1976. Transposition and fusion of the lac genes to selected promoters in 
Escherichia coli using bacteriophage lambda and Mu. J Mol Biol 104:541-55. 
Fath, M. J., L. H. Zhang, J. Rush, and R. Kolter. 1994. Purification and characterization of 
colicin V from Escherichia coli culture supernatants. Biochemistry 33:6911-7. 
Havarstein, L. S., H. Holo, and I. F. Nes. 1994. The leader peptide of colicin V shares 
consensus sequences with leader peptides that are common among peptide 
bacteriocins produced by gram- positive bacteria. Microbiology 140 ( Pt 9):2383-9. 
Klaenhammer, T. R. 1993. Genetics of bacteriocins produced by lactic acid bacteria. FEMS 
Microbiol Rev 12:39-85. 
Kok, J., J. M. van der Vossen, and G. Venema. 1984. Construction of plasmid cloning 
vectors for lactic streptococci which also replicate in Bacillus subtilis and Escherichia 
coli. Appl Environ Microbiol 48:726-31. 
Lagos, R., M. Baeza, G. Corsini, C. Hetz, E. Strahsburger, J. A. Castillo, C. Vergara, and O. 
Monasterio. 2001. Structure, organization and characterization of the gene cluster 
involved in the production of microcin E492, a channel-forming bacteriocin. Mol 
Microbiol 42:229-43. 
Lagos, R., J. E. Villanueva, and O. Monasterio. 1999. Identification and properties of the 
genes encoding microcin E492 and its immunity protein. J Bacteriol 181:212-7. 
Lopilato, J., S. Bortner, and J. Beckwith. 1986. Mutations in a new chromosomal gene of 
Escherichia coli K-12, pcnB, reduce plasmid copy number of pBR322 and its 
derivatives. Mol Gen Genet 205:285-90. 
Luchansky, J. B., P. M. Muriana, and T. R. Klaenhammer. 1988. Application of 
electroporation for transfer of plasmid DNA to Lactobacillus, Lactococcus, 
Leuconostoc, Listeria, Pediococcus, Bacillus, Staphylococcus, Enterococcus and 
Propionibacterium. Mol Microbiol 2:637-46. 
McCormick, J. K., T. R. Klaenhammer, and M. E. Stiles. 1999. Colicin V can be produced 
by lactic acid bacteria. Lett Appl Microbiol 29:37-41. 
75 
McCormick, J. K., R. W. Worobo, and M. E. Stiles. 1996. Expression of the antimicrobial 
peptide carnobacteriocin B2 by a signal peptide-dependent general secretory pathway. 
Appl Environ Microbiol 62:4095-9. 
Nemcova, R., Bomba, A., Gancarcikova, S., Herich, R., and Guba, P. 1999. Study of the 
effect of Lactobacillus paracasei and fructooligosaccharides on the faecal microflora 
in weanling piglets. Berl Munch Tierarztl Wochenschr. 112:225-8. 
O'Brien, G. J. and H. K. Mahanty. 1994. Colicin 24, a new plasmid-bome colicin from a 
uropathogenic strain of Escherichia coli. Plasmid 31:288-96. 
O'Brien, G. Molecular analysis of microcin 24: genetics, secretion, and mode of action of a 
novel microcin. 1996. Canterbury, NZ, University of Canterbury. 
Pons, A. M., I. Lanneluc, G. Cottenceau, and S. Sable. 2002a. New developments in non-post 
translationally modified microcins. Biochimie 84:531-7. 
Pons, A. M., N. Zom, D. Vignon, F. Delalande, A. Van Dorsselaer, and G. Cottenceau. 
2002b. Microcin E492 is an unmodified peptide related in structure to colicin V. 
Antimicrob Agents Chemother 46:229-30. 
Rodriguez, E., C. Gaggero, and M. Lavina. 1999. The structural gene for microcin H47 
encodes a peptide precursor with antibiotic activity. Antimicrob Agents Chemother 
43:2176-82. 
Solbiati, J. O., M. Ciaccio, R. N. Farias, J. E. Gonzalez-Pastor, F. Moreno, and R. A. 
Salomon. 1999. Sequence analysis of the four plasmid genes required to produce the 
circular peptide antibiotic microcin J25. J Bacteriol 181:2659-62. 
van de Guchte, M., J. M. van der Vossen, J. Kok, and G. Venema. 1989. Construction of a 
lactococcal expression vector: expression of hen egg white lysozyme in Lactococcus 
lactis subsp. lactis. Appl Environ Microbiol 55:224-8. 
van der Vossen, J. M., D. van der Lelie, and G. Venema. 1987. Isolation and characterization 
of Streptococcus cremoris Wg2-specific promoters. Appl Environ Microbiol 
53:2452-7. 
van Winsen R.L., Keuzenkamp D., Urlings B.A., Lipman L.J., Snijders J.A., Verheijden J.H., 
and van Knapen F. 2002. Effect of fermented feed on shedding of Enterobacteriaceae 
by fattening pigs. Vet Microbiol 87:267-76. 
Walker, D. C., K. Aoyama, and T. R. Klaenhammer. 1996. Electrotransformation of 
lactobacillus acidophilus group Al. FEMS Microbiol Lett 138:233-7. 
Wooley, R. E., P. S. Gibbs, and E. B. Shotts Jr. 1999. Inhibition of Salmonella typhimurium 
in the chicken intestinal tract by a transformed avirulent avian Escherichia coli. 
Avian Dis 43:245-50. 
76 
Wooley, R. E., B. W. Ritchie, M. F. Currin, S. W. Chitwood, S. Sanchez, M. M. Crane, and 
N. Lamberski. 2001. In vitro inhibition of Salmonella organisms isolated from 
reptiles by an inactivated culture of microcin-producing Escherichia coli. Am J Vet 
Res 62:1399-401. 
Worobo, R. W., M. J. Van Belkum, M. Sailer, K. L. Roy, J. C. Vederas, and M. E. Stiles. 
1995. A signal peptide secretion-dependent bacteriocin from Carnobacterium 
divergens. J Bacteriol 177:3143-9. 
Zhang, L. H., M. J. Fath, H. K. Mahanty, P. C. Tai, and R. Kolter. 1995. Genetic analysis of 
the colicin V secretion pathway. Genetics 141:25-32. 
77 
CHAPTER 3 
ANTIBIOTIC RESISTANCE IN SALMONELLA ENTERICA 
SEROTYPE TYPHIMURIUM EXPOSED TO MICROCIN-24 
PRODUCING ESCHERICHIA COLI 
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Medicine Iowa State University, Ames, IA 50010. 2Preharvest Food Safety and Enteric 
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Service, Ames, IA 50010. 
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Abstract 
Microcins are antimicrobial peptides that are produced by some enterobacteria and 
affect gram-negative bacteria. The mar phenotype is mediated by an efflux mechanism under 
the control of the mar operon. Repression of the mar operon is mediated by MarR, a DNA-
binding protein that prevents the expression of efflux proteins. The objective of our study 
was to evaluate the induction of microcin 24 (Mcc24) resistance in Salmonella enterica 
serotype Typhimurium (S. typhimurium). A lawn of S. typhimurium was plated along with a 
filter disc soaked with a known amount of a Mcc24-producing strain of E. coli and a zone of 
growth inhibition was observed. The S. typhimurium strain used was transformed with two 
plasmids. One plasmid contained the marR gene under the control of an arabinose inducible 
promoter. The other plasmid contained the cyan mutant of green fluorescence protein (GFP). 
The former plasmid was included in order to evaluate the role of the mar operon in Mcc24 
resistance development in S. typhimurium, while the latter was included in order to visually 
distinguish S. typhimurium from E. coli. Salicylate, a known inhibitor of MarR, was used to 
evaluate initial inhibition by Mcc24. Repeated selection of S. typhimurium colonies that 
bordered the zone of inhibition were expanded and replated in the presence of Mcc24-
producing E. coli until a resistant phenotype was selected. The initial zone of Mcc24 
inhibition could be reversed with salicylate. The border colonies became resistant after 18 
expansions and replatings. This resistance could be abolished by adding arabinose to the 
system presumably leading to an overexpression of the episomal marR and repression of the 
mar phenotype. Increased resistance to ciprofloxacin, tetracycline, chloramphenicol, and 
rifampin paralleled the development of resistance to Mcc24. This study indicates that S. 
typhimurium can develop resistance to an E. coli-derived microcin. 
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Introduction 
Microcins are antimicrobial peptides produced by bacteria in the family 
Enterobacteriaceae, primarily Escherichia coli, and inhibit the growth of related bacteria 
(Baquero et al., 1978). Their role is thought to be to gain a competitive advantage in 
microbial growth restrictive environments. Microcin 24 (Mcc24) was isolated from a 
uropathogenic strain of E. coli and has been shown to have anti-Salmonella activity (O'Brien 
and Mahanty, 1994). Expression of Mcc24 in an avirulent strain of avian E. coli led to 
inhibition of Salmonella enterica serotype Typhimurium (ST) in chicken intestinal tracts 
(Wooley et al., 1999). Later Mcc24 from this same strain of E. coli demonstrated strong 
inhibition against 44 of 57 reptilian strains of Salmonella in vitro (Wooley et al., 2001). It 
was suggested by these studies that Mcc24 may be used to competitively exclude Salmonella 
and it may provide an alternative to antibiotic use. 
Microorganisms have the ability to resist the effects of antimicrobial agents or drugs 
through a variety of mechanisms. Resistance may come in the form of genes or mutations, 
which alter the target of the drug, alter the drug itself, induce overproduction of the target, or 
extrude the drug from the microorganism (Walsh, 2000). These resistance mechanisms may 
be acquired, a result of mutations in existing genes or genetic exchange between 
microorganisms, or intrinsic, requiring only the activation of existing genes (Salyers and 
Amabile-Cuevas, 1997). 
In 1983, George and Levy (1983) described a chromosomal Multiple Antibiotic 
Resistance (MAR) system in E. coli that could be selected by a single drug (e.g., 
chloramphenicol or tetracycline) but conferred resistance to unrelated compounds such as (3-
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lactams, nalidixic acid and rifampin. A similar locus was later identified in Salmonella 
typhimurium (Cohen et al., 1993b). With some exceptions the level of resistance achieved 
with mar activation would still be treatable in a clinical setting (Alekshun and Levy, 1999). 
However, it has been proposed that the mar locus may be an important "stepping stone" to 
higher levels of resistance resulting from subsequent mutations elsewhere on the 
chromosome (Alekshun and Levy, 1997). 
Because Mcc24 may be a useful alternative to antibiotics for reduced shedding of 
Salmonella in animals, we elected to investigate the ability of ST to develop resistance to 
Mcc24. Additionally we evaluated how the development of Mcc24 resistance related to 
resistance to antibiotics and activation of the mar system. 
Materials and Methods 
Bacterial strains and plasmids 
Refer to Table 1. 
Development of GFP indicator plasmid 
Initial screening for fluorescence in Salmonella was performed by transforming GFP 
vectors (Living Colors®, pEGFP, pECFP, pEYFP; ampicillin resistance; Clontech 
Laboratories, Palo Alto, CA, USA) into electrocompetent ST LB5000, a restriction 
negative/modification positive strain of Salmonella (Allan et al, 1995). Electrocompetent 
bacteria were derived by washing and resuspending bacterial pellets three times in water. 
Bacterial pellets were then resuspended in 40% glycerol. During electroporation 
approximately 1010 bacteria along with and 0.1 |_ig plasmid DNA was placed into 0.2-cm 
cuvettes (BioRad Laboratories, Hercules, CA, USA). Electroporation was performed at 2.5 
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kV and 25 (J.F. Transformed ST LB5000 were plated on Lennox L (Life Technologies, 
Rockville, MD, USA) agar plates containing 100 ng/mL ampicillin. Based on a comparison 
in E. coli HB101 transformed with a GFP or GFP-like vector, expression of ECFP was found 
most conducive for standard UV light visualization in Salmonella. ECFP is a cyan emission 
mutant of GFP with excitation and emission spectra of 433 and 475 nm, respectively. 
Expression of ECFP in a Zeocin™-containing vector, pCR-Blunt II-TOPO 
(Invitrogen, Carlsbad, CA, USA) was performed after determining that insertless pCR-Blunt 
II-TOPO did not exhibit any inhibition against Salmonella. Using BamHl and Noll sites in 
the multiple cloning sites of each vector, the ECFP gene was transferred into pCR-Blunt II-
TOPO creating pBluntECFP. Specifically, both vectors were digested for 4 h in a single 20 
(j.1 reaction. DNA was precipitated by adding 0.1 volumes of 3 M sodium acetate (pH 5.5) 
and 2.5 volumes of 95% ethanol and then centrifuged at 15,000 rpm for 15 min at 4°C. 
Ligation of DNA was performed using T4 DNA ligase (New England Biolabs, Beverly, MA, 
USA) at 14°C for 4 h. Transformants were plated on low-salt Lennox L agar plates 
containing 25 (xg/mL Zeocin as per the manufacturer's protocol. A single colony was 
selected and amplified in 100 mL Lennox L broth containing 25 gg/mL Zeocin. Plasmid 
DNA from ST LB5000 with pECFP was prepared using the EndoFree™ plasmid prep kit 
(Qiagen, Valencia, CA, USA). 
Phenotypic evaluations of pBluntECFP in strains of ST revealed that the inclusion 
pBluntECFP had no effect on growth curves, invasion, or Zeocin-independent antibiograms 
while fluorescence was maintained in these assays. Fluorescence was maintained for up to 50 
propagations (0.1% subculturing followed by overnight propagation) under nonselective 
conditions. Exposure to 16 different antibiotics had no effect on expression of ECFP. 
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Construction of Salmonella indicator strain 
A plasmid containing the marR gene was prepared by amplifying the gene in S. 
typhimurium SL1344 and ligating it into pBAD-TOPO, a high copy plasmid with the pBMl 
replicon (Invitrogen, ampicillin resistance). The expression of marR in pBAD is under the 
control of the arabinose inducible promoter araBAD. marR was amplified with 5'-
ATGAAAAGCACCAGTGATCTGTTC-3' and 5'-
CCTACGGCAGATTTTTCTTGAGCAA-3 ' as forward and reverse primers, respectively. 
PCR was performed in an automated thermocycler with a hot bonnet (Hybaid, Teddington, 
UK). Reactions were performed in 0.2 ml tubes with 20 pi of reaction mix containing 300 
dATP, dTTP, dCTP and dGTP, 2.5 mM magnesium chloride, 4 pmoles of each primer, 
10 mM Tris-HCl, 50mM KC1, 0.5 units of AmpliTaq Gold (Perkin Elmer, Foster City, CA) 
and bacterial template. Cloning the PCR product into pBAD-TOPO was performed as per the 
manufacturers protocol and resulted in pBAD-TOPO/marR. Single transformed ST LB500 
colonies from Lennox L agar plates containing 100 pg/mL ampicillin were selected and 
amplified in 100 ml Lennox L broth containing 100 pg/mL ampicillin 
S. typhimurium SL1344 was co-transformed with pBAD-TOPO/mar/? and 
pBluntECFP and selected on Lennox L agar containing 100 |xg/ml ampicillin and 64 (J-g/ml 
kanamycin thus producing SL1344/CFP/marR. Preparation of electrocompetent bacteria and 
transformation protocol was performed as described above. The SL1344 co-transformants 
were designated SL 1344/CFP/marR and conveyed kanamycin resistance and fluorescence 
from the genes on pCR-Blunt II-TOPO and ampicillin resistance and arabinose inducible 
marR expression from genes on pBAD-TOPO. 
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Microcin 24-specific resistance 
SL 1344/CFP/marR was grown in the presence of a Mcc24-producing strain of E. coli 
MC4100pGC)B18, hereafter referred to as MC4100/GOB18 (ref). This was accomplished by 
flooding SL1344/CFP/mari? (approximately 2 x 10* bacteria) onto a Lennox L agar plate 
containing ampicillin, then placing a filter disc (Bacto concentration discs, sterile blanks, 
DIFCO) soaked with Lennox L broth containing MC4100/GOB18 (109/ml) in the center of 
the plate. The bacteria were grown together overnight at 37° C and observed for a zone of 
inhibition. S. typhimurium was visually distinct from E. coli due to fluorescence of CFP gene 
product. 
Similarly, supematants of MC41OO/GOB18 were concentrated using trichloroacetic 
acid (TCA) in a manner described by Fath et al. (1994). Briefly, supematants were removed, 
filter sterilized, and treated with TCA at a final concentration of 10%. Samples were 
incubated on ice for 45 min and then centrifiiged at 3,000 x g for 15 min. The supernatant 
was removed and the precipitate resuspended in 3.5 M Tris base (pH 9.5) at 1/250 of the 
original volume. The extract was used in place of broth culture to soak the disc that was 
subsequently placed on a SL1344/CFP/w«ri? background and observed for a zone of 
inhibition. Additionally Mcc24 is known to be susceptible to pronase E (O'Brien and 
Mahanty, 1994), therefore pronase E was inoculated onto the area where a disc soaked with 
TCA concentrated MC4!OOpGOB18 supernatant was to be placed. Observation for a zone of 
inhibition against SL 1344/ŒP/marR indicator background was performed as described. Also 
the mtflgene, encoding immunity to Mcc24, was amplified from pGOB18 using 5'-
AT GAGTTTT CTT A ATTTT GC A-3 ' and 5'-TCATATACATCTCCTGTATAA-3' as 
forward and reverse primers, respectively, and cloned into pCR-XL-TOPO (Invitrogen), a 
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high copy plasmid with a ColEl replicon and the Lac promoter for transcription of the insert, 
thus creating pCRXLimmunity. SL1344 was transformed with the pCRXLimmunity and 
used as the indicator strain for MC4100/GOB18 co-culture and TCA extracts experiments. 
Development of Mcc24 resistance 
SL1344/CFP/m«rR was co-cultured with MC4100/GOB18 soaked discs on media 
containing 3.5 mM salicylate and observed for a zone of inhibition. Subsequently, 0.2% 
arabinose was added to the media with 3.5 mM salicylate and SL1344/CFP/marR exposed 
(once or twice) to MC4100/GOB18 and observed for zones of inhibition. 
SL1344/CFPI marR colonies that bordered the zone of inhibition produced by 
MC4100/GOB18 (highest non-lethal Mcc24 exposure) were grown in Lennox L broth to log 
phase (4-6 hrs, 37° C, vigorous shaking) and re-exposed to MC4100/GOB18 using the 
soaked disc method. This expansion and replating was repeated until loss of zone of 
inhibition was observed. The resultant Mcc24 resistant SL1344/CFP/mari? was grown in the 
presence of 0.2% arabinose and observed for zone of inhibition. SL1344/CFPI marR colonies 
on the edge of the plate (not Mcc24 exposed) were also grown and re-exposed to 
MC4100/GOB18 soaked discs and observed zones of inhibition. Additionally S. typhimurium 
8431, which inducibly expresses the mar phenotype, was co-cultured with MC41QO/GOB18 
and observed for zone of inhibition. 
Mcc24 cross resistance to multiple antibiotics 
MIC values for ciprofloxacin, chloramphenicol, tetracycline, and rifampin were 
determined by inoculating 106 bacteria into 1 ml aliquots of Mueller-Hinton broth (DIFCO) 
containing serial dilutions of antibiotics as per NCCLS guidelines (1999). Bacteria were 
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grown aerobically and MIC values were ascribed based on lowest concentration of antibiotic 
that inhibited growth. 
Results 
Interest in Mcc24 as a possible alternative to antibiotic use in controlling Salmonella 
raises questions regarding Mcc24 resistance and potential cross resistance to common 
antibiotics. Additionally, mar-mediated resistance has been associated with multiple 
compounds toxic to bacteria. In this study a system was designed to control the level of mar 
activation in culture in order to assess the impact of mar during Mcc24 exposure. Also a 
fluorescent strain of Salmonella was engineered to monitor growth under co-culture 
conditions. Concurrently, changes in antibiotic susceptibilities were investigated to assess 
Mcc 24 cross resistance. 
Specific microcin 24 inhibition of S. typhimurium 
Mcc24 inhibition of Salmonella was visualized by co-culturing SL1344/CFP/marR 
and MC4100/GOB18 produced a clear zone in the fluorescent SL1344/CFP/mori? 
background around the filter disc containing MC4100/GOB18 (Figure 1). A similar zone was 
seen when TCA extracts from MC4100/GOB18 were used in place of culture (not shown). If 
pronase E was inoculated in the area where the filter disc was placed, no zone of inhibition 
was seen with MC4100/GOB18 TCA extracts (not shown). Also if a pCRXLimmunity 
containing strain of SL1344 was used as the indicator strain, no zone of inhibition was seen 
with MC4100/GOB18 co-culture (not shown). 
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mar-mediated Mcc24 resistance 
mar activation was manipulated by the presence or absence of salicylate and 
arabinose. When 3.5 mM salicylate was added to the medium and SL1344/CFP/mar/? was 
grown with E. coli MC4!OOpGOB18, sensitivity to Mcc24 was abolished as shown in Figure 
2. Subsequently, if 0.2% arabinose was added with 3.5 mM salicylate to the medium and 
inducing the episomal marR, SL1344/CFP/marR Mcc24 sensitivity was re-established as 
shown in Figure 3. The result of repeated exposure of SL1344/CFP/mari? to Mcc24 
eventually resulted in loss of the zone of inhibition around the disc containing the Mcc24 
producer as shown in Figure 4. This occurred on average of 12.7 re-exposures of border 
colonies to Mcc24 (average of three trials). When the resultant Mcc24 resistant strains were 
grown on Lennox L agar containing 0.2% arabinose, the zone of inhibition reappeared as 
shown in Figure 5. Additionally initial Mcc24 resistance was seen in S. typhimurium strain 
8431, a mutant that inducibly expresses the mar phenotype (not shown) (Carlson and Ferris, 
2000). No resistance to Mcc24 was seen in edge colonies (farthest from disc) grown and re-
exposed to Mcc24 as shown in Figure 6. 
Cross resistance between Mcc24 and antibiotics 
Development of Mcc24 cross resistance with antibiotics was assessed by measuring 
concurrent Salmonella susceptibility patterns throughout the experiment. The resistance of 
the indicator strain, SL1344/CFP/wrarK, to various antibiotics differed according to the 
resistance to Mcc24 as shown in Table 2. Initially SL 1344/CW/marR was sensitive to the 
ciprofloxacin, tetracycline, chloramphenicol, and rifampin. Addition of 3.5 mM salicylate to 
the media resulted in increased resistance to these same antibiotics (Figures 7 & 8, Table 2). 
Addition of 0.2% arabinose and 3.5 mM salicylate to the media resulted in lowered resistance 
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levels when compared to salicylate alone. This was further reduced when stimulated a second 
time with 0.2% arabinose (Table 2, Figure 7 & 8). Mcc24 resistant SL 1344/CFV/marR from 
repeated exposure to Mcc24 producing E. coli also had increased resistance to ciprofloxacin, 
tetracycline, chloramphenicol, and rifampin (Table 2, Figures 7 & 8). With 0.2% arabinose 
added to the media, the resistance to ciprofloxacin was lowered to levels approximately equal 
to the initial resistance level (Table 2, Figures 7 & 8). 
Discussion 
In this study repeated exposure if S. typhimurium to Mcc24 resulted in a resistant 
phenotype. In addition to Mcc24 resistance, S. typhimurium was also resistant to 
ciprofloxacin, tetracycline, chloramphenicol, and rifampin. The mechanism of this resistance 
pattern was shown to be due to activation of the mar system. How Mcc24 activates the mar 
system is not understood. In E. coli, a number of structurally dissimilar substances have been 
shown to activate the mar system, including tetracycline, chloramphenicol, menadine, 
phenazine methosulfate, paraquat, plumbagin, dinitrophenol, benzoate, 4% EtOH, 50mM 
NaCl, and salicylate (Ariza et al, 1994; Cohen et al., 1993a; Hachler et al., 1991; Martin and 
Rosner, 1995; Randall and Woodward, 2001; Seoane and Levy, 1995; Sulavik et al., 1994). 
While tetracycline and chloramphenicol can induce mar in E. coli (Hachler et al., 1991), it 
does not in Salmonella (Randall and Woodward, 2001). The most potent inducer in both E. 
coli (Cohen et al., 1993a) and Salmonella (Randall and Woodward, 2001) is salicylate. 
Although a specific cellular product generated upon exposure to these various compounds 
may be the natural inducer of mar, this product has yet to be identified (Alekshun and Levy, 
1997). If Mcc24 does degrade DNA intracellularly, this may initiate a stress-response 
cascade that leads to binding and sequestration of MarR. 
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In this study, Salmonella developed resistance to an E. co/z'-derived microcin, Mcc24. 
It was also demonstrated that the mechanism of Mcc24 resistance is mediated by activation 
of the mar system. This activation led to increased resistance to several antibiotics including, 
ciprofloxacin, tetracycline, chloramphenicol, and rifampin. Extrapolation of our results 
suggests that exposure of Salmonella to Mcc24 can lead to a multidrug-resistant phenotype 
and in selective environments may favor acquisition of genetic determinants of antibiotic 
resistance such as intégrons (Briggs and Fratamico, 1999; Hall and Stokes, 1993; Ridley and 
Threlfall, 1998). If Mcc24 is to provide an alternative to antibiotic use in the reduction of 
Salmonella shedding, this possibility needs further exploration. 
Additionally this study details the exogenous expression of a GFP-like molecule in S. 
typhimurium. This indicator system was also successfully demonstrated in S. typhimurium 
phagetype DTI 04 (DTI 04) (Frana and Carlson, 2001) and is of particular interest for the 
study of multiple antibiotic-resistant pathogens such as DTI 04. The antibiotic resistance 
profile of certain DTI 04 isolates is extensive (ampicillicn, chloramphenicol, streptomycin, 
sulfamethoxazole, tetracycline, erythromycin, kanamycin, neomycin, gentamicin, apramycin, 
etc); thus most conventional antibiotic selection-based plasmids are of little value. This GFP-
based system could be used in other in vitro and ex vivo assays as well, especially where 
long-term bacterial propagation is necessary, and in other multiple antibiotic-resistant 
bacteria. 
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Table 1. Bacterial strains and plasmids used in this study. 
Strain or plasmid Relevant characteristics Source/Reference 
E. coli MC4100 F~ ara D139 A(lacl PO ZYA-
argF), U169 rpsL thi recA-56 (Casadaban, 1976) 
E. coli GOB 18 Expresses Mcc24, ampicillin* (O'Brien and Mahanty, 1994) 
S. typhimurium 
LB5000 
restriction negative, modification 
positive (Bullas and Ryu, 1983) 
S. typhimurium 
SL1344 
Source of marR sequence in 
pBMAR (Wray and Sojka, 1978) 
S. typhimurium 
SL1344/CFP/marR 
Harbors pBAD-TOPO/mari? and 
pBAD-TOPO/marR This study 
S. typhimurium 
8431 
Constitutively expressed mar 
mutant 
(Carlson and Ferris, 
2000) 
pEGFP Expresses GFP, ampicillin^ Living Colors, Palo Alto, CA 
pECFP Expresses CFP, ampicillin^ Living Colors, Palo Alto, CA 
pEYFP Expresses YFP, ampicillin^ Living Colors, Palo Alto, CA 
pBAD TOPO tirmBAD promoter, ampicillin^ Invitrogen, Carlsbad, CA 
pCR Blunt II TOPO lac promoter, ZeocinR Invitrogen, Carlsbad, CA 
pCR XL TOPO lac promoter, KanR Invitrogen, Carlsbad, CA 
pBluntECFP Expresses CFP, ZeocinR This study 
pBAD-TOPO/mari? Expresses MarR in presence of 
arabinose This study 
pCRXLimmunity Expresses mtfl, Mcc24R This study 
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Figure 1. Mcc24-mediated zone of inhibition of SL 1344/CFP/marR. S L1344/C F VtmarR and 
E. coli GOB 18 (center of plate) were incubated together as described in the text. 
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Figure 2. Induction of the mar phenotype in SL1344/CFP/marR. SL1344/CFP/marR and E. 
coli GOB 18 (center of plate) were incubated together in the presence of 3.5 mM salicylate. 
92 
Figure 3. Repression of the mar phenotype in SL1344/CFP/marR. SL1344/CFP/mtiri? and E. 
coli GOB 18 (center of plate) were incubated together in the presence of 3.5 mM salicylate 
andO.2% arabinose. 
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Figure 4. Acquired Mcc24 resistance in SL1344/CFPImarR. SL1344/CFP/mari? colonies 
bordering zone of inhibition around E. coli GOB 18 were expanded and repeatedly co-
cultured with Mcc24-producing E. coli. until abolishment of zone of inhibition. 
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Figure 5. Return of Mcc24 sensitivity in previously resistant SL1344/CFP/mari?. Mcc24-
resistant SL1344/CFP/marR due to repeated exposure to Mcc24-producing E. coli is 
incubated with E. coli GOB 18 (center of plate) in the presence of 0.2% arabinose. 
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Figure 6. Edge colonies of SL1344/CFP/mar/? remain sensitive to Mcc24. 
SL1344/CFP/mari? colonies expanded from the edge of plates (farthest from disc) co-
cultured with E. coli GOB 18 (center of plate) remain sensitive to Mcc24. 
96 
Treatment Strain MIC ciprofloxacin 
None SL1344 0.125 fig/ml 
None SL1344/CPF/ma#4? 0.125 jig/ml 
3.5 mM salicylate SL1344/CPF/w«z-/? 4 pg/ml 
3.5 mM salicylate plus 0.2% 
arabinose SL1344/CPFImarR 0.5 fig/ml 
3.5 mM salicylate plus two 
exposures to 0.2% arabinose SL1344/CPFImarR 0.25pg/ml 
First exposure to Mcc24 SL1344/CPF//MA/1/? border 0.125 ftg/ml 
17 exposures to Mcc24 SL1344/CPF/ma#i? border 0.25 pg/ml 
18 exposures to Mcc24 SL1344/CPF/mflr/f border 2 ng/ml 
18 exposures to Mcc24, then 
0.2% arabinose SL1344/CPF/m<zrR border 0.5 ng/ml 
18 exposures to Mcc24, then 
two exposures to 0.2% SL1344/CPF/mar/t border 0.25fig/ml 
First expansion without 
exposure to Mcc24 SL1344/CPF/wflr/f edge 0.125 pg/ml 
18 expansions without 
exposure to Mcc24 
SL1344/CPF/wtiz-/Z edge 
colonies 0.125 pg/ml 
Table 2. Changes in ciprofloxacin MIC values with relationship to Mcc24 exposure. MIC 
values were determined according to NCCLS standards (1999). Concentrations of 
ciprofloxacin used were 8, 4,2, 0.5, 0.25 and 0.125 gg/ml. Unrelated experiments and 
control experiments are separated by filled rows. 
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Mcc24 S Mcc24 S+ Sal Mcc24 S Mcc24 R Mcc24 R 
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Salmonella phenotype and medium additions8 
Figure 7. Changes in ciprofloxacin MIC values with relationship to Mcc24 exposure. MIC 
values were determined according to NCCLS standards (1999). 
a Susceptible to Mcc24 (Mcc24 S); Acquired resistance to Mcc24 (Mcc24 R); 3.5 mM 
salicylate added to medium (Sal); 0.2% arabinose added to medium (ARA). 
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60 
Mcc24 S Mcc24 S + Mcc24 S Mcc24 R 
Sal + Ara/S al 
Salmonella genotype and medium addtions" 
Figure 8. Changes in tetracycline, chloramphenicol (CHPC), and rifampin MIC values with 
relationship to Mcc24 exposure. MIC values were determined according to NCCLS standards 
(1999). 
a Susceptible to Mcc24 (Mcc24 S); Acquired resistance to Mcc24 (Mcc24 R); 3.5 mM 
salicylate added to mediim (Sal); 0.2% arabinose added to medium (ARA). 
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CHAPTER 4 
EFFECTS OF MCC24-PRODUCING ESCHERICHIA COLI ON 
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PIGS 
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Abstract 
Objective To investigate the effect of daily, oral inoculations of an Escherichia coli 
producing microcin 24 (Mcc24) on Salmonella enterica serotype Typhimurium (ST) 
shedding in swine and to look for evidence of Mcc24-mediated mar (multiple antibiotic 
resistance) activation in vivo. 
Procedure-Two groups of crossbred, 17-day-old, weaned pigs (12 pigs/group) were orally 
dosed on a daily basis with either a Mcc24-producing E. coli or a non-Mcc24-producing E. 
coli and then challenged with ST %4232 (ST4232). A third group of six pigs received Mcc24-
producing E. coli and were challenged with a Mcc24-sensitive mar A deleted strain of 
ST4232 (ST4232AwarA). In addition, two groups of three pigs each were challenged with 
either the ST4232 or ST4232AmarA but did not receive E. coli. After ST challenge, each pig 
was monitored for ST shedding by fecal culture and ST isolates were then screened for 
resistance to ciprofloxacin. Fecal and tissue samples were collected until 20 days post-
challenge. 
Results-No difference in ST shedding was found between groups receiving Mcc24-
producing or non-Mcc24-producing E. coli. No significant differences were found in 
quantitative analysis between groups receiving Mcc24-producing E. coli and non-Mcc24-
producing E. coli. No evidence of Mar activation of ST was seen in any group. 
Conclusions and Clinical Relevance-Under the conditions of this 
experiment, Mcc24-producing E. coli did not exert an effect on ST 
shedding or mar activation in pigs. It may be difficult or impractical 
to produce the conditions required for Mcc24 to be effective as part of 
a food safety intervention to reduce ST shedding. 
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Introduction 
Microcins are a group of antimicrobial peptides produced by the Enterobacteriaceae 
(Baquero et al., 1978). Microcin 24 (Mcc24) was isolated from a uropathogenic strain of 
Escherichia coli and was found to inhibit growth of strains of Salmonella (O'Brien and 
Mahanty, 1994). 
Expression of Mcc24 in an avirulent strain of avian E. coli led to inhibition of 
Salmonella enterica serotype Typhimurium (ST) shedding in chicken intestinal tracts 
(Wooley et al., 1999). Additionally, Mcc24 from this same strain of E. coli demonstrated 
strong inhibition against reptilian strains of Salmonella in vitro (Wooley et al., 2001). It was 
suggested by these studies that Mcc24 may be used in a food safety intervention to exclude 
Salmonella and it may provide an alternative to antibiotic use. 
Recently, we reported that ST could develop resistance to Mcc24 after repeated 
exposure in vitro. Additionally it was shown that acquisition of Mcc24 resistance in ST led to 
concurrent resistance to multiple antibiotics (ciprofloxacin, tetracycline, chloramphenicol, 
rifampin) through activation of the multiple-antibiotic resistance (mar) operon (Carlson et 
al., 2001). This operon regulates resistance to a variety of foreign substances in Salmonella 
principally through activation a multidrug efflux pump (Cohen et al., 1989; Cohen et al., 
1993). The gene responsible for this activation is mar A (Alekshun and Levy, 1997). 
The purposes of this study were to determine if a Mcc24-producing E. coli fed daily 
to pigs could reduce the level of ST shedding after challenge-inoculation and to investigate 
the possibility that the mar system could be activated in ST exposed to Mcc24 in vivo by 
testing for induction of low-level ciprofloxacin resistance. 
Materials and Methods 
Bacterial Strains and Plasmids 
All strains were stored at -70°C in 20% (v/v) glycerol prior to the start of the 
experiment. Previously the genes responsible for Mcc24 production, immunity, and secretion 
were isolated from a 5.25 kb fragment of p24-2 harbored in E. coli 2424 (O'Brien, 1996). 
The insert was subsequently cloned into pBR322 producing the recombinant plasmid, 
pGOBIB (O'Brien, 1996). Aliquots of laboratory E. coli K-12 strain, MC4100 (Casadaban, 
1976), were prepared and electroporateda (25 |j,F, 2.5 kV, 200 Q) with 100 ng of either 
pGOBIS or insertless pBR322 (Bolivar et al., 1977) thus generating E. coli GOB 18 and E. 
coli BR322, respectively. E. coli GOB 18 was shown to have Mcc24 specific activity which 
inhibited the growth of ST and E. coli MC4100, while E. coli pBR322 did not. Additionally, 
presence or absence of the desired plasmid in E. coli MC4100 was confirmed by polymerase 
chain reaction (PGR). Both E. coli GOB 18 and E. coli BR322 strains were ampicillin 
resistant due to a beta-lactamase gene present on the pBR322 plasmid. Daily oral dosing of 
each strain consisted of 2 ml of overnight growth in Luria-Bertani brothb containing 
ampicillin0 (100 |ig/ml). Each strain was tested daily for the presence of Mcc24 activity 
against E. coli MC4100. Plasmid stability was tested by serially passing E.coli GOB 18 in 
Luria-Bertani broth overnight without ampicillin and testing for Mcc24 activity. 
Nalidixic acid-resistant ST %4232 (ST4232) (Curtiss and Kelly, 1987) and a modified 
ST4232 with mar A deletion (ST 4232 Amar A) were used as the challenge strains. ST4232A/warA 
was constructed in a manner similar to that of Datesenko and Wanner (2000). Briefly, 
primers were constructed containing homologous sequences to DNA upstream and 
downstream of ST4232 mar A. Each primer also had a sequence that allowed it to bind to the 
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plasmid pKD3 (Datsenko and Wanner, 2000). PCR was performed using pKD3 as a template 
which gave a linear piece of DNA, encoding chloramphenicol resistance, flanked by 50 bp of 
marA sequence on each end. This linear fragment was transformed into ST4232 containing 
pKD46 (Datsenko and Wanner, 2000), which encodes the genes needed for Red 
recombinase. Chloramphenicol resistant colonies were selected and the desired mutation was 
confirmed using PCR. 
ST4232 and ST4232A/MWA challenge strains were grown on blood agar plates and 
colonies were transferred into prewarmed Luria-Bertani media containing nalidixic acidd (50 
|ig/ml), which was incubated with shaking (220 rpm) for 3.5 hours at 37° C. The culture was 
centrifuged (7,900 x g for 20 minutes), supernatant was removed, and the pellet was 
resuspended in PBS to the desired optical density (0.35 OD at 595 nm) and colony-forming 
units (CFU)/ml of Salmonella. 
Microcin Activity 
Luria-Bertani plates were flooded with indicator strain (either E. coli MC4100, 
ST4232, or ST4232AmorA; approximately 2 x 108 bacteria) in broth and allowed to absorb the 
liquid (2-5 min). Sterile blank discs6 were placed on the plate surface and soaked with test 
strain (E. coli GOBI8, 10 jal). The plates were incubated overnight at 37° C and observed for 
zones of inhibition. Alternatively test strains were picked with a sterile toothpick and 
inoculated onto indicator-flooded plates. 
Mcc24 gene (mtfS) Polymerase Chain Reaction (PCR) 
PCR was conducted on diluted fecal and tissue samples. Selected colonies with 
typical E. coli morphology and Mcc24 activity were isolated on MacConkey's mediaf with 
ampicillin (100 }Ag/ml) from various animals, samples, and days. Extraction of plasmid DNA 
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was performed using a miniprep kit8. PCR was performed in an automated thermocyclerh 
with 0.2 ml tubes. Reactions were performed in 20 pi containing 200 uM dATP, dTTP, 
dCTP and dGTP, 0.5 |iM of each of each primer, 0.5 units of Taq DNA Polymerase1, 50 ng 
of template, IX QIAGEN PCR buffer, and 5 pi of water. Thermocycling entailed 94 C for 3 
min. then 35 cycles of 94 C for 30 sec., 55 C for 30 sec. and 72 C for 30 sec. Forward and 
reverse primers corresponding to sequences within mtjS (Mcc24 strutuctural gene) used were 
5'-GCTGGAGATCCGCTTGCAGAT-3' and 5'-TTATCCTTTACTTCCGTTCCA-3\ 
respectively. Visual detection of 225 bp amplicons was performed following agarose gel 
electrophoresis. 
Animals 
Thirty-six 17-day old, crossbred pigs were used in the study. Approximately 30 days 
prior to the study, sow fecal samples were collected and screened for the presence of 
Salmonella organisms by microbial culture. Offspring were selected from sows found to be 
negative. Fecal samples were collected and screened for Salmonella by microbial culture at 
7, 3, and 0 days prior to challenge-inoculation. 
Experimental Design 
Pigs were divided into 5 groups as shown in Table 1. Pigs were housed in groups of 
three in individual rooms with a solid, concrete floor in an isolation barn at the National 
Animal Disease Center (NADC) in Ames, IA. Pigs were fed a commercial ration containing 
no antibiotics and water ad libitum. All pigs were monitored daily for attitude, appetite, and 
stool consistency. Temperatures were taken either daily or every other day. Individual fecal 
samples were collected using plastic sleeves' attached to thermometer probes and floor pen 
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samples were collected from a mixed sample of stool. On day 20 of the study, pigs were 
euthanized and a necropsy was performed on each pig. Samples collected aseptically at 
necropsy included portions of the ileocecal lymph nodes, an approximate 10-cm portion of 
the distal ileum, colon contents, and cecal contents. All pigs used in this study were handled 
and treated in compliance with an NADC Institutional Animal Care and Use Committee 
(IACUC) certified protocol. 
Processing of sample 
All samples were transported to the laboratory within 1 hour after collection. Samples 
of ileocecal lymph nodes and distal ileum were collected aseptically and weighed. Two times 
the weight of buffered peptone water (0.1% BPW) was added in a sterile, zipper seal bag\ 
The samples were macerated with a rubber mallet and each sample was homogenized using a 
Stomacher1 (260 RPM for 1 minute). One ml of the homogenate was added to 9 ml of BPW. 
Samples of colon and cecal contents were weighed and diluted 1:10 in BPW. The weight of 
fecal samples collected from thermometer sleeves were determined by subtracting the sleeve 
weight from the gross sleeve and fecal weight. The net fecal weight was diluted 1:10 in 
BPW. If the amount of BPW was below 1.0 ml, the total volume was adjusted to 1.0 ml 
regardless of the net fecal weight. These initial 1:10 dilutions of sample in BPW were serially 
diluted (10"1) and 10 pi aliquots of each dilution were streaked in triplicate onto XLT4 agar1" 
containing nalidixic acid (50 ng/ml) because ST4232 is nalidixic acid resistant. Additionally, 
100 p.1 of the initial 1:10 dilution was spread onto XLT4 agar containing nalidixic acid (50 
gg/ml) and XLT4 agar containing nalidixic acid (50 jig/ml) and ciprofloxacin" (4 jig/ml). All 
plates were incubated at 37° C for 24 hours at which time Salmonella suspect colonies were 
enumerated. The samples in BPW were incubated at 37° C for 24 hrs and enriched by adding 
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a 100 pi of the BPW sample to 10 ml in Rappaport-Vassiliadis (RV) media0 with nalidixic 
acid (50 (ig/ml; incubated for 37° C for 24 hrs). A second enrichment in RV media with 
nalidixic acid followed similarly after which 100 jol aliquots were spread onto XLT4 agar 
containing nalidixic acid or nalidixic acid and ciprofloxacin, incubated at 37° C for 24 hours 
and observed for growth. Salmonella suspect colonies were transferred onto Rambach 
mediap, incubated at 37° C for 24 hrs and evaluated for the appearance of typical Salmonella 
morphology and color. Antibiotic resistance profiles of the test organisms were determined 
by the Kirby-Bauer method (Bauer et al, 1966). Antibiotics tested included ampicillin, 
chloramphenicol, ciprofloxacin, rifampin, and tetracycline. 
Analysis 
The proportion of Salmonella positive pigs (post-enrichment data) was modeled using 
a generalized linear model with a logit link function (Nelder and Wedderbum, 1972). The 
level of Salmonella shedding in pigs (pre-enrichment data) was analyzed by one-way 
analysis of variance (ANOVA) to evaluate single day and tissue differences. Additionally 
pre-enrichment data was analyzed using a mixed linear model with effects for group, day of 
study, and group by day of study interaction. Also, Wilcoxon Rank sum tests were conducted 
between groups for each tissue type and the maximum day count obtained. Effect of sample 
weight was considered in both pre- and post- enrichment analysis. A p-value of 0.05 was 
considered necessary for a statistically significant result. All results were analyzed using SAS 
V8 statistical software packaged 
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Results 
A study was conducted to investigate the effects of Mcc24-producing E. coli given to 
pigs while challenged with ST. Changes in ST shedding patterns and development of a ST 
multidrug resistance pattern were the primary outcome variables that were measured. 
One pig from group 3 and one pig from group 5 were culture positive for Salmonella 
spp prior to ST challenge and were no longer considered in the experiment. All other pigs 
were culture negative for Salmonella prior to ST4232 or ST4232AmarA challenge. A final plate 
count of the solution indicated a concentration of 2.0 x 108 CFU/ml of Salmonella in the 
challenge inocula. Mcc24 production from E. coli GOB 18 was detected after 20 consecutive 
passages in LB broth without ampicillin and after 20 days in sterile water at room 
temperature (25 C). E. coli MC4100 producing Mcc24 was re-isolated from the feces of pigs 
in groups 1 and 3 at a frequency of-1% (7/728) isolates tested. Pig fecal or tissue samples 
were PCR positive for the mtfS gene at a frequency of-11% (11/96). (data not shown). 
Post-enrichment results for pigs receiving ST4232 and either E. coli GOB 18 or E. coli 
BR322 are shown in Figure 1. No differences were found in the percentage of pigs that were 
Salmonella positive for the group receiving Mcc24-producing E. coli and for the group not 
receiving the Mcc24 E. coli. Salmonella was detected in a high percentage (>75%) in fecal 
samples of both groups 1 and 2 throughout the experiment and tissue samples collected at 
necropsy. The weight of the collected fecal sample was also considered as a covariate, but 
did not prove to be providing an important contribution to the predictive capability of the 
model and was therefore removed from the final model. 
Pre-enrichment results for pigs receiving ST4232 and either E. coli GOB 18 or E. coli 
BR322 are shown in Figure 2. This indicates a trend of lower numbers of Salmonella 
recovered from pigs receiving Mcc24-producing E. coli in the first 4 days following 
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challenge and also from ileocecal lymph nodes on day 20. However, there were no 
significant statistical differences between groups on a day or tissue basis in the one-way 
ANOVA. No differences between groups receiving E. coli GOB 18 or E. coli BR322 were 
detected in the mixed linear model or the Wilcoxon Rank sums test. Again the weight of the 
sample did not prove to be an important factor in the predictive capability of the modeling. 
After ST challenge, pigs had an average increase in rectal temperature of 0.95° F for 
the first four days when compared to pre-challenge temperatures. Most pigs exhibited a 
moderately decreased appetite, moderate depression, and loose stools for 1 -3 days following 
ST challenge. No significant clinical differences (temperature, appetite, attitude, stool 
consistency) were observed between groups receiving Mcc24-producing E. coli and non-
Mcc24-producing E. coli (data not shown). No significant differences in Salmonella 
shedding or clinical signs were observed between the groups receiving only ST4232 or 
ST4232A/MWA and the rest of the pig groups (data not shown). 
Antibiotic resistance studies revealed no change in the antibiograms of ST4232 
recovered from various pen floor and fecal samples. Specifically, the nalidixic acid resistance 
phenotype was retained but no resistance was observed for ampicillin, chloramphenicol, 
ciprofloxacin, rifampin or tetracycline. Additionally, Mcc24 resistance was not observed. 
Discussion 
Previous studies indicated that Mcc24 inhibited growth of ST in vitro and caused 
decreased shedding of ST in chickens (Wooley et al., 1999; Wooley et al., 2001). However, 
in vitro studies have shown that Mcc24 can induce a multidrug resistance phenotype in ST 
due to activation of the mar operon (Carlson el al., 2001). This included acquired resistance 
to ciprofloxacin, an important antibiotic used to treat infections in humans. Under the 
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conditions in this study, a Mcc24-producing E. coli was not shown to decrease shedding of 
ST after challenge-inoculation or to induce resistance to ciprofloxacin through mar 
activation. Although an apparent reduction in ST shedding of Mcc24 may have occurred in 
the first week following challenge along with reduced invasion of the ileocecal lymph nodes, 
this could not be supported statistically. There was no difference in the percentage of animals 
shedding ST regardless of whether they were fed Mcc24-producing E. coli or not. This study 
does not eliminate the possibility that Mcc24-producing E. coli could be effective in 
excluding ST. It does indicate, however, that the conditions for this to happen may be 
difficult or impractical to achieve. 
Consideration of the bacterial host is an obvious factor. We chose to use a non-host 
adapted strain of E. coli that expressed Mcc24 very efficiently. In this way we could assess 
the effect of transient passage of a Mcc24-producing E. coli in the gut on unattached 
Salmonella. Colonization in an intestine with an established microflora is a highly variable 
event and if an effect was noted it would be difficult to determine if establishment was a 
necessary requirement. It is noteworthy that even when the Mcc24 producer was a wild-type 
avian strain, it did not colonize 1 day-old chicks (Wooley et al., 1999). The possibility exists 
that our host failed to survive in adequate numbers in order for Mcc24 to affect ST shedding 
even though we were able to isolate Mcc24-producing E. coli from the feces of pigs 
receiving it orally. 
A follow-up study should consider characterizing swine adapted strains of E. coli for 
intestinal survival, colonization, and Mcc24 production as an attempt to increase the level of 
Mcc24 in the gut. Additionally using gnotobiotic pigs rather than conventionally raised 
animals would more closely approximate the conditions of the Wooley et al. (1999) study. 
Also it may be possible to produce Mcc24 from ST which opens the possibility of using a 
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non-pathogenic ST host for delivery. This would likely increase the level of Mcc24 in the ST 
microenvironment, but it would also raise public health considerations. Another 
consideration is heterologous expression of Mcc24 from a potentially beneficial intestinal 
microorganism such as bifidobacteria. Although an attempt by this lab to express Mcc24 
from lactic acid bacteria using methods described in McCormick et al. (1999) was not 
successful (see Chapter 2). 
Another factor to be considered is the delivery method of the Mcc24-producing E. 
coli. Even though we orally inoculated with a high dose on a daily basis, it may take a more 
continual route of Mcc24 exposure to be effective. Wooley et al. (1999) were able to show an 
effect when Mcc24-producing E. coli was delivered continually in the drinking water, but not 
when administered orally prior to challenge. 
We did not find evidence of mar activation of ST. Previously this occurred in vitro 
after repeated exposure of ST to the highest dose of Mcc24 tolerable (Carlson et al., 2001). 
Intestinal conditions may not allow the in vitro Mcc24 exposure levels to occur in vivo. 
Although increasing the level of Mcc24-producing E. coli in the gut or more closely 
matching the Mcc24-producing E. coli to the Salmonella microbiological niche may lead to 
mar activation. 
The results of this study indicate that the use of a Mcc24-producing E. coli to reduce 
ST in the intestinal contents and feces of pigs will require a detailed knowledge of the 
intestinal microbiological conditions conducive to competitive exclusion. Although Mcc24 
does have inhibitory activity against various Salmonella serotypes in vitro, extrapolation to a 
complex ecosystem such as the gut may prove daunting. The additional concerns of 
resistance and cross-resistance would require additional evaluation as well. Given all of these 
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complexities and concerns, it appears unlikely that Mcc24-producing E. coli will be a 
paradigm for microcin-based probiotics in swine. 
a Gene-Pulser II, BioRad Laboratories, Hercules, CA 
b Luria-Bertani broth, Becton Dickinson, Sparks. MD 
c Ampicillin, Sigma Chemical Co, St Louis, MO 
d Nalidixic acid, Sigma Chemical Co., St Louis, MO 
e Sterile discs, Bacto concentration discs, DIFCO 
f MacConkey's agar, Becton Dickinson, Sparks. MD 
8 Miniprep, Perfectprep, Eppendorf 
h Thermocycler, Hybaid, Teddington, UK 
1 Taq DNA polymerase, QIAGEN Inc., Valenecia CA) 
j Plastic sleeves, Relion, Omron Healthcare, Inc., Vernon Hills, IL 
k Fisherbrand sample bags 
1 Stomacher 400 Circulator, Seward Ltd, London, UK 
m XLT 4 agar, Becton Dickinson, Sparks, MD 
" Ciprofloxacin, Sigma Chemical Co., St Louis, MO 
0 Rappaport-Vassilialis media, Becton Dickenson, Sparks, MD 
p Rambach media, Chromagar Microbiology, Paris, France 
q SAS/STAT version 8, SAS Institute Inc., Cary, NC 
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Group Number of Pigs Mcc +
a Mcc-b ST4232C ST4232AmflrAd 
1 12 • • 
2 12 • • 
3 6 • • 
4 3 • 
5 3 • 
Table 1. Pig groups according to number of pigs per group and treatment with or without a 
Mcc24-producing E. coli and with or without a Salmonella enterica serotype Typhimurium 
challenge strain. 
a daily oral inoculations of E. coli GOB 18 containing 5-8 x 109 CFU from Day -4 to Day 19. 
b daily oral inoculations of E. coli BR322 containing 5-8 x 109 CFU from Day -4 to Day 19. 
c one time intranasal inoculation of ST4232 containing 2 x 108 CFU on Day 0. 
d one time intranasal inoculation of ST^zA/MarA containing 2 x 108 CFU on Day 0. 
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Figure 1. Shedding of Salmonella enterica serotype Typhimurium in feces and tissue (post-
enrichment) following experimental infection of pigs receiving E. coli GOB 18 (Mcc+) or E. 
coli BR322 (Mcc-). Results were expressed as the percentage of positive animals for 
Salmonella shedding in each group. Rectal samples were taken at -7d, -3d, Od and every 2d 
for 20 days following Salmonella inoculation. Day 20 samples were collected at necropsy. 
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Figure 2. Quantitative analysis of Salmonella enterica serotype Typhimurium in feces and 
tissue (pre-enrichment) following experimental infection of pigs receiving E. coli GOB 18 
(Mcc+) or E. coli BR322 (Mcc-). Results were expressed as mean logio Colony Forming 
Units (CFU) of Salmonella per gram of sample in each group. Rectal samples were taken 
every 2d for 20 days following Salmonella inoculation. Day 20 samples were collected at 
necropsy. Error bars indicate one Standard Deviation. 
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CHAPTER 5 
SITE-DIRECTED MUTAGENESIS OF A CONSERVED 
REGION IN MICROCIN 24 AND THE EFFECTS ON 
ANTIMICROBIAL ACTIVITY 
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Abstract 
A region with strong homology to microcin E492 was identified in microcin 24 after 
sequencing uncovered three guanine insertions not found in the published sequence for mtfS, 
the microcin 24 producing gene. Restriction enzyme analysis agreed with the presence of one 
of the guanine insertions. A series of mutants with amino acid substitutions in and near a 
helix-turn-helix motif found in the conserved region were constructed by using site-directed 
mutagenesis. The conserved region is expected to adopt a more extended helical structure 
when in contact with a cytoplasmic membrane and would fit the criteria for an amphipathic 
alpha helix. Microcin 24 activity was affected to various degrees by the substitutions. Lysine 
substitutions for alanine (A28K), leucine (L32K), and glycine (G42K) abolished or nearly 
abolished Mcc24 activity. The A28K and L32K mutants introduced the polar, charged lysine 
into a hydrophobic face of the potential amphipathic alpha helix. The G42K mutant 
eliminated a turn in the predicted secondary structure. A G31K mutant with the lysine on the 
hydrophilic face still retained Mcc24 activity. A L32R mutant retained Mcc24 activity, but to 
a lesser degree than the parent. Introducing a stop codon near the carboxy terminus of Mcc24 
abolished activity as did restoring the published sequence for the Mcc24 gene. Investigation 
of the mechanism of action for Mcc24 indicates that it possesses both membrane and 
endonuclease activity. 
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Introduction 
Microcin 24 (Mcc24) is an antimicrobial peptide produced by Escherichia coli. 
Mcc24 is thought to share a common ancestry with microcin E492 (MccE492) (Lagos et al., 
1999). This is based on predicted amino acid sequence comparisons between the structural 
and immunity genes for the Mcc24 and MccE492 systems (Lagos et al., 1999). The predicted 
amino acid sequences of mt/S and mceA, the structural genes for Mcc24 and MccE492 
respectively, share identity of 52% and similarity of 59% (Lagos et al., 1999). Additionally a 
conserved region shared between MccE492 and another microcin, Colicin V (ColV), is 
thought to be important to the activity of these peptides (Pons et al., 2002b). 
During previous experiments with Mcc24, we sequenced mtfS on numerous 
occasions. Consistently three guanine insertions were found that did not appear in the 
GenBank sequence (Acc # U47048). These differences lead to a change in the predicted 
amino acid sequence over a span of 11 residues. Of these 11 amino acids, eight were 
identical to a similar region in MceA. Additionally 5 of these amino acids were part of the 
conserved region previously identified in MccE492 and ColV (Pons et al., 2002b). The 
predicted secondary structure of this region in Mcc24 suggested a helix-turn-helix motif, 
which suggested it may be involved in protein-protein interactions. It is also possible that this 
region adopts an extended helical structure when in contact with cytoplasmic membranes, as 
is suggested for the homologous region of MccE492 (Destoumieux-Garzon et al., 2003). 
The objective of this study was to introduce mutations into a conserved region of 
Mcc24 using site-directed mutagenesis and to assess the effect on Mcc24 activity. 
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Materials and Methods 
Bacterial strains and plasmids 
The bacterial strains and primers used in this study are shown in Table 1. E. coli was 
grown in Luria-Bertani (LB, Gibco) broth at 37° C on a rotary shaker. Agar plates for the 
above medium was made with 1.5% agar (w/v) added. Antibiotics were added as needed in 
the following concentrations: ampicillin (100 pg ml"1) and kanamycin (64 j_ig ml"1) Stock 
cultures of the bacterial strains were stored in the appropriate broth containing 20% (v/v) 
glycerol at -70° C. 
Primers 
Primers used in this study are shown in Table 2. 
DNA manipulation and cloning techniques 
Small scale plasmid preparation 
Small scale extraction of plasmid DNA from gram-negative bacteria was performed 
using a miniprep kit (Perfectprep, Eppendorf). A 1-3 ml aliquot of overnight bacterial culture 
was poured into an Eppendorf tube and the cells pelleted by centrifugation (12,000rpm, 
2min). The supernatant was aspirated and 100 pi of Solution I (Buffered RNase A solution) 
was added and the pellet resuspended by vigorous vortexing. Then 100 pi of Solution II 
(Alkaline lysis solutions) was added and gently mixed by repeated inversion. Then 100 pi of 
Solution III (Potassium acetate solution) was added and mixed well by repeated inversion. 
The lysate was centrifuged (12,000 rpm, 10 min) and the supernatant transferred to a spin 
column to which 450 pi of DNA Binding Matrix Suspension in guanidine was added. After 
mixing, the column was centrifuged (12,000 rpm, 2 min) and the filtrate removed from the 
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collection tube. Then 400 pi of diluted Purification solution (Buffered salt solution) was 
added to the spin column and centrifuged (12,000 rpm, 2 min). The spin column was 
transferred to a fresh collection tube and 30-50 pi of 65°C sterile ddf^O water was added and 
vortexed briefly. The column was centrifuged (12,000 rpm, 2 min) and the eluted DNA 
stored at -20°C. 
Large scale plasmid preparation 
Large scale extraction of plasmid DNA from gram-negative bacteria was performed 
using a maxiprep kit (Maxiprep, Qiagen). A 500ml aliquot of overnight bacterial culture was 
harvested by centrifugation (7000rpm, 5min), and the supernatant removed. The pellet was 
resuspended in 10ml Buffer PI (Buffered RNase solution) by thoroughly pipetting up and 
down. Then 10ml Buffer P2 (Lysis buffer) was added and mixed by gentle inversion. Then 
10ml Buffer P3 was added and mixed thoroughly by inversion. The mixture was transferred 
to a polypropylene tube and centrifuged (17,000 rpm, 30 min, 4°C). The supernatant was 
transferred to a fresh polypropylene tube and centrifuged (17,000 rpm, 15 min, 4°C). The 
supernatant was then transferred to a QIAGEN-tip column previously equilibrated with 
Buffer QBT (Equilibration buffer) and allowed to enter the resin by gravity flow. The 
column was washed twice with 30ml Buffer QC (Wash buffer) and the column transferred to 
a polycarbonate tube. The plasmid DNA was eluted with 15ml Buffer QN (Elution buffer) 
and precipitated with 10.5 ml isopropranol and centrifugation (17,000 rpm, 30 min, 4°C). 
The resulting pellet was washed with 70% ethanol and allowed to air-dry. The DNA pellet 
was resuspended in 100-500ml of sterile ddHiO water according to pellet size. 
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Polymerase chain reaction (PCR) 
Typical reactions were performed in 0.2 ml tubes with 20 pi of reaction mix 
containing 300 gM dATP, dTTP, dCTP and dGTP, 2.5 mM magnesium chloride, 4 pmoles 
of each primer, 10 mM Tris-HCl, 50mM KC1, 0.5 units of AmpliTaq Gold (Perkin Elmer, 
Foster City, CA), 100-250 ng bacterial template, and ddHiO. Typically PCR was performed 
in an automated thermocycler with a hot bonnet (Hybaid, Teddington, UK) utilizing the 
following program: one cycle (95° C, 12 min), 40 cycles (denaturation, 94°C, lmin; 
annealing, 40° C, lmin; extension, 72° C, 1.5 min), final extension (60° C, 5 min and 72° C, 
5min). 
Restriction Enzyme Analysis 
Restriction enzyme analysis (REA) of pGOBIS, pXLGOB and pXLORI was 
performed with a double enzyme digestion using Hpa I (New England Biolabs) and PspOMI 
(New England Biolabs) in 20 pi reactions using the appropriate buffer (New England Biolab, 
Buffer 4) and incubated overnight at 37° C. The resultant DNA bands subjected to gel 
electrophoresis. 
Gel electrophoresis 
Agarose dissolved in lx TAE buffer was used for electrophoresis. The agarose 
(Perkin Elmer) content varied between 0.6-1.5% depending on the size of the fragment of 
interest. Ethidium bromide-stained DNA bands were visualized on a UV transilluminator 
using the BioRad GelDoc System. 
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Creation of pXLGOB 
Amplification of the 5.25kb SauAl fragment in pGOBIS (containing Mcc24 
production, transport and immunity genes) was accomplished using TaqPlus® Long PCR 
System (Stratagene). A 40 pi reaction was prepared using 1 pi pGOBIS (0.25 pg/pl) as 
template, 0.8 pi of an equal mixture PGOB18F and PGOB18R primers (25 pmol/pl), 2 pi an 
equal mix of dATP, dTTP, dCTP and dGTP (lOmM/ml), 4 pi TaqPlus® Long 10X low-salt 
buffer, 4 pi MgCl (25mM), and 28.2 pi of ddH20. TaqPlus® Long polymerase 1 pi ( 5 U/pl) 
was then added to the reaction. PCR was performed in an automated thermocycler with a hot 
bonnet (Hybaid, Teddington, UK) utilizing the following program: one cycle (95° C, 12 
min), 30 cycles (denaturation, 94°C, lmin; annealling, 40° C, lmin; extension, 72° C, 5 min), 
final extension (72° C, 15min). A 10 pi sample of the amplified product was visualized on 
0.6% agarose gel and ethidium bromide to insure the presence of a correct size product. The 
PCR product was cloned into the pXL-TOPO vector as per manufacturer's guidelines, 
transformed into E. coli TOP 10 cells and plated on LB agar with 64 pg/pl kanamycin. The 
transformants were screened for Mcc24 activity and plasmid DNA collected from a single 
active colony. mtfS from this colony was sequenced to ensure no changes had occurred 
during PCR and cloning and the resultant plasmid was dubbed pXLGOB. This plasmid DNA 
was used as template for subsequent site-directed mutagenesis reactions. 
Site-directed mutagenesis 
Mcc24 mutants were produced using the QuikChange™ XL Site-Directed 
mutagenesis kit (Stratagene). A 50 pi reaction was prepared with 5 pi 1 Ox reaction buffer, 1 
pi dNTP mix, 3 pi Quik solution, 1 pi (125 ng/pl) of each forward and reverse primer 
containing the mutational site (see Table 2), 38 pi of ddH%0 and 1 pi (10 ng/pl) of dsDNA 
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template (pXLGOB). Then 1 pi of Pfu turbo DNA polymerase (2.5 U/pl) was added and the 
reaction placed in the thermocycler. PCR was performed in an automated thermocycler with 
a hot bonnet (Hybaid, Teddington, UK) utilizing the following program: one cycle (95° C, 
30sec), 16 cycles (denaturation, 95°C, lmin; annealling, 55° C, lmin; extension, 68° C, 16-
18min). Following the temperature cycling, the reactions were cooled and 1 pi of Dpn I 
restriction enzyme (10 U/pl) added and then incubated for 1 hour at 37° C to digest the 
parental DNA. A 1 pi sample of the Dpn I treated DNA was electroporated into 
approximately 1010 E. coli HB101 cells using in 0.2-cm cuvettes (BioRad Laboratories, 
Hercules, CA) and performed at 2.5 kV and 25 pF (GenePulser, BioRad). The cells were 
plated on LB agar with 64 pg/pl kanamycin. The parental pXLGOB was transformed into 
HB101 in a similar manner. Plasmid DNA was prepared from 5 colonies for each 
mutagenesis reaction and submitted for sequencing. After an expected mutation was 
confirmed, the strain was evaluated for Mcc24 activity using the co-culture method as 
described below. 
Microcin concentration (Fath et al., 1994) 
Microcin producing strains were grown overnight under appropriate conditions as 
described above. The cultures were centrifuged (6000 x g for 5 min) and the supernatant 
filter sterilized (0.45 pm). Trichloroactetic acid (TCA) 100% was added to 10% (v/v). The 
mixture was held on ice for 45 min and centrifuged (6000 x g for 15 min). The supernatant 
was discarded and the pellet reconstituted with 3.5M Tris base (pH 9.5) at 1/250 of the 
original volume. 
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Co-Culturing for Mcc24 activity 
An overnight growth of E. coli indicator (MC4100 or TOP 10) was diluted to 1/10 
with sterile water to 0.1 O.D590. A 200 pi aliquot was spread onto a 150x15mm plate 
containing LB agar and allowed to soak for 2-5 min. Sterile discs were placed onto the LB 
agar and loaded with 15 pi of test strain. The plate was then incubated at 37° for 24 hours 
and the diameter of the zone of inhibition surrounding the disc recorded. 
Nuclease activity assay (Pugsley and Oudega, 1987,0'brien 1996) 
The Mcc24 and Mcc24 mutant extracts were prepared by TCA concentration as 
described above. A 2pl aliquot of the extract was mixed with 16 pi of Reaction Buffer and 2 
pi of X Hind III cut marker DNA to give a final volume of 20 pi. The mixture was incubated 
at 37°C for 40 minutes and then visualized by gel electrophoresis in a 0.6% agarose gel. 
Cell membrane permeabilization measurements (Beven et al., 1998) 
Using the dye-probe 3,3'-dipropyl thiacarbocyanine iodide (DiSCgfS]), cytoplasmic 
membrane permeabilization can be determined. Depending on membrane potential, the dye 
distributes between the medium and the cells and is concentrated and self-quenches once 
inside the cell (Wu et al., 1999). E. coli TOP 10 Mcc24 sensitive cells growing at exponential 
phase were harvested and resuspended in permeabilization buffer (5 mM HEPES buffer, Ph 
7.0, 50 mM D-glucose, 5 mM EDTA) to a density of OD^o = 0.1 (Beckman DU-64). 200 pi 
aliquots of the cell suspension were incubated with 0.4pM DiSCs[5] in a 96 well plate until 
the dye uptake was maximal (as indicated by a stable reduction of fluorescence). Five pi 
sample aliquots were added to the cell-dye suspension and the plate was loaded into 
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Spectromax Gemini (Molecular Devices) spectrofluorometer, exciting the sample at 622 nm. 
The fluorescence signal was measured at 675nm at 5 minute intervals for 20 min. 
Results 
Sequencing differences from published results for mtfS, the Mcc24 structural gene, 
were discovered during previous experiments. These differences resulted in an altered 
predicted amino acid sequence that more closely aligned with related MccE492, a related 
microcin. Additionally the region of difference appeared to harbor a motif that is commonly 
involved in protein-protein interactions which indicated the region may be importatant for 
Mcc24 activity. It was decided to introduce amino acid substitutions into this region and 
elsewhere in Mcc24 by site-directed mutagenesis in mtfS. The resulting Mcc24 mutants could 
then be investigated for the effects of structural changes on Mcc24 activity as well as clarify 
the mtfS sequence. 
Creation of pXLGOB and mtfS mutants 
Initial attempts to mutagenize pGOBIS were unsuccessful. Since map and sequence 
details of the pGOBIS plasmid were unavailable at the time, it was decided to clone the 5.25 
kb Mcc24 gene insert from pGOBIS into a separate vector. Construction of pXLGOB 
resulted from using the TaqPlus® Long PCR System to create PCR products of the entire 
5.25 kb Mcc24 system from pGOBIS which were cloned into pXL-TOPO, transformed into 
E. coli TOP 10, and tested for antimicrobial activity. The resultant strain exhibited similar 
inhibition and immunity activity as the parent pGOBIS in E. coli MC4100 (data not shown). 
Sequencing of mtfS did not reveal any differences from the parent, pGOBIS. Subsequent 
mutagenesis of the pXLGOB was successful in 15 of the 22 attempted sites and resulted in 
predicted conserved and nonconserved amino acid substitution as shown in Figure 1 (see also 
130 
Appendix A, Figure 2). The resulting plasmids with specific amino acid changes are listed in 
Table 1 and the sites on mtfS displayed in Figure 2. The actual nucleotide changes and the 
resulting predicted mtfS structural changes are shown in appendix A. 
Restriction Enzyme Analysis 
Restriction enzyme digestion of pGOBIS, pXLGOB, and pXLORI with Hpa I and 
PspOM I was performed as described above. As shown in the restriction enzyme map in 
Figure 3, two Hpa I sites are present in the 5.25 kb Mcc24 insert at nucleotides 847 and 
2406. Also as shown, a PspOM I site exists in the original published GenBank mt/S sequence 
and in the mutant pXLORI at bp 1244. This PspOM I site is not present in the sequencing 
results of mtfS performed in our previous experiments from pGOBIS or pXLGOB. The 
PspOM I site is due to one of the three guanine insertions previously discussed. A second, 
external PspOM I site is present in the pXL-TOPO vector and located at -63 bp from the 
insertion site of the Mcc24 genes. Therefore if a PspOM I site is present in pGOBIS the 
resultant restriction enzyme pattern should result in two fragments of 397 bp and 1192 bp. If 
the internal PspOM I site is not present, a single 1559 bp fragment should result. pXLGOB 
and pXLORI should have an additional 910 bp fragment due to cutting at the external 
PspOM I site. Gel electrophoresis of the results of the restriction enzyme digestion are shown 
in Figure 4 and indicate a single fragment of 1559 bp in pGOBIS, two fragments of 1559 bp 
and 910 bp in pXLGOB, and three fragments of 397 bp, 910 bp and 1192 bp in pXLORI. 
Antimicrobial activity 
E. coli HB101 strains containing pXL-TOPO derived plasmids were tested for 
inhibitory activity against Mcc24 indicator strains. The pXL-TOPO-derived plasmids 
included pXLGOB, pXLORI, and mtfS mutants with single nucleotide changes with 
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predicted amino acid substitutions as shown in Table 1. Using the co-culture test described 
above, zones of inhibition around the soaked discs were measured and varied from 0 to 4mm. 
Results are shown in Figure 5 with a score of 0 to 4 assigned based on size of the zone of 
inhibition. 
DNase activity 
The DNase activity of concentrated supematants collected from E. coli HB101 strains 
harboring pGOBIS and pXL-TOPO-derived plasmids were tested as described above. E. coli 
supernatant from strains harboring pGOBIS or pXLGOB demonstrated the ability to degrade 
cut single stranded DNA as shown in Figures 6 or 7. E. coli with pXL-TOPO-derived 
plasmids exhibiting little or no antimicrobial activity also had no apparent DNase activity as 
indicated in Figure 6. However, E. coli with pXL-TOPO-derived plasmids that exhibited 
antimicrobial activity equal or nearly equal to the parent plasmid also had no apparent DNase 
activity as indicated in Figure 7. 
Membrane activity 
Membrane activity of concentrated supematants collected from E. coli HB101 strains 
harboring pGOBIS and pXL-TOPO-derived plasmids were tested as described above. 
Samples collected with pGOBIS and pXLGOB were considered positive controls and E. coli 
HB101 samples without Mcc24 gene-containing plasmids and sterile water were used as 
negative controls. As shown in Figure 8, a sample collected from E. coli supernatant with 
pGOBIS induced the greatest increase in fluorescence. The E. coli strains with the pXL-
TOPO-derived plasmids had variable activity which generally exceeded the negative 
controls, but was less than the E. coli with pGOBIS. This was also true for the E. coli strain 
harboring pXLGOB. 
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Discussion 
During previous experiments with Mcc24, sequencing differences between our results 
and those published in GenBank for the mtfS gene were uncovered. These differences 
consisted of three guanine insertions after GenBank mtfS nucleotide positions 117, 135, and 
146 and resulted in an altered amino acid sequence over an eleven residue span. These 
differences are displayed in Figure 9. Restriction enzyme analysis of the 5.25 kb coding 
region for the Mcc24 genes in pGOBIS, pXLGOB, and pXLORI, which contained an mtfS 
sequence matching the GenBank sequence, revealed a pattern consistent with our sequencing 
results (Figure 4). Previously mtfS was shown to have a similar predicted amino acid 
sequence as another microcin-producing gene, mceA, which produces MccE492 (Lagos et 
al., 1999). These two genes were thought to share a common ancestor (Lagos et al., 1999). 
Comparing the predicted amino acid sequence from the DNA sequencing results we have 
obtained for mtfS to the predicted amino acid sequence of mceA indicates identity in 8 of the 
11 altered amino acids and increases the overall identity in aligned sections Mcc24 and 
MccE492 as shown in Figure 10 (see also Appendix A, Figure 1). These findings suggest that 
our sequencing results reflect the true sequence for the mtfS gene and that this is a conserved 
region of mtfS. Additionally, part of the sequence in question is also part of a conserved 
region identified in MccE492 and ColV, which is thought to be responsible for the pore-
forming activity of these microcins (Figure 11) (Pons et al., 2002b). 
The predicted secondary structure (Chou and Fasman, 1978) indicates that this region 
of mtfS has a helix-turn-helix motif which is known to be involved in protein-protein 
interactions. Based on the homology and secondary structure findings, we decided to 
introduce conserved and nonconserved amino acid substitutions into mtfS in this region and 
elsewhere and investigate the effects on Mcc24 activity. The result was fifteen mtfS mutants 
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that displayed various levels of inhibitory activity when co-cultured with Mcc24-sensitive E. 
coli as shown in Figure 5. 
Previously, Mcc24 has been shown to degrade single stranded DNA (O'Brien, 1996). 
When we tested concentrated supernatant from E. coli harboring pGOBIS or pXLGOB, we 
detected DNase activity in both samples (Figures 6 or 7). However none of the mtfS mutants 
displayed DNase activity using similar methods regardless of the inhibitory activity seen with 
co-culture (Figures 6 and 7). This suggests that the DNase activity of Mcc24 is easily 
disrupted and not confined to a specific region of the molecule. This could be explained if the 
DNase activity is related to the tertiary structure of the peptide and therefore more likely to 
be affected by single amino acid changes in any part. It also suggests that Mcc24 exerts 
activity through means other than purely DNA degradation. 
MccE492 had been shown to depolarize E. coli cytoplasmic membrane (de Lorenzo 
and Pugsley, 1985) and to form channels in phospholipid membranes (Lagos et al, 1993). 
Additionally, it has been shown that the cytoplasmic membrane is the target of ColV (Yang 
and Konisky, 1984). It is therefore reasonable to expect that Mcc24 might have membrane 
activity as well. We tested concentrated supematants from E. coli harboring pGOBIS, 
pXLGOB, and the pXL-TOPO-derived mtfS mutants using the dye-probe 3,3'-dipropyl 
thiacarbocyanine iodide (DiSC^5j). Samples collected from E. coli harboring pGOBIS 
displayed the highest level of cell membrane permeabilization activity. The pXL-TOPO-
derived samples displayed low to intermediate levels of membrane activity, including the 
pXLGOB sample (Figure 8). Other than the activity displayed by the pGOB18 derived 
samples, no distinct correlation of membrane activity to co-culture inhibition is can be seen. 
It is interesting, however, that three mtfS mutants with lysine substitutions (A28K, 
L32K, and G42K) completely abolished Mcc24 inhibitory activity and were among the 
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lowest in levels of membrane permeabilization. Lysine is a positively charged, polar amino 
acid and is frequently found a component of structure-function determinants. The positively 
charged amino group on lysine is sometimes involved in forming hydrogen bonds with 
negatively charged non-protein atoms (Betts and Russell, 2003). When substituted for the 
aliphatic, hydrophobic alanine or leucine at positions 28 and 32 respectively, the reactive, 
polar tendencies of lysine could perhaps not be tolerated. This is supported by viewing a 
"Schiffer-Edmundson" helical wheel (Schiffer and Edmundson, 1967) for the 20 amino acid 
residues of Mcc24 from positions 23-42 (Figure 12). In this predicted structure 8 glycine 
residues align to form essentially a hydrophilic face. While on the opposing face 10 of 12 
residues seen are classified as hydrophobic. Only an arginine at position 29 and a glycine at 
position 33 interrupt a complete hydrophobic face in this region. The alignment of 
hydrophilic and hydrophobic residues in this manner constitutes an amphipathic alpha helix 
if the region can adopt a helical structure (Oren and Shai, 1998). Lysine substitutions at 
positions 28 and 32 may interfere with critical hydrophobic interactions and inactivate a 
necessary feature for Mcc24 activity. It is interesting that a lysine substitution in the 
hydrophilic face, as seen with G31K, did not abolish Mcc24 activity but a similar substitution 
at position 42 (G42K) did abrogate activity. This may have less to do with the chemical 
properties of the lysine at the 42 position and more to with its physical nature. When 
secondary structures are compared between the parent Mcc24 sequence and the G42K 
mutant, it is observed that a turn following the helix-turn-helix motif is lost (See Appendix 
A, Figure 3). This dramatic change in the predicted secondary structure may alter binding 
either upstream or downstream of this site. Thus it could affect either receptor recognition or 
the orientation of the microcin active region. The G42K mutant also disrupts a conserved 
GAAGGA motif identified in Mcc E492, H47, L, 24 and ColV (Pons et al., 2002a). 
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It is also interesting that arginine and threonine substitutions for leucine at position 32 
(L32R and L32T) did not eliminate Mcc24 inhibition. Threonine is small and fairly neutral in 
regards to mutagenesis and this indifference may allow it to replace leucine without great 
impact on activity. The tolerance of the arginine substitution at this position is more difficult 
to explain. Although the level of Mcc24 activity appeared less than the parent (Figure 5), it 
was not completely abolished. Like lysine, arginine is a positively charged, polar amino acid 
that can form hydrogen bonds with negatively charged non-protein atoms. It is noteworthy 
that arginine is present in the parent Mcc24 sequence at position 29, so it may be that the 
guanidinium group on the arginine side chain is significantly different enough from the 
amino group in lysine to allow for some retention of activity. As for the other mtfS mutants 
without activity, the W70* substitution truncates Mcc24 by 5 residues and indicates the 
carboxy-terminus is important for activity. The triple mtfS mutant which restores the 
nucleotide sequence to the GenBank sequence provides further evidence that this sequence 
does not code for active Mcc24. 
These findings have significance to at least one other microcin and perhaps others. As 
indicated above, Pons et al. (2002b) previously identified a conserved 14 amino acid region 
in MccE492 and ColV thought to be involved in the pore-forming activity of MccE492. Part 
of our predicted sequence for Mcc24 overlaps this region and is identical or similar to 
MccE492 and ColV in the 5 amino acid residues involved. Pons et al. (2002a) later 
speculated that the class II microcins, which additionally includes MccH47 and MccL, may 
all share a common ancestor. These findings herein support that hypothesis. 
It is tempting to speculate that the membrane activity of class II microcins is related 
to the amphipathic helix structure illustrated in Figure 12. If so, the aligned glycine residues 
which are polar, flexible, and able to bind phosphate (Betts and Russell, 2003), would 
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interact with the head groups of membrane phospholipids. Although an alpha helix is not 
predicted throughout this region of Mcc24, it would be allowed by the flexibility of the 
glycine and would become more established with membrane contact. The hydrophobic 
residues would inbed themselves into the membrane lipid alkyl side chains. With enough 
Mcc24 contacting the cytoplasmic membrane, depolarization or pore-formation could occur. 
This process most closely approximates the carpet-like model described by Oren and Shai 
(Oren and Shai, 1998). This model is further supported by research indicating MccE492 
adopts a helical structure in the presence of micelles (Destoumieux-Garzon et al., 2003). 
Extracting purified Mcc24 from E. coli supematants would allow amino acid sequence 
determination and greatly facilitate mechanism of action experiments. This proved to be a 
challenging step that was not overcome in this study 
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Table 1. Bacterial strains and plasmids used in this study. 
Bacterial 
strains 
and 
plasmids 
Relevant Features Source 
E. coli 
MC4100 F~ ara D139 A(lacl PO ZYA-argF) U169 rpsL thi recA-56 
{Casadaban 
E. coli 
TOP 10 
F~mcrA A(mrr-hsdRMS-mcrBC) cp&OlacZ AM\5 AlacXIA reck 1 deoR 
araD 139 A(ara-leu)l697 galU galK rpsL (StrRJ endA\ nupG Invitrogen 
E. coli 
HB101 
F~ /7,sc/S20(rlfmB~) supEAA aral4 galK2 lacY\proA2 rps/20(StrR) xyl-
5 mtl-1 reel3 mcrB thi-l leuB6 Invitrogen 
pGOBIS 5.25 kb Sau3AI fragment in pBR322 with mtfl, mtfS, mtfA, mtfB & 
mdbA; AmpR; 9.8 kb 
{O'Brien 1996 
#47470} 
pG27A 
pXLGOB 18 with alanine to glycine condon substitution in Mcc24 at 
amino acid position 27 This study 
pA28T 
pXLGOB 18 with alanine to threonine codon substitution in Mcc24 at 
amino acid position 28 This study 
pA28K 
pXLGOB 18 with alanine to lysine condon substitution in Mcc24 at 
amino acid position 28 This study 
pR29N 
pXLGOB 18 with arginine to asparagine codon substitution in Mcc24 
at amino acid position 29 This study 
pG30A 
pXLGOB 18 with alanine to glycine codon substitution in Mcc24 at 
amino acid position 30 This study 
pG31A 
pXLGOB 18 with alanine to glycine codon substitution in Mcc24 at 
amino acid position 31 This study 
pG31K 
pXLGOB 18 with alanine to lysine codon substitution in Mcc24 at 
amino acid position 31 This study 
pL32I 
pXLGOB 18 with leucine to isoleucine codon substitution in Mcc24 at 
amino acid position 32 This study 
pL32K 
pXLGOB 18 with leucine to lysine codon substitution in Mcc24 at 
amino acid position 32 This study 
pL32R 
pXLGOB 18 with leucine to arginine codon substitution in Mcc24 at 
amino acid position 32 This study 
pL32T 
pXLGOB 18 with leucine to threonine codon substitution in Mcc24 at 
amino acid position 32 This study 
pG38A 
pXLGOB 18 with alanine to glycine codon substitution in Mcc24 at 
amino acid position 38 This study 
pG42K 
pXLGOB 18 with alanine to lysine codon substitution in Mcc24 at 
amino acid position 42 This study 
pW70* 
pXLGOB 18 with trytophan to stop condon substitution in Mcc24 at 
amino acid position 70 This study 
pXLORI 
pXLGOB 18 with guanosine deletions in mtsF at nucleotide postions 
117,136, & 148 This study 
pXLGOB 
pCR-XL-TOPO with 5.25 kb fragment of pGOB 18 with mtfl, mtfS, 
mtfA, mtfB and mdbA, KnR, 8.8 kb This study 
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Table 2. Primers used in this study. 
Primer 
ID Sequence Used for Source 
24GeneF GCTGGAGATCCGCTTGCAGAT sequencing ISU 
24GeneR TTATCCTTTACTTCCGTTCCA sequencing ISU 
PG0B18F GATCACCGCCGTGCAGAACTG PCR ISU 
PG0B18R GATCTCTACCCTTGAGTAATA PCR ISU 
G27AF TGGGGCGCCGCCTTTGCTGCCAGAGCCGGTTTA mutagenesis ISU 
G27AR TAAACCGCCTCTGGCAGCAAAGGCGGCGCCCCA mutagenesis ISU 
A28TF GGCGCCGCCTTTGGTACCAGAGGCGGTTTAGGG mutagenesis ISU 
A28TR CCCTAAACCGCCTCTGGTACCAAAGGCGGCGCC mutagenesis ISU 
A28KF GGCGCCGCCTTTGGTAAAAGAG GCGGTTTAGGG mutagenesis ISU 
A28KR CCCTAAACCGCCTCTTTTACCAAAGGCGGCGCC mutagenesis ISU 
R29NF GCCGCCTTTGGTGCCAATGGCGGTTTAGGGGGA mutagenesis ISU 
R29NR TCCCCCTAAACCGCCATTGGCACCAAAGGCGGC mutagenesis ISU 
G30AF GCCTTTGGTGCCAGAGCCGGTTTAGGGGGAATG mutagenesis ISU 
G30AR CATTCCCCCTAAACCGGCTCTGGCACCAAAGGC mutagenesis ISU 
G31AF TTTGGTGCCAGAGGCGCTTTAGGGGGAATGGCT mutagenesis ISU 
G31AR AGCCATTCCCCCTAAAGCGCCTCTGGCACCAAA mutagenesis ISU 
G31KF TTTGGTGCCAGAGGCAAATTAGGGGGAATGGCT mutagenesis ISU 
G31KR AGCCATTCCCCCTAATTTGCCTCTGGCACCAAA mutagenesis ISU 
L321F GGTGCCAGAGGCGGTATAGGGGGAATGGCTGTT mutagenesis ISU 
L32IR ACCAGCCATTCCCCCTATACCGCCTCTGGCACC mutagenesis ISU 
L32KF GGTGCCAGAGGCGGTAAAGGGGGAATGGCTGTT mutagenesis ISU 
L32KR AACAGCCATTCCCCCTTTACCGCCTCTGGCACC mutagenesis ISU 
L32RF GGTGCCAGAGGCGGTCGAGGGGGAATGGCTGTT mutagenesis ISU 
L32RR AACAGCCATTCCCCCTCGACCGCCTCTGGCACC mutagenesis ISU 
L32TF GGTGCCAGAGCCGGTACAGGGGGAATGGCTGTT mutagenesis ISU 
L32TR AACAGCCATTCCCCCTGTACCGCCTCTGGCACC mutagenesis ISU 
G38AF GGGGGAATGGCTGTTGCAGCCGCAGGTGGGGTT mutagenesis ISU 
G38AR AACCCCACCTGCGGCTGCAACAGCCATTCCCCC mutagenesis ISU 
G42KF GTTGGAGCCGCAGGTAAGGTTACGCAGACAGTT mutagenesis ISU 
G42KR ACCTGTCTGCGTAACCTTACCTGCGGCTCCAAC mutagenesis ISU 
W70*F CCGATGGGACCCTCATAGAACGGAAGTAAAGGA mutagenesis ISU 
W70*R TCCTTTACTTCCGTTCTATGAGGGTCCCATCGG mutagenesis ISU 
ORIF GGCATGGGGCCCGCCTTTGGTGCCAGAGCGGTT 
TAGGGGAATGGCTG 
mutagenesis ISU 
ORIR CAGCCATTCCCCTAAACCGCTCTGGCACCAAAG 
GCGGGCCCCATGCC 
mutagenesis ISU 
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ATTEMPTED MUTATIONS 
Nonconserved K K G 
Substitutions 
E K K R K K  K  * 
Wild type G27A28R29G30G31 L32.. .G38 . . G42.. .W 
Conserved 
Substituions A T K N A A I T A  A  
70 
Figure 1. Site-directed mutagenesis of the mtfS gene. Nonconserved substitutions shown 
above and conserved substitutions shown below (Betts and Russell, 2003). Substitutions 
shown in red were confirmed by sequencing. Substitutions shown in black could not be 
confirmed. Numbers indicate predicted residue designation in mtfS without leader sequence. 
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Figure 2. The predicted secondary structure of mature Mcc24 peptide according to Chou and 
Fasman (Chou and Fasman, 1978). Numbers indicate amino acid residues that were altered 
and arrows indicate approximate location. 
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GGGCGCC = our sequence 
G'GGCCC = GenBank 
PspOM 'spOM I Hpa 
910bp 1559bp 
847 397bp 1244 1162bp -63 2406 
Cloning site 
Figure 3. Restriction enzyme map of a region in the 5.25 kb Mcc24 insert including upstream 
region of pXL-TOPO. GenBank sequence contains PspOM I site internal of two Hpa I sites 
in the mtfS gene. Our sequence results indicate loss of PspOM I site due to "G" insertion 
shown in bold. Fragment sizes are indicated with double arrows. Nucleotide numbering 
based on 5.25 Kb insertion site with cloning site as starting point (single, upward arrow). 
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m 1 2 3 M 
Figure 4. Agarose gel electrophoresis of 5.25 kb Mcc24 insert observed following restriction 
enzyme digestion with Hpa I and PspOM. I. Lanes designated as "m" or "M" represents 50 or 
100 bp, respectively, molecular weight standards (GIBCO BRL). Lane 1 represents cut 
pGOBl 8 DNA. Lanes 2 represents cut pXLGOB DNA and Lane 3 represents cut pXLORI 
DNA. Specific molecular weight standards and amplicon sizes (bp) are indicated on both 
sides. 
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Plasmid 
in test 
strain 
Zone of 
inhibition 
Score 
pG27A 4 
pA28T 4 
pA28K 1 
pR29N 2 
pG30A 3 
pG31A 3 
pG31K 3 
pL32I 4 
pL32K 0 
pL32R 2 
pL32T 4 
pG38A 4 
pG42K 0 
pW70* 0 
pXLORI 0 
pXLGOB 4 
Figure 5. Inhibitory activity of mtfS mutants and pXLGOB co-cultured with Mcc24-sensitive 
E. coli. Luria-Bertani (LB) agar plates were flooded with indicator strain of E.coli 
(approximately 2 x 108 bacteria) in broth and allowed to absorb the liquid (2-5 min). Sterile 
blank discs (Bacto concentration discs, sterile blanks, DIFCO) were placed on the plate 
surface and soaked with lOjal of the test strain. The plates were incubated overnight (18-24 
hours) at 37° C and observed for zones of inhibition. Scoring was based on size (mm) of the 
zone of inhibition. 
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1 2 3 4 5 6 7 8 
Figure 6. Agarose gel electrophoresis of X Hind III cut marker DNA observed following 1 
hour incubation 37° C with various test samples. Lane 1 represents incubation with Reaction 
buffer only. Lane 2 represents incubation with concentrated supernatant from E. coli TOP 10 
collected at stationary phase. Lane 3 represents incubation with concentrated supernatant 
from E. coli MC4100 harboring pGOB18 collected at stationary phase. Lanes 4-8 represent 
incubation with concentrated supernatant from E. coli HB101 harboring pXL TOPO-derived 
mutants exhibiting little or no antimicrobial activity collected at stationary phase. 4= G28K, 
5= L32K, 6= G42K, 7= W70*, 8= XLORI. 
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1 2 3 4 5 6 7 8 9 10 11 12 13 
Figure 7. Agarose gel electrophoresis of X Hind III cut marker DNA observed following 1 
hour incubation 37° C with various test samples. Lane 1 represents incubation with Reaction 
buffer only. Lane 2 represents incubation with concentrated supernatant from E. coli HBlOl 
collected at stationary phase. Lane 3 represents incubation with concentrated supernatant 
from E. coli HBlOl harboring pXLGOB collected at stationary phase. Lanes 4-13 represents 
incubation with concentrated supernatant from E. coli HBlOl harboring pXL TOPO-derived 
mutants exhibiting antimicrobial activity equal or nearly equal to the parent collected at 
stationary phase. 4= G27A, 5= A28T, 6= R29N, 7= G30A, 8= G31A, 9= G31K, 10= L32I, 
11=L32T, 12= L32R, 13= G38A. 
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Figure 8. Representative experiment illustrating effects on cell permeability of concentrated 
supernatant from E, coli harboring plasmids with Mcc24-producing genes and mtfS mutants. 
E. coli TOP 10 cells suspended in in permeabilization buffer (5 mM HEPES buffer, Ph 7.0, 
50 mM D-glucose, 5 mM EDTA) were incubated with 0.4 ^M 3,3'-dipropyl thiacarbocyanine 
iodide (DiSCgfS]). Fluorescence was measured (excitation and emission wavelength 622 and 
675 nm repectively) in arbitrary units (A.U.) as a function of time following the addition of 
the concentrated supernatant sample. 
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mtfS in GenBank 
5'... ccgcctttggtgccagagcggtttagggga... 3' 
translation 
PPLVPERFRG 
GB Mcc24 PPL-VPERFRG 
L P consensus 
GB MccE492 AALGAPGGLGS 
AA GA GGLG 
AAFGARGGLGG 
consensus 
Our Mcc24 
AAFGARGGLGG 
| translation 
5'... GccgcctttggtgccagagGcggtttaggggGa... 3' 
mtfS our results 
Figure 10. Results of mtfS sequencing from our experiments and GenBank with a comparison 
to mceA gene product. Sequencing differences in mt/S from our experiments include three 
"G" insertions shown capitalized and in bold. Predicted MtfS amino acid sequences from 
GenBank and our experiments are aligned with MceA from MccE492 system with consensus 
sequences shown. 
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MccE4 92 
ColV 
Mcc24 
Consensus 
Figure 11. Multiple sequence alignment of a conserved region of MccE492, ColV, and 
Mcc24. Residues in bold indicate results predicted from our sequencing results. Alignment 
data : alignment length =14; identity (*) =8 is 57.14 %; strongly similar (:) =1 is 7.14 %; 
weakly similar (.) =3 is 21.43 %; different =2 is 14.29 % Consensus sequence shown below. 
Performed with CLUSTAL W (1.8) multiple sequence alignment method (Thompson et al., 
1994). 
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Figure 12. Helical wheel depiction of a 20 amino acid region in Mcc24. Number in box 
indicates residue number in Mcc24 without leader. Residues in red are hydrophobic and 
residues in black are hydrophilic (Kyte and Doolittle, 1982). Arrows point to site-directed 
amino acid substitutions introduced into mtfS. Inhibitory activity as seen in co-culture test 
associated with substitution is indicated by + (zone of inhibition present) or - (no zone of 
inhibition present). 
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CHAPTER 6 
GENERAL DISCUSSION 
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Discussion 
Microcins are a family of low molecular weight antimicrobial peptides produced by 
bacteria from the Enterobacteriaceae family, principally Escherichia coli. They are 
distinguished from classical antibiotics by method of production and spectrum of activity. 
Antibiotics are multi-gene products or secondary metabolites with a relatively wide range of 
activity. Microcins, on the other hand, are produced from a single gene and are generally 
only active against related species of bacteria. With the growing concern over antimicrobial 
resistance development in animal microflora and transfer of resistant organisms or 
mechanisms of resistance to human pathogens, microcins may provide a potential alternative 
to antimicrobial use in animals for specific pathogens. 
Microcin 24 (Mcc24) is produced from E. coli and has been shown to have activity 
against a variety of serotypes of Salmonella and strains of E. coli, including S. typhimurium 
and E. coli 0157:H7 (O'Brien and Mahanty, 1994; Wooley et al., 1999). In one experiment 
Mcc24 was shown to decrease the level of S. typhimurium shedding in chickens (Wooley et 
al., 1999). Decreased Salmonella shedding has also been seen by using probiotics, such as 
lactobacillus (vin Winsen et al., 2002). Additionally studies have indicated feeding fructo-
oligosaccharides (EOS), which are nondigestible sugars, prior to slaughter decreases the 
isolation rate for Salmonella spp. (Letellier et al., 2000). EOS is selectively utilized by 
beneficial bacteria, such as lactobacilli and bifidobacteria, and promotes their growth in the 
intestinal tracts. This apparently helps to competitively exclude pathogenic bacteria. 
McCormick et al. (1999) were able to produce ColV from LAB by replacing the natural 
ColV leader peptide with the signal peptide from divergicin A. This replacement allowed 
ColV to be secreted by the Sec-pathway, a general secretion pathway, in LAB rather than the 
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dedicated ColV pathway normally used in E. coli. One of the objectives of this study was to 
use the methods employed by McCormick et al., to produce Mcc24 from LAB, particularly 
lactobacillus. The genetically modified Lactobacillus would then be fed to pigs supplemented 
with FOS and studied for the effect on S. typhimurium shedding. 
The signal peptide from divergicin A was successfully fused to the mature gene for 
Mcc24 (mtfS), cloned into the expression vector, pMG36e, and transformed into 
Carnobacterium diver gens LV13, a LAB with similar characteristics as Lactobacillus. 
However, no Mcc24 activity could be detected. As discussed in Chapter 2, there are multiple 
possibilities for this lack of Mcc24 expression. This study suggests that heterologous 
expression of microcins in LAB is not generalizable. This is consistent with findings from 
other heterologous expression studies. It has been shown that the divergicin A signal peptide 
fused to mesentericin Y105 could be expressed in Leuconostoc strains but not lactococcal 
strains (Biet et al., 1998). Additionally, it is interesting that ColV was successfully expressed 
from Lactococcus lactis using the leader peptide of leucocin A and the secretion machinery 
of lactococcin A, but not when the leader peptide lactococcin A was used (van Belkum et al., 
1997). Also, the same plasmid which expressed ColV in L. lactis was able to induce secretion 
in L. gelidum (van Belkum et al., 1997). A concern that has emerged from heterologous 
experiments is that although secretion of bacteriocins may be successful using alternate 
secretion signals, secretion machinery and hosts, the levels of expression are usually 
significantly less than the natural system. This has lead some researchers to question 
potential value of heterologous expression in LAB for industrial purposes, at least in certain 
cases (Biet et al., 1998; Rodriguez et al., 2003). Thus it appears that the bacterial 
evolutionary processes leading to the selection of specific secretion pathways for bacteriocins 
in their respective hosts are not easily tampered with. 
155 
If the expression of Mcc24 from lactobacillus had gone as expected and if this 
proved to be a viable tool in a food safety intervention as was hoped, then the widespread, 
commercial use of Mcc24 may have become a reality. To address the inevitable questions of 
Mcc24 resistance development, it was decided to conduct an experiment that would offer 
insight into how quickly this would develop in S. typhimurium and whether the mar system 
had a role. This experiment is discussed in Chapter 3 and details the development of Mcc24 
resistance and the role of the mar regulon. As shown, S. typhimurium resistance to Mcc24 
developed after repeated exposure to the highest, non-lethal levels of Mcc24. Also as shown, 
the Mcc24 resistance exhibited was related to the level of MarR in the system and indicated 
the involvement of mar. Since mar activation is known to induce a multidrug resistant 
phenotype, which occurred in this experiment, it brings into question whether Mcc24 should 
be considered for widespread applications at all. This was the first time a microcin was 
shown to induce the mar phenotype and extends the range of compounds known to induce 
war-mediated resistance. Remembering that this result was produced under the artificial 
conditions of the laboratory, the next step was to see if similar results could be seen in a live 
animal. 
Chapter 4 discusses the experiment conducted to assess the ability of Mcc24 to affect 
S. typhimurium shedding in pigs and to look for evidence of Mcc24 activation of the mar 
phenotype in vivo. A Mcc24-producing E. coli was used as the source of the microcin and S. 
typhimurium %4232 and S. typhimurium i^i^marA were used as the challenge strains. Twelve 
pigs were inoculated daily starting three days prior and twenty days after challenge with the 
Mcc24-producing E. coli. Twelve other pigs received similar daily inoculations of E. coli 
without Mcc24 genes. Both groups were challenged with S. typhimurium imi- An additional 
six pigs received the daily inoculations of Mcc24 -producing E. coli and were challenged 
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with S. typhimurium x^iAmarA, which is unable to display the mar phenotype due to the 
deletion of the mar regulon activator gene, mar A. This group of six pigs served as a control 
group should evidence of mar activation be observed in the non -marA deleted strain of S. 
typhimurium. The results did not reveal evidence of mar activation in vivo, but also there was 
no indication that Mcc24-producing E. coli had an effect on S. typhimurium shedding. 
Factors considered relative to these results included bacterial host, method of delivery, and 
Salmonella ecology. 
This study used a non-colonizing E. coli to produce the Mcc24 in order to better 
assess the effect of transient passage of a Mcc24 producer. Colonization of the intestine 
varies between animals even under similar conditions. Therefore differential colonization of 
subjects would introduce a variable that would be difficult to assess. Additionally 
colonization would allow a Mcc24 producer to persist and in light of the previous 
experiment's demonstration of Mcc24's ability to induce multidrug resistance in a human 
pathogen, colonization may be regarded as too risky for commercial use. However a previous 
study, which used an avian-derived E. coli as the Mcc24 producer, did significantly affect S. 
typhimurium shedding in chickens even though the E. coli did not appear to colonize the gut 
(Wooley et al., 1999). A similar approach using an avirulent E. coli isolated from pigs may 
allow Mcc24 to reach levels high enough to impact S. typhimurium shedding. 
Another approach to increase the amount of Mcc24 present in the gut would be to 
continually supply the Mcc24 producer. Delivery in the water or feed would seem to be 
viable methods to accomplish this. However when compared, continual delivery of an 
Mcc24-producing E. coli in the water did lower S. typhimurium counts whereas delivery in 
the feed had no influence (Wooley et al., 1999). In the study presented here, Mcc24-
producing E. coli were administered to pigs as a single, high dose, oral inoculation. It was 
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thought this would ensure that pigs would have equivalent amounts of Mcc24 exposure. Even 
though Mcc24-producing E. coli was recovered from pigs, the frequency was low (-1%). 
Isolation of Mcc24-producing E. coli at time intervals less than 24 hours was not attempted. 
It may be the E. coli persisted only briefly in the animals and a continual supply would allow 
enough Mcc24 exposure to exert an effect. 
The complex intestinal environment is much different than co-culture on uniform 
media. Physical and chemical barriers in the intestine will likely impair the ability of Mcc24 
to inhibit S. typhimurium growth. Intimate contact between a Mcc24 producer and its target 
may be necessary for an effect to occur. It may be that E. coli in pigs, whatever the strain, 
may not provide suitable contact for Mcc24 to inhibit S. typhimurium shedding. If this is the 
case, producing Mcc24 from an avirulent S. typhimurium may provide a means to accomplish 
the goal. Although not attempted in this study, Mcc24 production from S. typhimurium is 
much more likely to be successful than from LAB. There would undoubtedly be concerns 
regarding potential reversion to virulence in the Mcc24-producing S. typhimurium, given the 
keen ability of Salmonella to acquire genetic elements. 
During the course of the previous studies the Mcc24 structural gene, mtfS, was 
sequenced on several occasions. Three nucleotide differences from the mtfS sequence 
published in GenBank were found and when translated produced an alternate predicted 
amino acid sequence over a span of eleven residues. MccE492 is a microcin produced by 
Klebsiella pneumoniae with a high degree of homology to Mcc24 (Lagos et al., 1999). 
Comparison of these eleven residues of Mcc24 with a similar region in MccE492 indicates 
that eight of them are identical (see Chapter 5, Figure 10). This suggests that the sequencing 
results found in these studies are the correct mtfS sequence. Additionally, restriction enzyme 
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analysis of mtfS and an mtfS mutant with the GenBank sequence further supports the 
sequencing results from these studies as discussed in chapter 5. 
Predicted secondary structure of this region in MtfS includes a helix-turn-helix motif 
which is known to be associated with protein-protein interactions. These intriguing findings 
suggested that this conserved region of MtfS is important for Mcc24 activity. It was decided 
to introduce substitutions into this region and assess the effect on Mcc24 activity. A series of 
mtfS mutants with conserved and nonconserved amino acid substitution were constructed 
using sited-directed mutagenesis as described in Chapter 5. The results showed various levels 
of effect on Mcc24 activity due to these substitutions (see Chapter 5, Figure 5). From these 
results the mtfS mutants can be divided into three groups. Mutants having equal or nearly 
equal Mcc24 activity as the parent plasmid, pXLGOB, (scores of 3 or 4). Mutants having 
little or no Mcc24 activity (scores of 0 or 1) and mutants having intermediate activity (score 
of 2). In general, the nonconserved substitutions had the most affect on Mcc24 activity in 
particular lysine substitutions as seen with leucine at position 32 and glycine at position 42. 
An alanine to lysine substitution at position 28 also greatly affected Mcc24 activity but the 
glycine to lysine substitution at position 31 had little effect. How these lysine substitutions 
account for their effect on Mcc24 activity is perhaps best explained by using a helical wheel 
representation of the amino acids in Mcc24 from positions 23 through 42 (see Chapter 5, 
Figure 12). The predicted secondary structure for this region is a helix-turn-helix-turn, but it 
may be that this region adopts a helical structure upon contact with a membrane surface as 
discussed in the models of membrane activity section (Chapter 1). The predominance of 
flexible glycines in this region (9 of 20) may allow this conformation. If this region of Mcc24 
were truly helical throughout, it would qualify as an amphipathic alpha helix. This is because 
one face is hydrophilic composed of eight glycine residues, and the other face is hydrophobic 
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with six alanine residues, one methionine residue, and one leucine residue, one valine 
residue, and one phenalanine residue. The hydrophobic face is interrupted only by arginine at 
position 29 and glycine at position 33. Lysine substitutions in the hydrophobic face (A28K 
and L32K) greatly reduce or eliminate Mcc24 activity, whereas a lysine substitution in the 
hydrophilic face (G31K) had little effect. The positively charged lysine is more reactive than 
the aliphatic, relatively inert alanine and leucine it replaces. It is interesting that the L32K 
substitution results in complete loss of Mcc24 activity while a similar substitution, L32R, 
still retains intermediate Mcc24 activity. The lysine for glycine substitution at position 42 
may be related to distortion of the secondary structure in this region since lysine is larger and 
more inflexible than the glycine. 
Previously it was reported that Mcc24 possessed non-specific nuclease activity 
(O'Brien, 1996). In the studies herein, concentrated supernatant from E. coli harboring 
plasmid with nonmutated mtfS degraded single stranded DNA (see Chapter 5, Figure 6). 
However, similarly prepared samples from E. coli harboring the mtfS mutants did not 
degrade DNA regardless of the Mcc24 activity displayed on the co-culture test (see Chapter 
5, Figures 6 and 7)). Additionally Mcc24 and MccE492 were thought to share a common 
ancestor (Lagos et al., 1999) and MccE492 has been shown to depolarize the cytoplasmic 
membrane of E. coli (de Lorenzo and Pugsley, 1985) and to form channels in phospholipid 
biplanar membranes (Lagos et al., 1993). Therefore the membrane activity of Mcc24 and the 
mtfS mutants was investigated using the dye-probe 3,3'-dipropyl thiacarbocyanine iodide 
(DiSC3[5]). 
The results indicated that the sample collected from E. coli harboring pGOB18 (a 
pBR322 derivative with the 5.25 kb Mcc24 insert) exhibited the highest level of 
fluorescence, while pXL-TOPO-derived samples regardless of the mtfS sequence had low to 
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moderate fluorescence. These results provide evidence that Mcc24 recovered from samples 
prepared with E. coli harboring pGOGIS has both DNase and membrane activity. This 
implies that Mcc24 is a bifunctional molecule which is not unique among microcins. 
Previous experiments indicated that microcin J25 (MccJ25) targets the cytoplasmic 
membrane in Salmonella (Rintoul et al., 2001) and RNA polymerase in E. coli (Delgado et 
al., 2001). Indeed, Mce492 may also possess bifunctional activity. Recent experiments have 
also shown the membrane permeablization activity of Mce492 does not account entirely for 
the microcin bactericidal activity and this suggests that other target(s) may be involved 
(Destoumieux-Garzon et al. 2003). 
However, the DNase and membrane results provided little evidence regarding the role 
of the amino acid substitutions in Mcc24 functional activity. One potential reason these 
results were not conclusive may be the quality of the samples used for testing. 
Trichloroacetic acid concentration of ColV supematants had approximately 50% yield (Path 
et al., 1994). It is unknown if similar yield are obtained from Mcc24 supematants. If higher 
levels of Mcc24 are present in the initial aliquots produced from E. coli harboring pGOBIS 
versus E. coli harboring pXL-TOPO as the parent, then an effect is more likely to be detected 
from the former. This appears to be the case for the membrane permeabilization experiment 
where a sample from E. coli harboring pGOBIS induced fluorescence well above a sample 
from E. coli harboring the pXLGOB. This was not as evident in the DNase experiment where 
both samples degraded DNA. Considerable effort was expended trying to produce purified 
samples of Mcc24. Published techniques for microcin purification using reverse-phase high 
performance liquid chromatography (RP HPLC), ion exchange chromatography, and size 
exclusion columns did not yield satisfactory results. 
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Recommendations for future research 
Some of the potential reasons why Mcc24 activity was not seen in lactic acid bacteria 
were previously discussed (Chapter 2). Development of high copy expression vectors 
suitable for lactic acid bacteria may overcome the potential problem of low Mcc24 
production in this study. A review of heterologous expression systems in lactic acid bacteria 
by Rodriguez et al. (2003) suggests possible systems based on PnisA or Pgad promoters as a 
mean of overexpression of bacteriocins. Unfortunately many of these expression systems are 
not easily obtained as they have not been made commercially available. 
Although induction of the mar system can be accomplished using compounds such as 
salicylate, chloramphenicol, and tetracycline, these are not thought to be natural inducers of 
mar (Alekshun and Levy, 1997). Investigation of the role Mcc24 plays in the activation of 
mar may shed insight into the regulation of this global response system. A two-hybrid system 
in E. coli to identify protein-protein interactions was attempted in these studies, but Mcc24 
proved unsuitable as a bait molecule (data not shown). A similar attempt in yeast is a 
possible alternative. Additionally a peptide inhibiting Mcc24 was produced independently 
using similar methods as described in Carlson et al. (2002). The translated sequence of this 
inhibiting peptide matched the predicted amino acid sequence from GenBank in the region of 
Mcc24 that differs from the sequencing results found in this study (data not shown). An 
explanation of how this finding fits with other results obtained in this study is not readily 
apparent. 
Further studies reporting the use of Mcc24 as an inhibitor of Salmonella are likely to 
continue even though an effect in pigs was not found in these studies herein. The possibility 
of Mcc24 as an alternative to antibiotic use provides considerable incentive. Also, identifying 
the active region(s) of Mcc24 and a better understanding of its mechanism of activity may 
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lead to the development of synthetic peptides with a broader spectrum of activity. 
Developing a suitable purification technique for Mcc24 is critical for future investigation 
along these lines. Purified Mcc24 would most likely yield more conclusive results regarding 
mechanism of action and structure-function studies. Sequencing of the peptide could also 
resolve the lingering questions over the active form of the peptide. 
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APPENDIX A 
ADDED SEQUENCE AND STRUCTURE INFORMATION FOR 
MCC24 
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( a )  
MtfS 
Ours 
Prim.cons. 
AGDPLADPNSQIVRQIMSNAAWŒPLVPER-FRGMAVGAAGGVTQTVLQGAAAHMPVNVP 
AGDPLADPNSQIVRQIMSNAAWCAAFGARGGLGGMAVGAAGGVTQTVLQGAAAHMPVNVP 
-k k A- kr -k •> -k -k -k -k -k -k A" k -k k k -k k- -k ~k k- • . -k k -k k -k k k -k k 'A -k A A k A- -t.- ,4- A '• V y A k k 
AGDPLADPNSQIVRQIMSNAAWG2 2 222 2 2G2 2GMAVGAAGGVTQTVLQGAAAHMPVNVP 
MtfS 
Ours 
70 
I 
IPKVPMGPSWNGSKG 
IPKVPMGPSWNGSKG 
Prim.cons. IPKVPMGPSWNGSKG 
Alignment data : Alignment length : 75 Identity (*) : 65 is 86.67 Strongly similar (:) : 2 is 2.67 % Weakly similar (.) : 4 is 5.33 % 
Different : 4 is 5.33 % Sequence 1 : MtfS ( 74 residues). Sequence 2 : Ours ( 75 residues). 
( b )  
MtfS AGDPLADPNSQIVRQIMSNAAWGPPL-VPERFRGMAVGAAGGVTQTVIjOGAAAHMPVNVP 
MceA AGE—TDPNTQLLNDLGNNMAWGAALGAPGGLGSAALGAAGGALQTVGQGLIDHGPVNVP 
k -A" • » k -k ~k • A- • • . . -k k k k -1" -*• . A- • A A "» l" -4 A- ;»• À ' A » I 1 I 
Prim.cons. AG2PL2DPN2Q2222222N2AWG22LG2P222222A2GAAGG22ï)V2QG222H2PVNVP 
70 80 
MtfS 
MceA 
IPKVPMGPSWNGS-KG 
IP-VLIGPSWNGSGSGYNSATSSSGSGS 
•k k k • k k k k ~k ~k "A' 'k 
Prim.cons. IPKV22GPSWNGSG2GYNSATSSSGSGS 
Alignment data : Alignment length : 88 Identity (*) : 40 is 45.45 % Strongly similar (:) : 10 is 11.36 % Weakly similar (.) : 8 is 
9.09 % Different : 30 is 34.09 % Sequence 1 : MtfS ( 74 residues). Sequence 2 : MceA ( 85 residues). 
(C) 
Ours 
MceA 
Prim.cons, 
AGDPLADPNSQIVRQIMSNAAWGAAFGARGGLGGMAVGAAGGVTQTVLQGAAAHMPVNVP 
AGE—TDPNTQLLNDLGNNMAWGAALGAPGGLGSAALGAAGGALQTVGQGLIDHGPVNVP 
k ~k • • k k k • -A' • • • • k 'k k k k k • k k 'k k ~k k k • k k k k k k > « A ' k > 1 
AG2PL2DPN2Q2222222N2AWGAA2GA2GGLG22A2GAAGG22QTV2QG222H2PVNVP 
70 80 
I I 
Ours IPKVPMGPSWNGS-KG 
MceA IP-VLIGPSWNGSGSGYNSATSSSGSGS 
A- k A- o k k k A A -k k A" 
Prim.cons. IPKV22GPSWNGSG2GYNSATSSSGSGS 
Alignment data : Alignment length : 88 Identity (*) : 46 is 52.27 % Strongly similar (:) : 10 is 11.36 % Weakly similar (.) : 5 is 
5.68 % Different : 27 is 30.68 % Sequence 1 : Ours ( 75 residues). Sequence 2 : MceA ( 85 residues). 
Figure 1. Alignment data for GenBank MtfS (Accession # U47048), Our MtfS, and 
GenBank MceA (Accession # AF063590). (a) GenBank MtfS versus Our MtfS, (b) GenBank 
MtfS versus GenBank MceA, (c) Our MtfS versus GenBank MceA. Area of MtfS sequence 
difference is underlined. Performed with CLUSTAL W (1.8) pairwise sequence alignment 
method (Thompson et al., 1994). 
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(a) 
File : G27A.DNA 
Range : 1 - 33 Mode : Normal 
Codon Table : Universal 
9 18 27 
5' TGG GGC GCC GCC TTT GCT GCC AGA GGC GGT TTA 3' 
1 G A A F .  A A R G G L  
(b) 
File : A28T.DNA 
Range : 1 - 33 Mode : Normal 
Codon Table : Universal 
9 18 27 
5' GGC GCC GCC TTT GGT ACC AGA GGC GGT TTA GGG 3' 
G A A F G T R G G L G  
(c) 
File : A28K.DNA 
Range : 1 - 33 Mode : Normal 
Codon Table : Universal 
9 18 27 
5' GGC GCC GCC TTT GGT AAA AGA GGC GGT TTA GGG 3' 
G A A F G K R G G L G  
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(d) 
File : R29N.DKA 
Range ; 1 - 33 Mode : Normal 
Codon Table ; Universal 
9 16 27 
5' GCC GCC TTT GGT GCC AAT GGC GGT TTA GGG GGA 3' 
A A F G A N G G L G G  
(e) 
File : G30A.DNA 
Range : 1 - 33 Mode : Normal 
Codon Table : Universal 
9 18 27 
51 GCC TTT GGT GCC AGA GCC GGT TTA GGG GGA ATG 3 
A F G A R  A G L G G M  
(0 
File : G31A.DNA 
Range : 1 - 33 Mode : Normal 
Codon Table : Universal 
9 18 27 
5» TTT GGT GCC AGA GGC GCT TTA GGG GGA ATG GCT 3 
F G A R G A L G G M A  
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(g) 
File : G31K.DNA 
Range : 1 - 33 Mode : Normal 
Codon Table : Universal 
9 18 27 
5' TTT GGT GCC AGA GGC AAA TTA GGG GGA ATG GCT 3' 
F G A R G K L G G M A  
(h) 
File : L32I.DHA 
Range : 1 - 33 Mode : Normal 
Codon Table : Universal 
9 18 27 
5' GGT GCC AGA GGC GGT ATA GGG GGA ATG GCT GTT 3' 
G A R G G I G G M A V  
(i) 
File : L32K.DNA 
Range : 1 - 33 Mode : Normal 
Codon Table : Universal 
9 18 27 
51 GGT GCC AGA GGC GGT AAA GGG GGA ATG GCT GTT 3' 
G A R G G K G G M A V  
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(k) 
File : L32R.DNA 
Range : 1 - 33 Mode : Normal 
Codon Table : Universal 
9 18 27 
5* GGT GCC AGA GGC GGT CGA GGG GGA ATG GCT GTT 3' 
G A R G G R G G M A V  
(1) 
File : L32T.DNA 
Range : 1 - 33 Mode : Normal 
Codon Table ; Universal 
9 18 27 
5* GGT GCC AGA GGC GGT ACA GGG GGA ATG GCT GTT 3» 
G A R G G T G G M A V  
(m) 
File : G38A.DNA 
Range : 1 - 33 Mode : Normal 
Codon Table : Universal 
9 18 27 
5* GGG GGA ATG GCT GTT GCA GCC GCA GGT GGG GTT 3' 
G G M A V A A A G G V  
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(n) 
File : G42K.DNA 
Range : 1 - 33 Mode : Normal 
Codon Table : Universal 
9 18 27 
5* GTT GGA GCC GCA GGT AAG GTT ACG CAG ACA GTT 3' 
V G A A G K V T Q T V  
(o) 
File : W71STOP.DNA 
Range : 1 - 33 Mode : Normal 
Codon Table : Universal 
9 18 27 
5' CCG ATG GGA CCC TCA TAG AAC GGA AGT AAA GGA 3' 
P M G P S * N G S K G  
(P) 
File : ORIGINAL.DNA 
Range : 1 - 47 Mode : Normal 
Codon Table : Universal 
9 18 27 36 45 
5' GGC ATG GGG CCC GCC TTT GGT GCC AGA GCG GTT TAG GGG AAT GGC TG 3» 
G M G P A F G A R A V * G N G  
A  t f  G P P L V P E R F R G  M  A  
H G A R L W C Q S  G L G B W L  
Figure 2. Sequence changes in MtfS due to site-directed mutagenesis. The altered residue(s) 
are underlined. 
(a) 
File: G0BHCC24.ÀKI 
Size: 75 aa 
Seq: 1 - 75 
Function: Chou and Fasman 
== : HELIX hkxkxhm : SHEET : TURN mummm : COIL 
Wiffl-iWi-Hti-
(b) 
File: G27A.ÀHI 
Size: 75 aa 
Seq: 1 - 75 
Function: Chou and Fasman 
: HELIX KKKKKKH : SHEET : tùkN miHimmi : COIL 
173 
(c) 
File: À28K.AHI 
Size: 75 aa 
Seq: 1 - 75 
Function: Chou and Faaaan 
•www : HELIX kkxhxkh : SHEET : ruwH iwwwwt : COIL 
I 
(d) 
!ï«; A28T 75 aa 
Seq: 1 - 75 
Function: Chou and Fasman 
2 HELIX mkkhkhh ï SHEET «««. 2 TURH mimcim* : COIL 
l 
1 
1 
gMWWXWWM IHMWHHHOOOO^MXK» 
I 
| 
0 
174 
(e) 
File: R29W.ÀHI 
Size: 75 aa 
Seq: 1 - 75 
Function: Chou and Fasman 
: HELIX «CM»» : SHEET *««««»:«• : TURN H» : COIL 
i 
|
 
r
—
 
! 
MBMMWMUnniKHIX» ; 
J ! 
I 
(f) 
File: G30A.AHI 
Size: 75 aa 
Seq: 1 - 75 
Function: Chou and Fasman 
-w : HELIX HMWMW : SHEET : TURN inwnmm : COIL 
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(g) 
File: G31À.AHI 
Size: 75 aa 
Seq: 1 - 75 
Function: Chou and Fasman 
__ : HELIX : SHEET , : TURN : COIL 
rooooooooooer-MK-r^x-wtiw 
(h) 
File: G31K.AHI 
Size: 75 aa 
Seq: 1 - 75 
Function: Chou and Fasman 
: HELIX K»»..». : SHEET : TURN : COIL 
^y/x-y//-:w-x-,x-
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(i) 
File: L32I.AMI 
Size: 75 aa 
Seq: 1 - 75 
Function: Chou and Fasman 
HELIX SHEET TURN : COIL 
I 
***********( 
(j) 
File: L32K.AMI 
Size: 75 aa 
Seq: 1 - 75 
Function: Chou and Fasman 
: HELIX kkhkhkh : SHEET «««<»:<«. : TURN »m : COIL 
I 
•OHOOIKMMOCKW, 
177 
(k) 
File: L32R.ÀHI 
Size: 75 aa 
Seq: 1 - 75 
Function: Chou and Fasman 
mmmmmm : HELIX KHHHMW : SHEET vsrM-yM» : TURN NtBNtHHMc : COIL 
(1) 
File: L32T.AHI 
Size: 75 aa 
Seq: 1 - 75 
Function: Chou and Fasman 
: HELIX iooooo« : SHEET : TURN hmhhhhh : COIL 
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(m) 
File: G38À.AHI 
Size: 75 aa 
Seq: 1 - 75 
Function: Chou and Fasman 
: HELIX wwMoa : SHEET #***«* : TUPfi ******** : COIL 
(n) 
File: G42K.ÀMI 
Size: 75 aa 
Seq: 1 - 75 
Function: Chou and Fasman 
: HELIX hhhhkhh : SHEET ««m» : TUPfi mi m» : COIL 
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(o) 
File: H70ST.AHI 
Size: 69 aa 
Seq: 1 - 69 
Function: Chou and Fasman 
: HELIX hkhkkmh : SHEET «**«*«** : TUPN wiwpwm : COIL 
Figure 3. The predicted secondary structure of MtfS mutants according to Chou and Fasman 
(Chou and Fasman, 1978). 
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APPENDIX B 
SUPPLEMENTAL RESEARCH 
Relative distribution of genes encoding aminoglycoside-modifying 
enzymes in veterinary isolates of multiple antibiotic resistant 
Salmonella typhimurium phagetype DT104 obtained in 1998. 
Key words: Salmonella, antibiotic resistance, aminoglycosides, DTI04 
This chapter contains research conducted by Timothy S. Frana in pursuit of Doctor of 
Philosophy in Veterinary Microbiology. A version of this chapter appeared in Applied and 
Environmental Microbiology 67(l):445-448 (January 2001) by Timothy S. Frana1, Steve A. 
Carlson2 and Ronald W. Griffith1, department of Microbiology and Preventive Medicine, 
Iowa State University College of Veterinary Medicine, Ames, IA 50011. 2Pre-harvest Food 
Safety and Enteric Disease Research Unit, National Animal Disease Center, USD A, 
Agricultural Research Service, Ames, IA 50010. 
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Abstract 
PCR was used to identify genes encoding aminoglycoside-modifying enzymes in 425 
veterinary isolates of Salmonella typhimurium. The isolates were collected from 32 states 
and included various phagetypes (DTI04, U302, DT193, DT208, DTI20), and were isolated 
from multiple animal species. Identities of extra-integron genes encoding resistance to 
gentamicin, kanamycin, and apramycin were evaluated. Gentamicin resistance was seen in 
37 isolates and conveyed by the aadB gene. Kanamycin resistance was seen in 125 isolates 
and conveyed by the aphAl-Iab gene (114 isolates) and the Kn gene (11 isolates). 
Apramycin resistance was seen in 24 isolates and conveyed by the aacC4 gene. Analysis of 
gene distribution did not reveal significant differences with regards to phagetype, animal 
species of origin, or geographical region. The only exception to this related to the Kn gene, 
which predominated in nonclinical isolates. Streptomycin resistance was seen in all 425 
isolates and was attributed to the aadA2 gene. This gene is integron-associated in DTI04 and 
other phagetypes, but was not found with the integron-associated pentaresistant gene cluster 
in DT208 in this study. The data from this study indicates that pentaresistant DTI04 does not 
acquire extra-integron genes in an animal species- or geographic- specific manner, which 
further supports clonal expansion as the method of spread of this organism. 
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Introduction 
Infections with Salmonella are an important health problem worldwide (Slusker et al., 
1998). In recent years, testing of Salmonella isolates in the United States and abroad has 
shown that an increasing proportion of isolates are resistant to several antimicrobial agents 
(Glynn et al., 1998; Low et al., 1997). Of particular concern is a distinct strain of Salmonella 
enterica serotype Typhimurium, characterized as definitive type 104 (DTI 04), that is 
commonly resistant to five antibiotics (ampicillin, chloramphenicol, streptomycin, 
sulfonamides, and tetracycline; ACSSuT antibiogram). First reported in the United Kingdom 
in 1984, DTI04 is now the second most prevalent Salmonella isolated from humans in 
England and Wales (Ridley and Threlfall, 1998). Salmonella infections caused by 
multiresistant DTI04 have also been reported in cattle (Imberechts et al., 1998), swine 
(Poppe et al, 1998), marine wildlife (Foster et al, 1998; Low et al., 1996), and a variety of 
other species (Besser et al., 1997). 
DTI04 can develop resistance to antibiotics by acquiring the genes that confer 
antibiotic resistance. This can be facilitated by genetic elements such as plasmids, 
transposons, and mobile cassettes of DNA called "intégrons" (Hall and Stokes, 1993; 
Recchia and Hall, 1997). Recent studies have identified a genetic arrangement in the 
chromosome of DTI 04 for the ACSSuT antibiotic resistance pattern (Briggs and Fratamico, 
1999; Ridley and Threlfall, 1998; Sandvang et al., 1998). This genetic arrangement is 
composed largely of two intégrons containing the genes PSE-1, a cmlA homologue, aadA2, 
sull, and tetA that respectively encode resistance to ampicillin, chloramphenicol, 
streptomycin/spectinomycin, sulfonamides, and tetracycline. 
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The ability to acquire and maintain resistance genes is not unique to DTI04, however. 
Related phagetypes (e.g. U302) and unrelated phagetypes (e.g. DT120, DTI93 and DT208) 
can have similar resistance patterns and mechanisms for acquiring the genotype leading to 
the ACSSuT phenotype. (Carlson et al., 1999). Non-ACSSuT antibiotic resistance can be 
found within isolates of all these phagetypes that may be unrelated to the intégrons that have 
been characterized. Our study was conducted to determine the "extra-integron" genes 
conferring resistance to several aminoglycoside antibiotics in bacterial strains recovered from 
various animal isolates within the United States. Specific differences between species or 
geographic areas may reveal differences in modes of spread or gene acquisition among the 
phagetypes. 
Materials and Methods 
Bacterial strains. 
The sample pool consisted of pentaresistant S. typhimurium isolates (n=425) 
submitted in 1998 to the National Veterinary Services Laboratory in Ames, lowa.The isolates 
used in the survey were obtained from ruminant species, swine, non-clinical settings (i.e. 
Food Safety and Inspection Service), avian species and companion animals (including 
horses). The phagetypes included DTI04 (n=315), U302 (n=54), DTI93 (n=33), DT208 
(n=13) and DTI20 (n=10). The isolates were submitted from 32 different states and are 
summarized in Table 1. 
Antibiogram determination. 
Resistance breakpoints of antibiotics used were derived from those established by 
bthe NCCLS guidelines (1999). Antibiotics used were streptomycin (64 |ig/ml), gentamicin 
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(16 ng/ml), kanamycin (64 (ig/ml), and apramycin (32 gg/ml) and were obtained from Sigma 
Chemicals. Bacteria were classified as resistant based on macroscopic observations of 
overnight growth (approximate ODeoo >0.1) in Lennox L broth (GIBCO-BRL) containing 
antibiotics. 
DNA isolation. 
Crude DNA was isolated from 1 ml of a Lennox L broth (GIBCO-BRL) culture 
(approximately 109 cells). Cells were pelleted (14,000 rpm for 1 min., 25 °C), resuspended 
in 200 gl distilled water and boiled (10 min.). Following boiling, lysates were centrifuged 
(14,000 rpm for 5 min., 4 °C), and supernatants were diluted 1:1 with distilled water. 
Purified DNA was isolated from broth using the GNome kit (Biol01, Vista, CA, Cat. #2010-
600) as per manufacturer's protocol. DNA concentration was determined using the 
spectrophotometry analysis of Kalb and Bemlohr (1977). 
Polymerase Chain Reaction (PCR) 
A GenBank search was conducted for genes conferring resistance to gentamicin, 
kanamycin, and apramycin. Sequences of oligonucleotide primers (Integrated DNA 
Technologies, Coralville, IA) for the genes investigated are described in Table 2. PCR was 
performed in an automated thermocycler (Hybaid, Teddington, United Kingdom) with 0.2 ml 
tubes. Reactions were performed in 20 (il containing 300 uM dATP, dTTP, dCTP and dGTP, 
2.5 mM magnesium chloride, 4 pmoles of each of six primers, 10 mM Tris-HCl, 50 mM 
KC1, 0.5 units of AmpliTaq Gold (Perkin Elmer, Foster City, CA), 50 ng of template, and 
10.4 jul of water. Thermocycling entailed 95 °C for 5 min. then 40 cycles of 95 °C for 1 min., 
48 °C for 30 sec. and 72 °C for 30 sec. 
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Agarose Gel Electrophoresis 
PCR products (10 jj.1 of the reaction) were electrophoreses in 2.0% agarose (Perkin 
Elmer) gels for 1.5 hr at 150 V with Tris (40 mM)-acetate (20 mM)-EDTA (1 mM) as the 
running buffer. Ethidium bromide-stained amplicons were visualized on a UV 
transilluminator using the BioRad GelDoc System. 
Analysis 
Resistance genes were analyzed for differences with regards to animal classification, 
geographic region and phagetype using Pearson chi-square analysis and multiple logistic 
regression. Host classification included ruminant (total isolates =133; cattle = 129, camel = 
1, deer = 1, elk = 1, goat = 1), swine (total isolates =119), nonclinical (total isolates =110), 
avian (total isolates = 37; turkeys = 11, chickens =10, unclassified avian =10, quail = 6), 
companion animal (total isolates = 23; horses = 8, cats = 6, dogs = 5, ferret = 1, mink = 1, 
guinea pig = 1, primate = 1),) and unclassified (total isolates = 3). Geographic regions of the 
U.S. were arbitrarily classified as eastern (including AL, CT, DE, FL, GA, IN, KY, MA, 
MD, ME, MI, MS, NC, NH, NJ, NY, OH, PA, RI, SC, TN, VA, VT, VW), middle (AR, IA, 
IL, KS, LA, MN, MO, ND, NE, OK, SD, TX, WI) and western (AK, AZ, CA, CO, HI, ID, 
MT, NM, NV, OR, UT, WA, WY). Twenty one isolates were unclassified by region. 
Phagetypes included DTI04 (total = 315), U302 (total = 54), DT193 (total = 33), DT208 
(total = 13), and DTI20 (total = 10). P-values <0.05 were deemed significant. Analysis was 
performed using JMP IN (3.2.6 software; SAS Institute Inc.). Gene comparison was 
performed using DNASIS (2.6 version; Hitachi Software). 
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Results 
Because of the prevalence of antibiotic resistance in isolates of S. typhimurium, we 
used antibiotic resistance genes as markers in an epidemiologic survey. The targets of this 
study were integron-independent antibiotic resistance genes of pentaresistant S. typhimurium 
since intégrons seem to be ubiquitous in S. typhimurium. Aminoglycoside resistance genes 
were the focus of this study because these antibiotics are widely utilized in clinical settings 
and because aminoglycoside resistances, apart from streptomycin resistance, are conferred by 
genes outside of the intégrons. Identifying differences with regards to host, geography, or 
phagetype would be useful in understanding the spread of pentaresistant S. typhimurium as 
well as acquisition of antibiotic resistance genes. 
Aminoglycoside resistance patterns 
The aminoglycoside resistant isolates included 37 that were gentamicin resistant, 125 
that were kanamycin resistant, and 24 that were apramycin resistant. Some of the isolates 
were resistant to more than one these three antibiotics. All isolates were resistant to 
streptomycin. 
Aminoglycoside resistance genes 
All of the 37 gentamicin resistant isolates were found to contain the aadB gene, 
which encodes for 2-aminoglycoside acetyltransferase (AF078527) (Figure 1). Similarly a 
single gene, aacC4 that encodes for the 6-N-aminoglycoside acetyltransferase (AJ009820), 
conferred all of the resistance in the 24 apramycin resistant isolates (Figure 2). Kanamycin 
resistance was conferred by two genes, aphAl-Iab (114 isolates) (AF093572) and Kn (11 
isolates) (U66885) (Figure 3). Both of these encode for an aminoglycoside 3' 
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phosphotransferase product, but there is only 54% identity between these genes. The results 
of chi square analysis and multivariate logistic regression are shown in Table 3. No 
significant gene differences were identified with regards to host, geographic region, or 
phagetype, except for the Kn gene. Of the eleven isolates found to contain this gene, eight 
were nonclinical in origin. Streptomycin resistance is explained in phagetype DTI04 by the 
presence of an integron containing the aadA2 gene (Briggs and Fratamico, 1999). All non-
DT104 phagetypes were tested for the presence of the DT104-specific integron. Only 
phagetype DT208 isolates lacked this element, as determined by the cmlA/tetR amplicon 
(Figure 4.), but all DT208 contained the aadA2 gene. 
Discussion 
Infections due to S. typhimurium strains resistant to multiple antibacterial drugs have 
rapidly increased over the past 10 years worldwide. Pentaresistance has been closely 
associated with phagetype DT104. The genes conferring the ACSSuT pattern have been 
characterized as belonging to two class I intégrons within a 13-kb fragment of genomic DNA 
that may be part of a larger transposable element within DTI 04 (Ridley and Threlfall, 1998; 
Sandvang et al., 1998). The consistency of this genetic array, along with other genetic 
characterization techniques suggests a clonal expansion of DTI 04. 
However, many isolates of DTI 04 have additional antibiotic resistances not explained 
by this genetic array. In addition, non-DT104 phagetypes with similar antibiograms may or 
may not carry the described genetic array. The purpose of our study was to determine if 
aminoglycoside-modifiying genes conferring resistance to gentamicin, kanamycin, and 
apramycin varied in their distribution with regards to host, geography, and phagetype. 
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The results of the study indicate that single genes are responsible for conferring 
gentamicin and apramycin resistances with no host, geographic (Figure 5) or phagetype 
differences noted. Two genes, however, conferred kanamycin resistance, although a single 
gene conferred kanamycin resistance in the clinical isolates. The Kn gene was much more 
likely to be seen in non-clinical isolates suggesting that the presence and/or expression of this 
gene is not compatible with overt virulence. This is consistent with our recent finding that 
certain kanamycin resistant DTI04 isolates are less invasive and less pathogenic than the rest 
of the group (Carlson et al, 1999). Alternatively, it is possible that the Kn gene is abundant 
in slaughterhouses and the presence of this gene in the non-clinical isolates represents a 
postharvest concern. 
Another finding in the study indicates that multiresistant phagetype 208 does not 
contain the characterized genetic array for the ACSSuT pattern, but does have the aadA2 
gene typically associated with the DT104-specific integron. This suggests that phagetype 
208 may contain an uncharacterized integron harboring this and perhaps other antibiotic 
resistance genes. Further studies will elucidate the source of pentaresistance in phagetype 
208. 
Understanding gene acquisition and mode of spread of multiresistant DTI 04 will 
provide insight into its emergence as an important health concern worldwide. Our study, 
aimed at detecting integron-independent genes encoding aminoglycoside-modifying enzymes 
in veterinary isolates, did not find significant differences in the genes conferring gentamicin, 
kanamycin, and apramycin resistance in clinical isolates. This suggests that DTI04 did not 
acquire these genes in a geographic- or species-specific manner. Our data further supports 
the clonal dissemination theory of DTI 04 spread and should be comparable to similar studies 
performed in human isolates. 
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Table 1. Sample pool of pentaresistant Salmonella typhimurium isolates submitted in 1998 to the National 
Region Phagetype Ruminants Swine Nonclinical Avian Companion Unclassified Total 
Eastern8 DTI 04 24 48 9 22 4 0 107 
U302 2 12 2 3 0 0 19 
DTI 93 7 0 0 1 0 0 8 
DT208 1 0 0 0 1 0 2 
DTI 20 0 3 0 1 0 i o : 4 
S ubtotal 34 63 11 27 5 0 r 140 
Middle1* DTI 04 42 47 33 4 8 3 137 
IJ302 16 4 9 1 1 0 31 
DTI 93 4 0 1 5 0 0 10 
DT208 9 1 0 0 0 0 10 
DTI 20 2 1 1 0 0 0 4 
(Subtotal 73 53 44 10 9 3 r 192 
Western0 DTI 04 21 : 25 0 8 0 56 
I ,'302 0 0 3 0 0 0 3 
DTI 93 2 0 9 0 1 0 12 
D'1'208 1 0 0 0 0 0 1 
DTI 20 0 0 0 0 0 0 0 
Subtotal 24 2 37 0 9 o r 72 
Unclassified*1 DT104 1 1 13 0 0 1 0 I 15 
U302 0 0 1 0 0 0 1 
D1 193 0 0 3 0 0 0 3 
DT208 0 0 0 0 0 0 0 
D1 120 1 0 1 0 0 0 2 
Subtotal 2 1 18 0 0 0 21 
Total 133 119 110 37 23 3 425 
"AL, CT, DE, FL, GA, IN, KY, MA, MD, ME, MI, MS, NC, NH, NJ, NY, OH, PA, RI, SC, TN, VA, VT, VW 
b AR, IA, IL, KS, LA, MN, MO, ND, NE, OK, SO, TX. WI ! 
°AK AZ^CA, CO, HI, ID, MT, NM, NV, OR, UT, WA, WY 
id The states from which the isolates were obtained were not identified; 18 strains were from the F SIS, two strains were from foreign 
; sources; and the origin of one strain was not recorded. 
eDT 104 n=315, U302 n=54, DTI93 n=33, DT208 n=13, DTI20 n=10 | 
1 1 
191 
Table 2. Nucleotide sequences of oligonucleotide primers used in polymerase chain reaction 
(PCR) assays for gentamicin, kanamycin, apramycin, and streptomycin resistance genes. 
Gene Resistance Accès ion no. Primers* 
aac(3)-la Gentamicin U90945 F=TTGATCTTTTCGGTCGTGAGT 
R=T A A GCCGCGA GA GCGCC A A CA 
aacCl Gentamicin U12338 F=ATGTT A CGCA GCA GCA A CGA T 
R=T A A GCCGCGA GA GCGCCA A CA 
aac(6 )-Ib Gentamicin U90945 F=GTT A CTGGCGA A TGC A TC A CA 
R=TGTTTGA ACCATGTACA CGGC 
aadB Gentamicin AF078527 F=GA GCGA A A TCTGCCGCTCTGG 
R=CTGTT A C A A CGGA CTGGCCGC 
aacC3 Gentamicin X55652 F=A A A CTGGTGGC A A T A GA A GGA T 
R=CT A TCCGTA TGA CGCTGA GTC 
2™ Gentamicin M 55521 F=A A GCGCA CGA A GCGCGGGCTG 
R= A A GGCGGGCCT C A A GGA GGT C 
aacC2 Gentamicin X51534 F=GGC A A TA A CGGA GGC A A TTCGA 
R=CTCGA TGGCGA CCGA GCTTC A 
aacA-aphD Gentamicin M18086 F=AGCCA A A TTATTGGA GTA A A GGA A 
R=AACTGGCAATATCTCGTTTTA 
aph(2 ")-Id Gentamicin AF016483 F=CA A T A CA A T A GA GA TTTCA GGA G 
R=ATGCTTCTGATTTCATTTA ATCCC 
aadD Kanamycin AF051917 F=ATATTGGATAAATATGGGGAT 
R=T CCA CCTTCC A CTC A CCGGTT 
aphA-3 Kanamycin U51474 F=CT GTTCCA A A GGT CCT GCA CT 
R=C A A TTCGGCT A A GCGGCTGTC 
aphA/aph( 3 ) -la Kanamycin Z48231 F=A T GGGCGCCT A TC A CA A TTGG 
R=T CGCCTCCA GCTCTT CGT A GA 
aphA-7 Kanamycin M29953 F=GGA A A CA CA TA GA TTGCTTTA 
R=CTCCA CA TCTTGCCA A A T CA T 
aphAl-IAB Kanamycin AF093572 F=A A A CGTCTTGCTCGA GGC 
R=CA A A CCGTTA TTC A TTCGTGA 
Kn Kanamycin U66885 F=A CT GGCT GCT A TTGGGCGA 
R=CGTC A A GA A GGCGA T A GA A GG 
Kan Kanamycin K02552 F=GTGTTTATGGCTCTCTTGGTC 
R=CCGT GTCGTTCTGTCCACTCC 
kamB Apramycin M64625 F=TGCCCA A CCTGCTGTA CCTGT 
R=CCCCA CGGCA GCTGCGGT 
kamC Apramycin M 64626 F=T GCGCCGA A CCT GCT CT GCGT 
R=A A GT A CCGCGCCT CCT CCA 
aacC4 Apramycin AJ009820 F=A CT GA GCA T GA CCTT GCGA T GCT CT A 
R=T A CCTTGCCTCTC A A A CCCCGCTT 
kamA Apramycin D13170 F=A GGA CCCA GGCGGCC A 
R=A TCGA GGA CA CCCGCA TCCA C 
aadA2 Streptomycin ÂF071555 F=GCGTGCTA GCGGA A TTTTTGC 
R=CT A TCCGTA TGA CGCTGA GTC 
a F, forward; R, reverse 
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Table 3. Chi square analysis for genes found to confer resistance to gentamicin, 
kanamycin, and apramycin by phagetype, species, region, and multivariate regression 
— 
: 
Gene Phagetype Species8 Region® Multivariate"b 
1 
aadB 0.2810 0.6521 0.4744 0.5902 
aphA 1-IAB 0.6858 0.4627 0.7336 0.6066 
Kn 0.6147 0.0101 0.0667 0.0089 
aacC4 0.9002 0.5943 0.1568 0.7257 
a Unclassified isolates were not included in the analysis. 
b Phage type, species, and region were imcluded in the analysis. 
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Gentamicin Antibiogram 
Resistant 
(aadB ) 
37 
Sensitive 
388 
Figure 1. Gentamicin antibiogram of pentaresistant Salmonella typhimurium isolates 
submitted in 1998 to the National Veterinary Services Laboratory in Ames, Iowa. 
194 
Apramycin Antibiogram 
Resistant 
(aacC4) 
24 
Sensitive 
401 
Figure 2. Apramycin antibiogram of pentaresistant Salmonella typhimurium isolates 
submitted in 1998 to the National Veterinary Services Laboratory in Ames, Iowa. 
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Kanamycin Antibiogram 
Sensitive 
300 
Resist 
aphA1-lab 
114 
Kn 
11 
Figure 3. Kanamycin antibiogram of pentaresistant Salmonella typhimurium isolates 
submitted in 1998 to the National Veterinary Services Laboratory in Ames, Iowa. 
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3 0 0  b p  
600 bp 
350 bp 
250 bp 
M 2  3 4  5  6  7  8 9  1 0  m  
Fig. 4. Agarose gel electrophoresis of amplicons observed following PGR for 
aminoglycoside-modifying genes of multiresistant S. typhimurium isolates. Lanes designated 
as "M" or "m" represent 100 or 50 bp, respectively, molecular weight standards (GIBCO 
BRL). Lane 1 represents the aadB amplicon obtained using template DNA from a 
representative gentamicin resistant strain. Lanes 2 and 3 represent the aphA-Iab and Kn 
amplicons, respectively, obtained using template DNA from representative kanamycin 
resistant strains. Lane 4 represents the aacC4 amplicon obtained using template DNA from a 
representative apramycin resistant strain. Lane 5 represents the aadA2 amplicon obtained 
using template DNA from a representative phagetype DT208 isolate (all isolates yielded this 
amplicon, data not shown). Lanes 6-10 represent cmlA/tetR amplicons, or lack thereof, 
obtained using template DNA from a representative of phagetype DTI 04 (Lane 6), U302 
(Lane 7), DTI93 (Lane 8), DT120 (Lane 9) and DT208 (Lane 10). Specific molecular 
weight standards and amplicon sizes (bp) are indicated on both sides. 
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FS1S 
Foreiggn * 
LEGEND 
SâiB* » 
apliAI-IAB' 
K# m • 
aacC4 » • 
Figure 5. Geographic distribution of strains possessing genes encoding aminoglycoside-
modifying enzymes. Individual isolates are indicated on the basis of their genes, (red, aadB\ 
green, aacC4; black, Kn\ blue, aphA-Iab). For isolates with two or more genes, there is a 
colored dot for each gene. Nine isolates, all obtained from FSIS, were not attributed to a 
geographic location. One isolate was obtained from outside the United States. 
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